<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN""http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html><head><title>Patent US6469012 - Pyrazolopyrimidinones for the treatment of impotence - Google Patents</title><script>(function(){(function(){function e(a){this.t={};this.tick=function(a,c,b){var d=void 0!=b?b:(new Date).getTime();this.t[a]=[d,c];if(void 0==b)try{window.console.timeStamp("CSI/"+a)}catch(e){}};this.tick("start",null,a)}var a;window.performance&&(a=window.performance.timing);var f=a?new e(a.responseStart):new e;window.jstiming={Timer:e,load:f};if(a){var c=a.navigationStart,d=a.responseStart;0<c&&d>=c&&(window.jstiming.srt=d-c)}if(a){var b=window.jstiming.load;0<c&&d>=c&&(b.tick("_wtsrt",void 0,c),b.tick("wtsrt_",
"_wtsrt",d),b.tick("tbsd_","wtsrt_"))}try{a=null,window.chrome&&window.chrome.csi&&(a=Math.floor(window.chrome.csi().pageT),b&&0<c&&(b.tick("_tbnd",void 0,window.chrome.csi().startE),b.tick("tbnd_","_tbnd",c))),null==a&&window.gtbExternal&&(a=window.gtbExternal.pageT()),null==a&&window.external&&(a=window.external.pageT,b&&0<c&&(b.tick("_tbnd",void 0,window.external.startE),b.tick("tbnd_","_tbnd",c))),a&&(window.jstiming.pt=a)}catch(g){}})();})();
</script><link rel="stylesheet" href="/patents/css/_8a2b04e7bf975d5171d8e4c0b6365c7a/kl_intl_patents_bundle.css" type="text/css" /><script src="/books/javascript/atb_8a2b04e7bf975d5171d8e4c0b6365c7a__en.js"></script><script>function googleTranslateElementInit() {new google.translate.TranslateElement({pageLanguage: "en",gaTrack: true,gaId: "UA-27188110-1",multilanguagePage: true});}</script><script src="//translate.google.com/translate_a/element.js?cb=googleTranslateElementInit"></script><meta name="DC.type" content="Patent"><meta name="DC.title" content="Pyrazolopyrimidinones for the treatment of impotence"><meta name="DC.contributor" content="Peter Ellis" scheme="inventor"><meta name="DC.contributor" content="Nicholas Kenneth Terrett" scheme="inventor"><meta name="DC.contributor" content="Pfizer Inc" scheme="assignee"><meta name="DC.date" content="1994-5-13" scheme="dateSubmitted"><meta name="DC.description" content="The use of a compound of formula (I) wherein R1 is H; C1-C3 alkyl; C1-C3 perfluoroalkyl; or C3-C5 cycloalkyl; R2 is H; optionally substituted C1-C6 alkyl; C1-C3 perfluoroalkyl; or C3-C6 cycloalkyl; R3 is optionally substituted C1-C6 alkyl; C1-C6 perfluoroalkyl; C3-C5 cycloalkyl; C3-C6 alkenyl; or C3-C6 alkynyl; R4 is optionally substituted C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkanoyl, (hydroxy)C2-C4 alkyl or (C2-C3 alkoxy)C1-C2 alkyl; CONR5R6; CO2R7; halo; NR5R6; NHSO2NR5R6; NHSO2R8; SO2NR9R10; or phenyl, pyridyl, pyrimidinyl, imidazolyl, oxazolyl, thiazolyl, thienyl or triazolyl any of which is optionally substituted with methyl; R5 and R6 are each independently H or C1-C4 alkyl, or together with the nitrogen atom to which they are attached form an optionally substituted pyrrolidinyl, piperidino, morpholino, 4-N(R11)-piperazinyl or imidazolyl group; R7 is H or C1-C4 alkyl; R 8 is optionally substituted C1-C3 alkyl; R9 and R10 together with the nitrogen atom to which they are attached form an optionally substituted pyrrolidinyl, piperidino, morpholino or 4-N(R12)-piperazinyl group; R11 is H; optionally substituted C1-C3 alkyl; (hydroxy)C2-C3 alkyl; or C1-C4 alkanoyl; R12 is H; optionally substituted C1-C6 alkyl; CONR13R14; CSNR13R14; or C(NH)NR13R14; and R?13? and R14 are each independently H; C1-C4 alkyl; or substituted C2-C4 alkyl; or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity, for the manufacture of a medicament for the curative or prophylactic treatment of erectile dysfunction in a male animal, including man; a pharmaceutical composition for said treatment; and a method of said treatment of said male animal with said pharmaceutical composition or with said either entity."><meta name="DC.date" content="2002-10-22" scheme="issued"><meta name="DC.relation" content="CN:93117097" scheme="references"><meta name="DC.relation" content="DE:4230755:A1" scheme="references"><meta name="DC.relation" content="EP:0143357:A1" scheme="references"><meta name="DC.relation" content="EP:0201188:A2" scheme="references"><meta name="DC.relation" content="EP:0439320:A1" scheme="references"><meta name="DC.relation" content="EP:0463756:A1" scheme="references"><meta name="DC.relation" content="EP:0526004:A1" scheme="references"><meta name="DC.relation" content="FR:2547501" scheme="references"><meta name="DC.relation" content="JP:H0344324" scheme="references"><meta name="DC.relation" content="JP:H09503996" scheme="references"><meta name="DC.relation" content="JP:S5310599" scheme="references"><meta name="DC.relation" content="US:3987160" scheme="references"><meta name="DC.relation" content="US:4521421" scheme="references"><meta name="DC.relation" content="US:5145852" scheme="references"><meta name="DC.relation" content="US:5270323" scheme="references"><meta name="DC.relation" content="US:5278192" scheme="references"><meta name="DC.relation" content="US:5399581" scheme="references"><meta name="DC.relation" content="US:5436272" scheme="references"><meta name="DC.relation" content="US:5489610" scheme="references"><meta name="DC.relation" content="US:5565466" scheme="references"><meta name="DC.relation" content="US:5891904" scheme="references"><meta name="DC.relation" content="US:6037346" scheme="references"><meta name="DC.relation" content="WO:1989010123:A1" scheme="references"><meta name="DC.relation" content="WO:1994028902:A1" scheme="references"><meta name="DC.relation" content="WO:1996016644:A1" scheme="references"><meta name="DC.relation" content="WO:1999021562:A1" scheme="references"><meta name="DC.relation" content="WO:2000066114:A1" scheme="references"><meta name="citation_reference" content="“Chemical A Factor in Male Impotence”, Jan. 9, 1992, NY Times, D. Blakeslee."><meta name="citation_reference" content="“Double Blind Trial of Oral Prostaglandin E1 on Impotence” (1992) (abstract submitted in English)."><meta name="citation_reference" content="“Stop Fancying Each Other”, News Paper Article."><meta name="citation_reference" content="“What About the Female Partner&#39;s Quality of Life in ED?” (2000), Chevret-Measson et al."><meta name="citation_reference" content="11487 Appeal."><meta name="citation_reference" content="15th World Congress of Sexology. Jun. 24, 2001, M. A. Perelman, Abstract Book:181."><meta name="citation_reference" content="15th World Congress of Sexology. Jun. 24, 2001; Van Lunsen Abstract Book:240."><meta name="citation_reference" content="28th British Congress of Obstetrics and Gynaecology Abstract Status Report (1998), No. 7085."><meta name="citation_reference" content="A Pilot Study of the Effect of Viagra (sildenafil citrate) on Vaginal Blood Flow in Female Subjects (2000)."><meta name="citation_reference" content="A) Notification of refusal of Jun. 19, 1997 in Japanese Patent Application 7501234 B) Response dated Jan. 8, 1998 from the patentees C) Further response dated Feb. 17, 1998 and Tables attached thereto D) Footnotes by the present opponents referring to 4(C)."><meta name="citation_reference" content="ABPI Data Sheet Compendium 1990-91—D9, pp. 740-742."><meta name="citation_reference" content="ABPI Data Sheet Compendium 1991-1992 (Datapharm Publications Limited 1991) p. 588 Entry on Trental."><meta name="citation_reference" content="Abstract 88:6075 from IPA database (1988)."><meta name="citation_reference" content="Action to declare void and to re-establish the right of Pfizer Research and Development Company."><meta name="citation_reference" content="Admissions by Respondent by letters."><meta name="citation_reference" content="Affidavit of Dr. Yaakov Ramon (unsigned)."><meta name="citation_reference" content="Am J Psychiatry; Oct. 1999; 156(10):1664."><meta name="citation_reference" content="American College of Obstetrics and Gynecologists (ACOG) 48th Annual Clinical Meeting: Abstract Status Report (May 20-24, 2000), No. 7217."><meta name="citation_reference" content="Angiology. vol. 42(5), 1991, p. 418-420 Kent S. Allenby et al “Pentoxifylline in the treatment of vascular impotence—Case reports”."><meta name="citation_reference" content="Annex A to Petitioner&#39;s Skeleton Argument."><meta name="citation_reference" content="Annexes to Appellant&#39;s Notice of Appeal."><meta name="citation_reference" content="Answer."><meta name="citation_reference" content="Anti-Impotence Drug by Debra McGarry, CBS Market Watch (Jan. 12, 2000)."><meta name="citation_reference" content="Appeal Brief."><meta name="citation_reference" content="Appellant&#39;s Notice."><meta name="citation_reference" content="Appellant&#39;s Skeleton Argument."><meta name="citation_reference" content="Application as Filed."><meta name="citation_reference" content="Argument Papers from Dutch Revocation Proceeding."><meta name="citation_reference" content="Aronson et al (1991) J. Urology 145: Abstract 516-D1."><meta name="citation_reference" content="Arzneimittel-Forschung (Germany), 1988, vol. 38, pp. 379-382; by P. Cazzulani et al."><meta name="citation_reference" content="Asia Pacific Journal of Pharmacology, 1991, pp. 213-227 by Adaikan et al."><meta name="citation_reference" content="Bayer 1."><meta name="citation_reference" content="Bayer 2."><meta name="citation_reference" content="Bayer Exhibits (2 volumes)."><meta name="citation_reference" content="Bayer Opposition Statement (with Exhibits)."><meta name="citation_reference" content="Bayer: SCRAPS BAY 19-8004 for Asthma and COPD in P2-Jun. 14, 2001(vardenafil)."><meta name="citation_reference" content="Bayer&#39;s Exhibits Produced During Opening Speeches and Cross-Examination (2 binders)."><meta name="citation_reference" content="Bayer&#39;s Statement of Argument (D1-16) (w/attachments)."><meta name="citation_reference" content="Biochemical Pharmacology, 46(5), p. 833-839 (1993), Sacki et al."><meta name="citation_reference" content="Bowman, Anne et al., British J. Pharmac., 81, 665-674 (1984)."><meta name="citation_reference" content="Br J Obstet Gynaecol. Jun. 2001; 108:Editor&#39;s Choice Introduction."><meta name="citation_reference" content="Br. J. Dis. Chest (1986) 80, 157; by J. Reiser et al."><meta name="citation_reference" content="Br. J. Pharmacol. (1983), 108, 562-568; by J. Cortijo et al."><meta name="citation_reference" content="BR. J. Pharmocol. (1993) 108, 562-568."><meta name="citation_reference" content="Brief Requesting Urgent Prosecution of Appeal May 31, 2001."><meta name="citation_reference" content="Brit. J. Urology, 71: 365 (Mar. 1993)."><meta name="citation_reference" content="British Journal of Diseases of the Chest, 77, p78-86 (1983), Rudd et al."><meta name="citation_reference" content="British Journal of Obstetrics &amp; Gynaecology, Jun. 2001, vol. 108, pp. 623-628."><meta name="citation_reference" content="British Journal of Pharmacology (1998) 124, 000-000, Cellek et al."><meta name="citation_reference" content="British Journal of Pharmacology, (1992), 106, p. 1028-1034, de Boer et al."><meta name="citation_reference" content="British Journal of Urology (1996), 78, 257-261 by Boolell et al."><meta name="citation_reference" content="Bush, Peggy A., et al., J. of Urology, 147, 1650-1655 (1992)."><meta name="citation_reference" content="Butcher and Sutherland, Biochem J, 1962, 237: 1244-1250."><meta name="citation_reference" content="Challiss et al, Br J Pharmacol (1998) 124, 47-52."><meta name="citation_reference" content="Cialis (SD) Launch &#39;02E, Pk sales Est $1B, 30% SOM &#39;07E (Jan. 9, 2001)."><meta name="citation_reference" content="Cialis&#39;s Unfavorable Results in Female Sexual Dysfunction ( SG Cowen Securities/Scala, Jun. 18, 2001)."><meta name="citation_reference" content="Clin. Res. vol. 36(1), 123A, 1988, Korenman SG “Treatment of vasculogenic sexual dysfunctionwith pentoxifylline”."><meta name="citation_reference" content="Clinics in Endocrinology and Metabolism (1982), 11(3), Nov., pp. 785-789, by John Bancroft."><meta name="citation_reference" content="Closing Submissions of Pfizer."><meta name="citation_reference" content="CNN interactive on line—“Viagra? No, vuka vuka?” Jun. 19, 1998 (www.cnn.com)."><meta name="citation_reference" content="Curr Psychiatry Rep. 2001 (3): 188-194, Shabsigh."><meta name="citation_reference" content="Current Opinion in Neurobiology (1999) 9: 751-758, Pfaus."><meta name="citation_reference" content="Day Eight Minuscript: Dec. 19, 2000."><meta name="citation_reference" content="Day Five Minuscript: Nov. 30, 2000."><meta name="citation_reference" content="Day Four Minuscript: Nov. 29, 2000."><meta name="citation_reference" content="Day Nine Minuscript: Jan. 17, 2001."><meta name="citation_reference" content="Day Seven Minuscript: Dec. 18, 2000."><meta name="citation_reference" content="Day Six Minuscript: Dec. 17, 2000."><meta name="citation_reference" content="Day Three Minuscript: Nov. 28, 2000."><meta name="citation_reference" content="Day Two Minuscript: Nov. 27, 2000."><meta name="citation_reference" content="Decision Dated Dec. 21, 2001."><meta name="citation_reference" content="Decision Dated Mar. 27, 2001."><meta name="citation_reference" content="Decision of the District Court of Hague dated Oct. 4, 2000 (including English Translation)."><meta name="citation_reference" content="Declaration of Alonso Acuna Canas."><meta name="citation_reference" content="Declaration of Cesar Jaramillo."><meta name="citation_reference" content="Declaration of Clive Page."><meta name="citation_reference" content="Declaration of David Goren (with Appendixes)."><meta name="citation_reference" content="Declaration of Dr. Inigo Saenz de Tejada."><meta name="citation_reference" content="Declaration of Ian Eardley (w/Annexes)."><meta name="citation_reference" content="Declaration of Ken Murray (w/exhibits)."><meta name="citation_reference" content="Declaration of Laurence Howard Skillern (w/attachments)."><meta name="citation_reference" content="Declaration of Laurence Howard Skillern."><meta name="citation_reference" content="Declaration of Louis J. Ignarro (with References)."><meta name="citation_reference" content="Declaration of Nicolas K. Terrett (co-inventor)."><meta name="citation_reference" content="Declaration of Peter Ellis (with References)."><meta name="citation_reference" content="Declaration of R.A. John Chaliss (w/Annexes)."><meta name="citation_reference" content="Declaration of Stephen A. Ballard (in the Korean Industrial Property Office)."><meta name="citation_reference" content="Declaration of Steven Ballard."><meta name="citation_reference" content="Defendant&#39;s Schedule in relation to Commercial Success."><meta name="citation_reference" content="Disclosure Document # 110: The Lancet, vol. 340. Oct. 10, 1992."><meta name="citation_reference" content="Disclosure Document # 117: Science, vol. 258. Dec. 18, 1992."><meta name="citation_reference" content="Disclosure Document # 18 : DN&amp;P 4(7), Sep. 1991."><meta name="citation_reference" content="Disclosure Document # 368: Pfizer&#39;s Public Affairs Briefing: Press Reports on Clinical Trials of UK-92,480 Jan. 1995."><meta name="citation_reference" content="Dissertation of Margaret Bush (part of “BQ”)."><meta name="citation_reference" content="Doctors Find Viagra Works Just as Well in Women (The Sunday Telegraph—UK)."><meta name="citation_reference" content="Documents Being Submitted by Lilly in EPO Opposition (May 14, 2001)."><meta name="citation_reference" content="Documents Containing Production of Exhibits, also Containing Skeleton Arguments (w/translation) &amp; Letter of Jul. 7, 2000."><meta name="citation_reference" content="Documents Filed by the Proprietors: D 86-D 118 (Binder B)."><meta name="citation_reference" content="Documents Filed with EPO by Opponent 2 (May 14, 2001)."><meta name="citation_reference" content="Documents Filed with the EPO: D 119-D 140 (Binder C)."><meta name="citation_reference" content="Documents Filed with the EPO: D 141-D 163 (Binder D)."><meta name="citation_reference" content="Drug Therapy, vol. 19(8), 102-111, 1989, Fishman I. J. “Treating Erectile dysfunction”."><meta name="citation_reference" content="Eardley, Current Opinion in Urology, 3(2): V 24."><meta name="citation_reference" content="Eardley, Current Opinion in Urology, 3(5): II-40."><meta name="citation_reference" content="Effect of Vasoactive Agents in Modulating Vaginal Smooth Muscle Contractility: Implications for Treatment of Female Sexual Dysfunction (2000), Berman et al."><meta name="citation_reference" content="Efficacy and Safety of Viagra (sildenafil citrate) in Estrogenised Women with Sexual Dysfunction Associated with FSAD."><meta name="citation_reference" content="Efficacy and Safety of Viagra (sildenafil citrate) in Non-Oestrogenised Women with Sexual Dysfunction Associated with FSAD (2000)."><meta name="citation_reference" content="English Translation of Argument Filed on Jan. 8, 1998."><meta name="citation_reference" content="English Translation: Haen &amp; Emslander: Optimizing Therapy with Methylxanthines; German Gazette for Physicians, 86 (33), 1989, C-1435-C-1437 (Reference D3 from the opposition of Bayer AG)."><meta name="citation_reference" content="English Translation: Prof. Dr. Med. J. C. Frolich, Oct. 12, 1998. (Exhibit 2 from the opposition of Bristol Myers Squibb)."><meta name="citation_reference" content="English Translation: Rote Liste 1992, pp. 36 073 and 54 108, (Persantin®, INN: Dipyridamole and Trental®, INN: Pentoxyfyline). (Reference 5 from the opposition of Bristol Myers Squibb)."><meta name="citation_reference" content="English Translation: von Koenen: “Heil-und Giftpflanzen in Sudwestafrika”, Akademischer Verlag Winkhoek, S.W.A., 1979, p. 61. (Reference D13 from the opposition of Bayer AG)."><meta name="citation_reference" content="EPO Preliminary Opinion."><meta name="citation_reference" content="European Heart Journal (1993, 14, (Supp. 1), pp. 141-148—Lugnier et al."><meta name="citation_reference" content="European Journal of Pharmacology 400(2000) 305-312, Frith et al."><meta name="citation_reference" content="Excerpts from the UCLA doctoral dissertation of Margaret Ann Bush, including pp. ii-Xvii, 1 and 154-161, 1993."><meta name="citation_reference" content="Exhibit 1; Gray&#39;s Anatomie, Churchill Livingstone, 38th Edition."><meta name="citation_reference" content="Exhibit 2; Prof. Dr. Med. J. C. Frölich, Oct. 12, 1998."><meta name="citation_reference" content="Exhibits Produced at Trial."><meta name="citation_reference" content="Exp. Clin. Endocrinol. vol. 98, No. 2, 1991, pp. 61-69 by R. J. Levin."><meta name="citation_reference" content="Experimental Report to Israeli Opposition Statement."><meta name="citation_reference" content="Expert Report of Dennis Smith (w/Annexes)."><meta name="citation_reference" content="Expert Report of Ian Eardley (w/Annexes)."><meta name="citation_reference" content="Expert Report of John Pryor (w/Annexes)."><meta name="citation_reference" content="Expert Report of Kenneth Duncan Macrae (w/Annexes)."><meta name="citation_reference" content="Expert Report of Lawrence Kruse (w/Annexes)."><meta name="citation_reference" content="Expert Report of Louis Ignarro (w/Annexes)."><meta name="citation_reference" content="Expert Report of Peter Ellis (w/Annexes)."><meta name="citation_reference" content="Expert Report of Robert Challis (w/Annexes)."><meta name="citation_reference" content="Expert Report of Robert Gristwood (w/Annexes)."><meta name="citation_reference" content="Expert Report of Robin Leatherbarrow (w/Annexes)."><meta name="citation_reference" content="F. Holmquist et al., Arta Physiol Scand, 1991, vol. 143, pp. 299-304."><meta name="citation_reference" content="Female Sexual Dysfunction by Cheryl Terhorst (Apr. 18, 2001)."><meta name="citation_reference" content="Female Sexual Dysfunction—Mosaic Study #16—Nov. 1999."><meta name="citation_reference" content="Fernandes et al, Am J Prspir Crit Care Med vol. 150, 1384-1390."><meta name="citation_reference" content="Fertil Steril. Sep. 2001; 76(3 Suppl 1): S255 (#P-430)."><meta name="citation_reference" content="Fifth Witness Statement of Mark Thomas Hodgson (w/Exhibits)."><meta name="citation_reference" content="Fifth Witness Statement of Trevor Martin Cook."><meta name="citation_reference" content="FIGO World Congress of Gynecology and Obstetrics (2000), Abstract Status Report, Nos. 7279, 7280 &amp; 7281."><meta name="citation_reference" content="First Declaration of Stephen A. Ballard (in the U. S. Patent and Trademark Office)."><meta name="citation_reference" content="First Witness Statement of Dr. Kenneth M. Ferguson (w/Exhibits)."><meta name="citation_reference" content="First Witness Statement of James Michael Marshall (w/Exhibits)."><meta name="citation_reference" content="First Witness Statement of Mark Thomas Hodgson (w/Exhibits)."><meta name="citation_reference" content="First Witness Statement of Robert Geoffrey Paget Williams (w/Exhibits)."><meta name="citation_reference" content="First Witness Statement of Trevor Martin Cook (w/Exhibits)."><meta name="citation_reference" content="Fourth Witness Statement of Mark Thomas Hodgson (w/Exhibits)."><meta name="citation_reference" content="Fourth Witness Statement of Trevor Martin Cook."><meta name="citation_reference" content="Further Substantive Submission by O-6 (May 2, 2001)."><meta name="citation_reference" content="Further Substantive Submissions (in German) (May 2, 2001) (w/translation)."><meta name="citation_reference" content="Further Substantive Submissions by O-10 (May 16, 2001)."><meta name="citation_reference" content="Further Substantive Submissions by O-11 (May 16, 2001)."><meta name="citation_reference" content="Further Substantive Submissions by O-12 (May 16, 2001)."><meta name="citation_reference" content="Further Substantive Submissions by O-3 (May 14, 2001)."><meta name="citation_reference" content="Further Substantive Submissions by O-8 (May 30, 2001)."><meta name="citation_reference" content="Further Substantive Submissions by O-9 (w/English Translation) (May 11, 2001)."><meta name="citation_reference" content="Further Substantive Submissions on Behalf of O-2 and O-5 (Jul. 4, 2001)."><meta name="citation_reference" content="German Gazette for Physicians 86, No. 33, Aug. 17, 1989, C-1436 to 1440, Haer et al."><meta name="citation_reference" content="Gristwood and Owen, British Journal of Pharmacology, 1986, 87, 91P."><meta name="citation_reference" content="Gristwood et al, Br J Pharmacol, 1986, 89: 573P."><meta name="citation_reference" content="Grounds for Rejection."><meta name="citation_reference" content="Grounds of Opposition of Opponent II, ICOS Corp, to EP-B-0702555."><meta name="citation_reference" content="Gruetter et al, J Cyclic Nucleotide Res 5: 211-124, 1979."><meta name="citation_reference" content="Hager&#39;s Handbuch der Pharmazeutischen Praxis, 4. Aufl., 1971, S. 675-676."><meta name="citation_reference" content="Harvey C. Taub, et al., Urology, 1993, vol. 42, No. 6, pp. 698-704."><meta name="citation_reference" content="Hysterectomy &amp; Sexual Dysfunction: Effects of Sildenafil in a Clinical Setting (May 2, 2000), Berman et al."><meta name="citation_reference" content="Impotence, 1995, vol. 22, No. 4, pp. 879-886—Morales et al."><meta name="citation_reference" content="Int J Impot Res (2000); 12 Supp 3:S32-S39, Min et al."><meta name="citation_reference" content="Int J Impot Res (2000); 12 Supp 4:S152-S157, Goldstein."><meta name="citation_reference" content="Int J Impot Res Apr. 2000;12(Supp 2):S17."><meta name="citation_reference" content="Int. J. Impotence Res. (1992) 4 Suppl. 2, Abstracts of the 5th World Congress on Impotence, Milan, Sep. 14-17, 1992, Taher et."><meta name="citation_reference" content="Int. J. Impotence Res. (1992) 4, Suppl. 2 p. 11, Taher et al."><meta name="citation_reference" content="International Journal Impotence Research, 1995, pp. 13, by H. H. Knispel et al."><meta name="citation_reference" content="International Journal of Impotence Research (Jun. 1996), vol. 8, No. 2, pp. 47-52, Boolell et al."><meta name="citation_reference" content="International Journal of Impotence Research vol. 6, No. 1, Mar. 1994, pp. 33-35."><meta name="citation_reference" content="International Journal of Impotence Research, 4 (Suppl. 2) (1992) p. 19."><meta name="citation_reference" content="International Journal of Impotence Research, Supp 12: S32-S39, Min et al."><meta name="citation_reference" content="International Journal of Impotence Research, Supplement 1, Sep. 1995."><meta name="citation_reference" content="Israeli Opposition Statement of Bayer Aktiengesellschaft."><meta name="citation_reference" content="J Sex Marital Ther (2000) Apr.-Jun.; 26:133-140."><meta name="citation_reference" content="J Sex Marital Ther. 2001: 27:427-433, Berman et al."><meta name="citation_reference" content="J Sex Marital Ther. 2001; 27:411-420, Berman et al."><meta name="citation_reference" content="J Sex Martial Ther. Oct. 2001; 27(5):421-425, Berman et al."><meta name="citation_reference" content="J Sex Res. 2001; 38(2): 89-96."><meta name="citation_reference" content="J Urol. 2001, May; 165(5) Supplement: P227 (#935)."><meta name="citation_reference" content="J. Berman&#39;s Poster at 1999 AUA Conference."><meta name="citation_reference" content="J. Mol. Cell. Cardio vol. 12(10), 1980, 939-954, 1980, Argel M.I. et al., “Effect of phosphodiesterase inhibitors onheart contractile behaviour, protein kinase activity and cyclic nucleotide level”(abstract)."><meta name="citation_reference" content="J. of Ethnopharmacology, 12 (1984) 35-74, particularly p. 42, Arnold et al."><meta name="citation_reference" content="J. of Sexual &amp; Marital Therapy, 27:411-420, 2001, Berman et al."><meta name="citation_reference" content="J. of Steroid Biochemistry &amp; Molecular Biology 69 (1999) 177-184, S.R. Davis."><meta name="citation_reference" content="J. of Urol. (1993), vol. 149(4), p. 285A."><meta name="citation_reference" content="J. Steroid Biochem. Molec. Biol. vol. 39, No. 6 pp. 873-881, 1991 by Williams-Ashman et al."><meta name="citation_reference" content="JAGS 41: 363-366, 1993; by Stanley G. Korenman et al."><meta name="citation_reference" content="Journal of Ethnopharmacology, 12 (1984) 35-74."><meta name="citation_reference" content="Journal of Japanese Society of Urology, 83(10, p 1655-1661 (1992), Kawanishi et al."><meta name="citation_reference" content="Journal of Medicine, vol. 10, No. 6, 1979; by J. L. Ambrus et al."><meta name="citation_reference" content="Journal of Sex &amp; Marital Therapy, 26: 191-208 (2000)."><meta name="citation_reference" content="Journal of Urology (1999), 161, pp. 940-944 by Tarcan et al."><meta name="citation_reference" content="Journal of Urology 147, 4th Supplement, p. 454A, 1992, No. 967, Aronson et al."><meta name="citation_reference" content="Journal of Urology 149:285A (Apr. 1993)."><meta name="citation_reference" content="Journal of Urology 150: 1310-1315 (Oct. 1993), Holmquist."><meta name="citation_reference" content="Journal of Urology, vol. 149, 872-877, 1993, Trigo-Rocha et al, The role of cyclic adenosine monophosphate, cyclic guanosine monophosphate, endothelium and nonadrenergic, noncholinergic neurotransmission in canine penile erection."><meta name="citation_reference" content="Judgment Given at Hearing on Aug. 17, 2000."><meta name="citation_reference" content="Judgment given by Justice Laddie in the Revocation Action Nov. 10, 2000 (part of “BQ”)."><meta name="citation_reference" content="Judgment of Invalidity Proceedings in the District Court of the Netherlands Oct. 4, 2001 (part of “BQ”)."><meta name="citation_reference" content="Judgment of Nov. 8, 2000."><meta name="citation_reference" content="Karl-Erik Anderson et al. The American Physiological Society, 1995, vol. 75, pp. 191-236."><meta name="citation_reference" content="Krall, Fittinghoff and Rajfer, Biol Reprod, 39(4): 913-22."><meta name="citation_reference" content="Kukovetz et al (1979) Naunyn-Schmiedeberg&#39;s Arch. Pharmacol. 310: 129-138—D6."><meta name="citation_reference" content="Lepakhin Publication (1988) (w/excerpt translated)."><meta name="citation_reference" content="Letter by Opponent Bayer (Mar. 30, 2001)."><meta name="citation_reference" content="Letter Dated Dec. 20, 2000 to European Patent Office."><meta name="citation_reference" content="Letter Dated Dec. 21, 2000 with Submissions to European Patent Office."><meta name="citation_reference" content="Letter Dated Jun. 14, 2000 (including English Translation) with the New Notice of Experiments Attached."><meta name="citation_reference" content="Letter Dated Jun. 30, 2000 (w/English translation) with Additional Exhibits 1-5 Attached."><meta name="citation_reference" content="Letter Enclosing Annex G by O-2 (May 16, 2001)."><meta name="citation_reference" content="Letter from Opponent VII of May 16, 2000."><meta name="citation_reference" content="Letter of Feb. 22, 2000."><meta name="citation_reference" content="Letter of Jul. 3, 2000 (w/translation)."><meta name="citation_reference" content="Letter of Mar. 27, 2000."><meta name="citation_reference" content="Letter of Mar. 28, 2000."><meta name="citation_reference" content="Letter to by O-2 (May 16, 2001)."><meta name="citation_reference" content="Letter to EPO by O-2 dated Jun. 14, 2001."><meta name="citation_reference" content="Letter to EPO by O-5 dated Jun. 15, 2001."><meta name="citation_reference" content="Letter to EPO dated Dec. 30, 2000."><meta name="citation_reference" content="Letter to EPO Filing Further Documents (Apr. 5, 2001) (w/documents)."><meta name="citation_reference" content="Letter to Patentee dated Jun. 14, 2001."><meta name="citation_reference" content="Letters dated Apr. 30, 2000 &amp; Sep. 8, 1999."><meta name="citation_reference" content="Letters Discussing Repeats of Experiments."><meta name="citation_reference" content="M. F. Meyer et al., Ann Urol., 1993, vol. 27, No. 3, pp. 179-182."><meta name="citation_reference" content="Martindale Extra Pharmacopoeia 29th Edition 1989, p. 1423, Heading 14026-m."><meta name="citation_reference" content="Minutes of the Oral Proceedings before the Opposition Division (w/annexes) (Jul. 16, 2001)."><meta name="citation_reference" content="Mirone, V., et al., British J. of Urology, 71, 3, 365 (1993)."><meta name="citation_reference" content="Mol Cell Biol Res Commun (1999) 2(2): 131-137, Traish et al."><meta name="citation_reference" content="Molecular Pharmacology 36(5), 773-781, 1989, Gillespie P. G. Et Beavo J. A. “Inhibition and stimulation of photoreceptor phosphodiesterases by dipyridamole and M&amp;B22, 948”."><meta name="citation_reference" content="Murray, Kenneth J., Drug News &amp; Perspectives, 6, 150-156 (1993)."><meta name="citation_reference" content="New Scientist, Mar. 1999, p. 15."><meta name="citation_reference" content="Nicholson et al., TIPS, Jan. 1991, vol. 12, pp. 19-27."><meta name="citation_reference" content="Notice of Acceptance of Request for Invalidation Re: Patent Invention No. 94192386.X."><meta name="citation_reference" content="Notice of Opposition (Lab. Rec.) Feb. 12, 1999 (w/translation)."><meta name="citation_reference" content="Notice of Opposition to EPO Patent (Merck) (w/translations)."><meta name="citation_reference" content="Notice of Opposition to EPO Patent (Vivus)."><meta name="citation_reference" content="Nullity Action and Restitution Against Resolution Nos. 0112 of Jan. 18, 2000 and 10169 of May 16, 2000."><meta name="citation_reference" content="Nullity Action."><meta name="citation_reference" content="Observations After Viagra: Study on “Estrogenized” Women is Released (2000), Berman et al."><meta name="citation_reference" content="Offer of Information (12 references) (w/references)."><meta name="citation_reference" content="Offer of Information (7 references) (w/references)."><meta name="citation_reference" content="Offer of Information (Japan) citing 12 documents."><meta name="citation_reference" content="Offer of Information (Japan) citing 7 documents."><meta name="citation_reference" content="Offer of Information with translations (4 references) (w/references)."><meta name="citation_reference" content="Offer of Information with translations (7 references) (w/references)."><meta name="citation_reference" content="Opponents&#39; Submissions from Apr. 6, 2001 onwards (Binder A, Tabs 5-20)."><meta name="citation_reference" content="Opposition (w/references) (w/translation)."><meta name="citation_reference" content="Opposition by Bayer to Pfizer&#39;s Patent Application No. 121836."><meta name="citation_reference" content="Opposition Statement by Opponent 1: Virus."><meta name="citation_reference" content="Opposition Statement of Bayer AG."><meta name="citation_reference" content="Opposition Statement of Bristol-Myers Squibb."><meta name="citation_reference" content="Opposition Statement of Eisai Co., Ltd."><meta name="citation_reference" content="Opposition Statement of Eli Lilly and Company."><meta name="citation_reference" content="Opposition Statement of Fujisawa."><meta name="citation_reference" content="Opposition Statement of ICOS Corporation."><meta name="citation_reference" content="Opposition Statement of Merck Patent Gmblt."><meta name="citation_reference" content="Opposition Statement of Mochida Pharmaceutical Co."><meta name="citation_reference" content="Opposition Statement of Ortho McNeil Pharmaceutical, Inc."><meta name="citation_reference" content="Opposition Statement of Schering-Plough Corp."><meta name="citation_reference" content="Opposition Statement of Synthelabo."><meta name="citation_reference" content="Opposition Statement of Tanabe Seiyaku Co., Ltd."><meta name="citation_reference" content="Oral Arguments on C.J.J.C. Van Nispen (w/translation)."><meta name="citation_reference" content="Order of Mr. Justice Laddie—Dec. 5, 2000."><meta name="citation_reference" content="Original First Pleadings Regarding Jurisdiction, Admissibility of Certain Claims and Setting Aside Certain Parties."><meta name="citation_reference" content="Original Fourth Pleadings Regarding Jurisdiction and Admissibility of Claims."><meta name="citation_reference" content="Original Second Pleadings Containing Counterclaim for Abuse of Procedure."><meta name="citation_reference" content="Original Third Pleadings Regarding Jurisdiction and Admissibility of Claims."><meta name="citation_reference" content="Original Writ of Summons."><meta name="citation_reference" content="Paediatrics, Andrology, Infertility, Editorial Comment, by Ian Eardley, Department of Urology, Apr. 1993, Leeds General Infirmary, Leeds, UK."><meta name="citation_reference" content="Paediatrics, Andrology, Infertility, Editorial Comment, by Ian Eardley, Department of Urology, Sep. 1993, Norfolk and Norwich Hospital, UK."><meta name="citation_reference" content="Patent in Suit."><meta name="citation_reference" content="Petition for Leave to Appeal."><meta name="citation_reference" content="Petition for Reconsideration Against Resolution No. 358."><meta name="citation_reference" content="Petition of Lilly Icos LLC, for Leave to Cross Appeal."><meta name="citation_reference" content="Petition."><meta name="citation_reference" content="Petitioner&#39;s Civil Evidence Act Notices and attachments."><meta name="citation_reference" content="Petitioner&#39;s Closing Submissions."><meta name="citation_reference" content="Petitioner&#39;s Letter to Respondent (Jul. 4, 2000)."><meta name="citation_reference" content="Petitioner&#39;s Notice of Experiments."><meta name="citation_reference" content="Petitioner&#39;s Opening Submissions for Trial Before Laddie J.—Oct. 4, 2000."><meta name="citation_reference" content="Petitioner&#39;s response to Notice to Admit Facts."><meta name="citation_reference" content="Petition—Feb. 17, 1998."><meta name="citation_reference" content="Pfizer Statement on Salvatore Caruso&#39;s Study (May 21, 2001)."><meta name="citation_reference" content="Pfizer-Exhibits of the Opening Speeches."><meta name="citation_reference" content="Pfizer—Exhibits of the Opening Speeches."><meta name="citation_reference" content="Pfizer&#39;s Combined Response."><meta name="citation_reference" content="Pfizer&#39;s Exhibits Produced During Opening Speeches and Cross-Examination."><meta name="citation_reference" content="Pfizer&#39;s Reply to Statement of Argument (w/attachments)."><meta name="citation_reference" content="Pfizer&#39;s Response to Bayer&#39;s Reply to the Application to Amend the Claims (w/translation)."><meta name="citation_reference" content="Pfizer&#39;s Skeleton Argument."><meta name="citation_reference" content="Pharmac. Ther. vol. 51, pp-13-31, 1991; by W. Joseph Thompson."><meta name="citation_reference" content="Pharmacological Reviews 43(2) (1991) pp. 109-142, Moncada et al."><meta name="citation_reference" content="Physicians&#39; Desk Reference, 46th edition, 1992, p. 409, 905, 1190."><meta name="citation_reference" content="Physiol. Rev 75(4), 725-748, 1995, Beavo J. A., “Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms”."><meta name="citation_reference" content="Pilot Study on the Effectiveness of Viagra for Treatment of Female Sexual Dysfunction: Physiologic Predictor for Success (2000), Chai et al."><meta name="citation_reference" content="Pleading Notes of Mr. L. Oosting (w/translation)."><meta name="citation_reference" content="Podium 18, “Alpha Blockade and Vaginal Blood Flow Response in Postmenopausal Women with Female Sexual Arousal Disorder” by Rubio et al. pp. 55 (2000)."><meta name="citation_reference" content="Porst, J Urol (1993) 149, 1280-1283."><meta name="citation_reference" content="Positive Effects of Sildenafil in Female Sexual Dysfunction Following Hysterectomy (2000)."><meta name="citation_reference" content="Post Graduate Medicine 88(2) (1990) 139-152, Whitehead, et al."><meta name="citation_reference" content="Post Graduate Medicine, vol. 88(2), 139-152, 1990 Whithead E. D. “Treatment alternatives for impotence”."><meta name="citation_reference" content="Postgraduate Medicine, vol. 93, No. 3, Impotence, Feb. 15, 1993, Morley."><meta name="citation_reference" content="Premenopausal Health Care, 20 (2), Jun. 1993 by Gloria A. Bachman, MD."><meta name="citation_reference" content="Priority Document."><meta name="citation_reference" content="Proceedings of the American Urological Association, vol. 155, May 1996, Supplement 623A."><meta name="citation_reference" content="Progress with Viagra for FSD (Scrip daily News) Mar. 15, 2000."><meta name="citation_reference" content="Proprietor&#39;s Submissions from May 16, 2001 onwards (Binder A, Tabs 1-4)."><meta name="citation_reference" content="Psychiatric Services; Aug. 1999; 50(8):1076-1078."><meta name="citation_reference" content="Psychosomatic Medicine, vol. 38, No. 6 (Nov.-Dec. 1976) pp. 418-425 by Leon A. Abramov."><meta name="citation_reference" content="Pyrazolopyrimidinones for the Treatment of Impotence (submitted by Opponent II, ICOS Corp.)."><meta name="citation_reference" content="Radiology 2000, 214(2):611."><meta name="citation_reference" content="Rajfer, Jacob, et al., New England Journal of Medicine, 326, 2, 90-94 (1992)."><meta name="citation_reference" content="Re-amended Particulars of Objections."><meta name="citation_reference" content="Reason for Revocation."><meta name="citation_reference" content="Rebuttal Brief by Appellant."><meta name="citation_reference" content="Rebuttal Brief by Plaintiff."><meta name="citation_reference" content="References Filed wit the EPO: D 1-D85 (2 binders)."><meta name="citation_reference" content="Reissue of Summons (Dec. 4, 2000)."><meta name="citation_reference" content="Reply to Opposition Dec. 7, 1999."><meta name="citation_reference" content="Report of Repeat Experments the subject of the Repsondent&#39;s Notice of Experiments dated Aug. 11, 2000 (w/Appendixes)."><meta name="citation_reference" content="Reports of Repeats of the Petitioner&#39;s Notice of Experiments 1-4."><meta name="citation_reference" content="Request for Correction—Feb. 19, 2001."><meta name="citation_reference" content="Request for Invalidation."><meta name="citation_reference" content="Resolution No. 00112 dated Jan. 18, 2000."><meta name="citation_reference" content="Respondent&#39;s Notice in the Court of Appeal."><meta name="citation_reference" content="Respondent&#39;s Notice of Experiments."><meta name="citation_reference" content="Respondent&#39;s Response to Notice to Admit Facts."><meta name="citation_reference" content="Respondent&#39;s Skeleton Argument."><meta name="citation_reference" content="Response to Opposition Preliminary Opinion by Patent Office (w/attachments) (May 16, 2001)."><meta name="citation_reference" content="Response to Reasons for Revocation."><meta name="citation_reference" content="Response to the Non-Compliance Action."><meta name="citation_reference" content="Response to the Notice of Acceptance of Request for Invalidation of the Above Patent Issued by the Patent Reexamination Board."><meta name="citation_reference" content="Response to the Request for Adjournment (w/translation)."><meta name="citation_reference" content="Response."><meta name="citation_reference" content="Rote Liste 1992 (Persantin®, INN: Dipyridamole and Trental®, INN: Pentoxifylline), ECV."><meta name="citation_reference" content="Ruling of Dutch Court: Nov. 11, 1999 (w/translation)."><meta name="citation_reference" content="Science, vol. 257, Jul. 17, 1992, pp. 401-403—Burnett et al."><meta name="citation_reference" content="SCRIP Daily News (Apr. 25, 2000)."><meta name="citation_reference" content="SCRIP No. 2369 Sep. 11th 1998 p 22."><meta name="citation_reference" content="Scrip&#39;s Complete Guide to Women&#39;s Health Care, 2000, Chapters 1-8."><meta name="citation_reference" content="Scrip&#39;s Complete Guide to Women&#39;s Healthcare: Female Sexual Dysfunction (Chapter 7) (2000)."><meta name="citation_reference" content="Second Declaration by Dr. Kenneth Murray Dated Apr. 9, 2001."><meta name="citation_reference" content="Second Expert Report of Robert Gristwood (w/Annexes)."><meta name="citation_reference" content="Second Witness Statement of Dr. Javier Angulo."><meta name="citation_reference" content="Second Witness Statement of Dr. Margaret Bush."><meta name="citation_reference" content="Second Witness Statement of Mark Thomas Hodgson (w/Exhibits)."><meta name="citation_reference" content="Second Witness Statement of Trevor Martin Cook (w/Exhibits)."><meta name="citation_reference" content="Sixth Witness Statement of Trevor Martin Cook."><meta name="citation_reference" content="Skeleton for the Hearing on Oral Arguments on Jul. 7, 2000 (w/translation)."><meta name="citation_reference" content="Slides."><meta name="citation_reference" content="Statement Containing Submission of Exhibits (w/translation) with Exhibits."><meta name="citation_reference" content="Statement of Claims with Exhibits (w/translation)."><meta name="citation_reference" content="Statement of Defense by Pfzer in the District Court of the Hague."><meta name="citation_reference" content="Statement of Defense, also Containing A Request for Suspension (w/translation)."><meta name="citation_reference" content="Statement of the Patentee&#39;s Case on Claims 10 and 11."><meta name="citation_reference" content="Statement of Villouta."><meta name="citation_reference" content="Submission to EPO dated Dec. 21, 2000."><meta name="citation_reference" content="Submissions to the EPO (S 14-15; S 17; S 19; S 20; S 35-36; S47-52)."><meta name="citation_reference" content="Summary of Interview—Feb. 19, 2000."><meta name="citation_reference" content="Summary of KIPO Answer."><meta name="citation_reference" content="Supplementary Expert Report of Kenneth Duncan Macrae (w/Annexes)."><meta name="citation_reference" content="Sutherland, J Biol Chem, 1958, 32: 1077-1091."><meta name="citation_reference" content="Tanaka et al, 1992, Xenobiotica, vol. 22, pp 57-64."><meta name="citation_reference" content="Technical Primer from the High Court Proceedings."><meta name="citation_reference" content="The Berman Sisters, Pioneers in the Study of Women&#39;s Sexual Dysfunction (LA Times) (Feb. 12, 2001)."><meta name="citation_reference" content="The Intellectual Property Tribunal 13th Panel—Trial Decision."><meta name="citation_reference" content="The Journal of Pharmacology and Experimental Therapeutics, 251(3), pp. 1000-1005 (1989), McMahon et al."><meta name="citation_reference" content="The Journal of Reproductive Medicine, 44(6) 535-542 (Jun. 1999)."><meta name="citation_reference" content="The Journal of Urology (Apr. 1997), vol. 157, No. 4, Suppl. 1, and p. 204."><meta name="citation_reference" content="The Journal of Urology (May 1996), vol. 155, No. 5, AUA Ninety-First Annual Meeting, 495A, 676A."><meta name="citation_reference" content="The Journal of Urology, 1989, vol. 141 pp. 546-548 by Owen et al."><meta name="citation_reference" content="The Journal of Urology, vol. 151, No. 5, p. 495A, 1994."><meta name="citation_reference" content="The Orgasm Pill: Are You Ready for It? By Erin Kelly, Cosmopolitan."><meta name="citation_reference" content="The Second Sexual Revolution by Jack Hitt, NY Times Magazine, (Feb. 20, 2000)."><meta name="citation_reference" content="Thesis Statement of Margaret Ann Bush, PhD."><meta name="citation_reference" content="Third Declaration of Stephen A. Ballard (in the USPTO)."><meta name="citation_reference" content="Third Expert Report of Robert Gristwood."><meta name="citation_reference" content="Third Witness Statement of Mark Thomas Hodgson (w/Exhibits)."><meta name="citation_reference" content="Third Witness Statement of Trevor Martin Cook (w/Exhibits)."><meta name="citation_reference" content="Title Page of the Braunwald Publication (w/excerpt translated)."><meta name="citation_reference" content="Tohoku J. Exp. Med. by Yoshlastu Takahashi et al., published in 1991, 165-49-58."><meta name="citation_reference" content="Torphy et al, Journal Pharmacol Exper Ther, 1993, 265: 1213-1223."><meta name="citation_reference" content="Trail Transcripts-Dec. 17-19, 2000."><meta name="citation_reference" content="Trail Transcripts—Dec. 17-19, 2000."><meta name="citation_reference" content="Transcript of Hearing on Jul. 19, 2000."><meta name="citation_reference" content="Transcript of Hearing on Jun. 22, 2000."><meta name="citation_reference" content="Transcript of Hearing on May 17, 2000."><meta name="citation_reference" content="Transcript of Hearing on May 26, 2000."><meta name="citation_reference" content="Transcript of Ian Eardley Examined by Mr. Kitchell w/attachments."><meta name="citation_reference" content="Transcript of Ian Eardley with Attachments."><meta name="citation_reference" content="Transcript of Proceedings from Day Five: Dec. 17, 2001."><meta name="citation_reference" content="Transcript of Proceedings from Day Four: Dec. 14, 2001."><meta name="citation_reference" content="Transcript of Proceedings from Day One: Dec. 11, 2001."><meta name="citation_reference" content="Transcript of Proceedings from Day Three: Dec. 13, 2001."><meta name="citation_reference" content="Transcript of Proceedings from Day Two: Dec. 12, 2001."><meta name="citation_reference" content="Translation of Tab 10 from Binder A."><meta name="citation_reference" content="Translation of Tab 17 from Binder A."><meta name="citation_reference" content="Translation of the Petition Filed on Feb. 17, 1998."><meta name="citation_reference" content="Trends in Pharmacological Sciences including Toxicological Sciences, 11, No. 4, pp 150-155 (1990, Apr.), Bearo et al."><meta name="citation_reference" content="Trends Pharmacol. Sci. (TiPS), vol. 12, pp. 19 to 27 (1991), Nicholson et al, Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes."><meta name="citation_reference" content="Trial Transcript-Oct. 10, 2000."><meta name="citation_reference" content="Trial Transcript—Oct. 10, 2000."><meta name="citation_reference" content="Trial Transcript-Oct. 11, 2000."><meta name="citation_reference" content="Trial Transcript—Oct. 11, 2000."><meta name="citation_reference" content="Trial Transcript-Oct. 12, 2000."><meta name="citation_reference" content="Trial Transcript—Oct. 12, 2000."><meta name="citation_reference" content="Trial Transcript-Oct. 13, 2000."><meta name="citation_reference" content="Trial Transcript—Oct. 13, 2000."><meta name="citation_reference" content="Trial Transcript-Oct. 17, 2000."><meta name="citation_reference" content="Trial Transcript—Oct. 17, 2000."><meta name="citation_reference" content="Trial Transcript-Oct. 18, 2000."><meta name="citation_reference" content="Trial Transcript—Oct. 18, 2000."><meta name="citation_reference" content="Trial Transcript-Oct. 4, 2000."><meta name="citation_reference" content="Trial Transcript—Oct. 4, 2000."><meta name="citation_reference" content="Trial Transcript-Oct. 5, 2000."><meta name="citation_reference" content="Trial Transcript—Oct. 5, 2000."><meta name="citation_reference" content="Trial Transcript-Oct. 6, 2000."><meta name="citation_reference" content="Trial Transcript—Oct. 6, 2000."><meta name="citation_reference" content="Trial Transcripts-Nov. 26-30, 2000."><meta name="citation_reference" content="Trial Transcripts—Nov. 26-30, 2000."><meta name="citation_reference" content="Trigo-Rocha, Flavio, et al., Am. Physiological Society, 264, H419-H422 (1993)."><meta name="citation_reference" content="UK Appeal Judgment."><meta name="citation_reference" content="UK Confidentiality Appeal Judgment."><meta name="citation_reference" content="Urology 1999; 53 (3): 481-486, Kaplan et al."><meta name="citation_reference" content="Urology 54 (1999): 385-391 by Berman et al."><meta name="citation_reference" content="Urology 55(6) 812-815 (2000), Sipski et al."><meta name="citation_reference" content="Vaginal Sildenafil: A Preliminary Report of a Novel Method to Improve Uterine Artery Blood Flow and Endometrial Development in Patients Undergoing in Vitro Fertilization, Sher et al."><meta name="citation_reference" content="Viagra Doesn&#39;t Work in Women (SCRIP No. 2419, Mar. 12th 1999, p 23)."><meta name="citation_reference" content="Viagra Fails in Female Study ( Scrip Daily News) (May 31, 2000)."><meta name="citation_reference" content="Viagra Fails Test to Help Women by Phil Galewitz, AP Business Writer."><meta name="citation_reference" content="Viagra Priapism ( SCRIP No. 2387 Nov. 13th 1998 p 12)."><meta name="citation_reference" content="Voluntary Further Information concerning para 2(I) and 2(IV)."><meta name="citation_reference" content="von Koenen: “Heil-und Giftpflanzen in Südwestafrika”, Akademischer Verlag Windhoek, S.W.A., 1979, p. 61."><meta name="citation_reference" content="W. Meinhardt et al., International Journal of Impotence Research, 1997, vol. 9, pp. 17-26."><meta name="citation_reference" content="Why Viagra Doesn&#39;t Work for Women by James Le Fanu, The Daily Telegraph."><meta name="citation_reference" content="Witness Statement of Dr. Francois Hyafil (w/Annexes)."><meta name="citation_reference" content="Witness Statement of Dr. Javier Angulo (w/Annexes)."><meta name="citation_reference" content="Witness Statement of Dr. Stephen Ballard."><meta name="citation_reference" content="Witness Statement of Julianna Jenkins (part of “BQ”)."><meta name="citation_reference" content="Witness Statement of Julianna Jenkins (w/Annexes)."><meta name="citation_reference" content="Witness Statement of Kate Loughney (w/Annexes)."><meta name="citation_reference" content="Witness Statement of Lothar Uher (w/Annexes)."><meta name="citation_reference" content="Witness Statement of Margaret Bush (part of “BQ”)."><meta name="citation_reference" content="Witness Statement of Margaret Bush (w/Annexes)."><meta name="citation_reference" content="Witness Statement of Martyn Burslem."><meta name="citation_reference" content="Witness Statement of Michael J. Allen (from Chinese Prosecution)."><meta name="citation_reference" content="Witness Statement of Mitradev Boolell (from Chinese Prosecution)."><meta name="citation_reference" content="Witness Statement of Nicholas Kenneth Terrett (co-inventor) (from Chinese Prosecution)."><meta name="citation_reference" content="Witness Statement of Peter Ellis (w/Annex)."><meta name="citation_reference" content="Witness Statement of Peter Ellis."><meta name="citation_reference" content="Witness Statement of Sharon Wolda (w/Annexes)."><meta name="citation_reference" content="Women are Eager to Participate in the Viagra Revolution by Lan N. Nguyen."><meta name="citation_reference" content="Women Could Get Viagra in 3 Years by Helen Rumbelow, The Times, Oct. 27, 1999."><meta name="citation_reference" content="World Foundation for Medical Studies in Female Health, (1999), Abstract Status Report, Nos. 7214, 7215."><meta name="citation_reference" content="WPIDS abstract, AN 95-051606 [07], Coates et al., WO 9429277 (1994).*"><meta name="citation_reference" content="Writ of Summons in Accelerated Proceedings on the Merits (w/translation)."><meta name="citation_reference" content="Written Decision to Revoke Patent by EPO (Oct. 11, 2001) (Adverse EPO decision)."><meta name="citation_reference" content="Written Submissions/Presentations Made During the Hearing from Jul. 16-18, 2001 (Binder A, Tabs 21-26)."><meta name="citation_reference" content="Y.-M. Lin et al., Urol. Res, 1990, vol. 24, pp. 27-32."><meta name="citation_patent_number" content="US:6469012"><meta name="citation_patent_application_number" content="US:08/549,792"><link rel="canonical" href="http://www.google.com/patents/US6469012"/><meta property="og:url" content="http://www.google.com/patents/US6469012"/><meta name="title" content="Patent US6469012 - Pyrazolopyrimidinones for the treatment of impotence"/><meta name="description" content="The use of a compound of formula (I) wherein R1 is H; C1-C3 alkyl; C1-C3 perfluoroalkyl; or C3-C5 cycloalkyl; R2 is H; optionally substituted C1-C6 alkyl; C1-C3 perfluoroalkyl; or C3-C6 cycloalkyl; R3 is optionally substituted C1-C6 alkyl; C1-C6 perfluoroalkyl; C3-C5 cycloalkyl; C3-C6 alkenyl; or C3-C6 alkynyl; R4 is optionally substituted C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkanoyl, (hydroxy)C2-C4 alkyl or (C2-C3 alkoxy)C1-C2 alkyl; CONR5R6; CO2R7; halo; NR5R6; NHSO2NR5R6; NHSO2R8; SO2NR9R10; or phenyl, pyridyl, pyrimidinyl, imidazolyl, oxazolyl, thiazolyl, thienyl or triazolyl any of which is optionally substituted with methyl; R5 and R6 are each independently H or C1-C4 alkyl, or together with the nitrogen atom to which they are attached form an optionally substituted pyrrolidinyl, piperidino, morpholino, 4-N(R11)-piperazinyl or imidazolyl group; R7 is H or C1-C4 alkyl; R 8 is optionally substituted C1-C3 alkyl; R9 and R10 together with the nitrogen atom to which they are attached form an optionally substituted pyrrolidinyl, piperidino, morpholino or 4-N(R12)-piperazinyl group; R11 is H; optionally substituted C1-C3 alkyl; (hydroxy)C2-C3 alkyl; or C1-C4 alkanoyl; R12 is H; optionally substituted C1-C6 alkyl; CONR13R14; CSNR13R14; or C(NH)NR13R14; and R?13? and R14 are each independently H; C1-C4 alkyl; or substituted C2-C4 alkyl; or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity, for the manufacture of a medicament for the curative or prophylactic treatment of erectile dysfunction in a male animal, including man; a pharmaceutical composition for said treatment; and a method of said treatment of said male animal with said pharmaceutical composition or with said either entity."/><meta property="og:title" content="Patent US6469012 - Pyrazolopyrimidinones for the treatment of impotence"/><meta property="og:type" content="book"/><meta property="og:site_name" content="Google Books"/><meta property="og:image" content="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><link rel="image_src" href="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><script>(function(){try{var aa=function(a,b,c,d){d=d||{};d._sn=["cfg",b,c].join(".");window.gbar.logger.ml(a,d)};var g=window.gbar=window.gbar||{},l=window.gbar.i=window.gbar.i||{},m={},n;function _tvn(a,b){var c=parseInt(a,10);return isNaN(c)?b:c}function _tvf(a,b){var c=parseFloat(a);return isNaN(c)?b:c}function _tvv(a){return!!a}function p(a,b,c){(c||g)[a]=b}g.bv={n:_tvn("2",0),r:"",f:".67.",e:"0",m:_tvn("0",1)};
function q(a,b,c){var d="on"+b;if(a.addEventListener)a.addEventListener(b,c,!1);else if(a.attachEvent)a.attachEvent(d,c);else{var f=a[d];a[d]=function(){var a=f.apply(this,arguments),b=c.apply(this,arguments);return void 0==a?b:void 0==b?a:b&&a}}}var s=function(a){return function(){return g.bv.m==a}},ba=s(1),ca=s(2);p("sb",ba);p("kn",ca);l.a=_tvv;l.b=_tvf;l.c=_tvn;l.i=aa;var da=window.gbar.i.i;var t,u,v,w;function ea(a){v=a}function fa(a){var b;if(b=v&&window.encodeURIComponent)b=a.href,b=!b.match(/^http[s]?:\/\/accounts\.google\.[^/]*\/ClearSID/i)&&!b.match(/^http[s]?:\/\/[^/]*\/accounts\/ClearSID/i);if(b=b&&encodeURIComponent(v()))a.href=a.href.replace(/([?&]continue=)[^&]*/,"$1"+b)}function ga(a){window.gApplication&&(a.href=window.gApplication.getTabUrl(a.href))}
function ha(a){var b=document.forms[0].q,c=window.encodeURIComponent&&b&&b.value,b=b&&b.placeholder;c&&c!=b&&(a.href=a.href.replace(/([?&])q=[^&]*|$/,function(a,b){return(b||"&")+"q="+encodeURIComponent(c)}))}n=l.a("")?ga:ha;
function x(a,b,c,d,f,e){var h=document.getElementById(a);if(h){var k=h.style;k.left=d?"auto":b+"px";k.right=d?b+"px":"auto";k.top=c+"px";k.visibility=u?"hidden":"visible";f&&e?(k.width=f+"px",k.height=e+"px"):(x(t,b,c,d,h.offsetWidth,h.offsetHeight),u=u?"":a)}}
var y=[],ia=function(a,b){y.push(b)},ja=function(a){a=a||window.event;var b=a.target||a.srcElement;a.cancelBubble=!0;null==t&&(a=document.createElement(Array.every||window.createPopup?"iframe":"div"),a.frameBorder="0",t=a.id="gbs",a.src="javascript:''",b.parentNode.appendChild(a),q(document,"click",z));var c=b,b=0;"gb3"!=c.className&&(c=c.parentNode);a=c.getAttribute("aria-owns")||"gbi";var d=c.offsetWidth,f=20<c.offsetTop?46:24;document.getElementById("tphdr")&&(f-=3);var e=!1;do b+=c.offsetLeft||
0;while(c=c.offsetParent);var c=(document.documentElement.clientWidth||document.body.clientWidth)-b-d,h,d=document.body,k=document.defaultView;k&&k.getComputedStyle?(d=k.getComputedStyle(d,""))&&(h=d.direction):h=d.currentStyle?d.currentStyle.direction:d.style.direction;h="rtl"==h;if("gbi"==a){for(d=0;k=y[d++];)k();A(null,window.navExtra);h&&(b=c,e=!0)}else h||(b=c,e=!0);u!=a&&z();x(a,b,f,e)},z=function(){u&&x(u,0,0)},A=function(a,b){var c,d=document.getElementById("gbi"),f=a;f||(f=d.firstChild);
for(;b&&(c=b.pop());){var e=d,h=c,k=f;w||(w="gb2");e.insertBefore(h,k).className=w}},ka=function(a,b,c){if((b=document.getElementById(b))&&a){a.className="gb4";var d=document.createElement("span");d.appendChild(a);d.appendChild(document.createTextNode(" | "));d.id=c;b.appendChild(d)}},la=function(){return document.getElementById("gb_70")},ma=function(){return!!u};p("qs",n);p("setContinueCb",ea);p("pc",fa);p("tg",ja);p("close",z);p("addLink",ka);p("almm",A);p("si",la);p("adh",ia);p("op",ma);var B=function(){},C=function(){},F=function(a){var b=new Image,c=D;b.onerror=b.onload=b.onabort=function(){try{delete E[c]}catch(a){}};E[c]=b;b.src=a;D=c+1},E=[],D=0;p("logger",{il:C,ml:B,log:F});var G=window.gbar.logger;var H={},na={},I=[],oa=l.b("0.1",.1),pa=l.a("1",!0),qa=function(a,b){I.push([a,b])},ra=function(a,b){H[a]=b},sa=function(a){return a in H},J={},K=function(a,b){J[a]||(J[a]=[]);J[a].push(b)},ta=function(a){K("m",a)},L=function(a,b){var c=document.createElement("script");c.src=a;c.async=pa;Math.random()<oa&&(c.onerror=function(){c.onerror=null;B(Error("Bundle load failed: name="+(b||"UNK")+" url="+a))});(document.getElementById("xjsc")||document.getElementsByTagName("body")[0]||
document.getElementsByTagName("head")[0]).appendChild(c)},N=function(a){for(var b=0,c;(c=I[b])&&c[0]!=a;++b);!c||c[1].l||c[1].s||(c[1].s=!0,M(2,a),c[1].url&&L(c[1].url,a),c[1].libs&&m.d&&m.d(c[1].libs))},O=function(a){K("gc",a)},P=null,ua=function(a){P=a},M=function(a,b,c){if(P){a={t:a,b:b};if(c)for(var d in c)a[d]=c[d];try{P(a)}catch(f){}}};p("mdc",H);p("mdi",na);p("bnc",I);p("qGC",O);p("qm",ta);p("qd",J);p("lb",N);p("mcf",ra);p("bcf",qa);p("aq",K);p("mdd","");p("has",sa);
p("trh",ua);p("tev",M);var Q=l.b("0.1",.001),R=0;
function _mlToken(a,b){try{if(1>R){R++;var c,d=a,f=b||{},e=encodeURIComponent,h=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&jexpid=",e("17483"),"&srcpg=",e("prop=22"),"&jsr=",Math.round(1/Q),"&ogev=",e("u5btU66jJcS9sASYhYKACg"),"&ogf=",g.bv.f,"&ogrp=",e("1"),"&ogv=",e("1407723702.0"),"&oggv="+e("es_plusone_gc_20140723.0_p0"),"&ogd=",e("com"),"&ogc=",e("ITA"),"&ogl=",e("en")];f._sn&&(f._sn="og."+
f._sn);for(var k in f)h.push("&"),h.push(e(k)),h.push("="),h.push(e(f[k]));h.push("&emsg=");h.push(e(d.name+":"+d.message));var r=h.join("");S(r)&&(r=r.substr(0,2E3));c=r;var Aa=window.gbar.logger._aem(a,c);F(Aa)}}catch(Na){}}var S=function(a){return 2E3<=a.length},va=function(a,b){return b};function T(a){B=a;p("_itl",S,G);p("_aem",va,G);p("ml",B,G);a={};H.er=a}l.a("")?T(function(a){throw a;}):l.a("1")&&Math.random()<Q&&T(_mlToken);I.push(["m",{url:"//ssl.gstatic.com/gb/js/scm_7385cc5883250b43a39405734c1bea59.js"}]);g.mcf("c",{});g.sg={c:""};if(l.a("1")){var wa=l.a("");I.push(["gc",{auto:wa,url:"//ssl.gstatic.com/gb/js/abc/gci_91f30755d6a6b787dcc2a4062e6e9824.js",libs:"googleapis.client:plusone:gapi.iframes"}]);var xa={version:"gci_91f30755d6a6b787dcc2a4062e6e9824.js",index:"",lang:"en"};H.gc=xa;var U=function(a){window.googleapis&&window.iframes?a&&a():(a&&O(a),N("gc"))};p("lGC",U);l.a("1")&&p("lPWF",U)};window.__PVT="";if(l.a("1")&&l.a("1")){var V=function(a){U(function(){K("pw",a);N("pw")})};p("lPW",V);I.push(["pw",{url:"//ssl.gstatic.com/gb/js/abc/pwm_45f73e4df07a0e388b0fa1f3d30e7280.js"}]);var W=[],ya=function(a){W[0]=a},za=function(a,b){var c=b||{};c._sn="pw";B(a,c)},Ba={signed:W,elog:za,base:"https://plusone.google.com/u/0",loadTime:(new Date).getTime()};H.pw=Ba;var X=function(a,b){for(var c=b.split("."),d=function(){var b=arguments;a(function(){for(var a=g,d=0,e=c.length-1;d<e;++d)a=a[c[d]];a[c[d]].apply(a,b)})},f=g,e=0,h=c.length-1;e<h;++e)f=
f[c[e]]=f[c[e]]||{};return f[c[e]]=d};X(V,"pw.clk");X(V,"pw.hvr");p("su",ya,g.pw)};function Ca(){function a(){for(var b;(b=e[h++])&&"m"!=b[0]&&!b[1].auto;);b&&(M(2,b[0]),b[1].url&&L(b[1].url,b[0]),b[1].libs&&m.d&&m.d(b[1].libs));h<e.length&&setTimeout(a,0)}function b(){0<f--?setTimeout(b,0):a()}var c=l.a("1"),d=l.a(""),f=3,e=I,h=0,k=window.gbarOnReady;if(k)try{k()}catch(r){da(r,"ml","or")}d?p("ldb",a):c?q(window,"load",b):b()}p("rdl",Ca);var Da={D:1,H:2,da:3,p:4,W:5,M:6,F:7,g:8,ha:9,U:10,L:11,T:12,S:13,N:14,Q:15,P:16,fa:17,w:18,O:19,ga:20,ea:21,u:22,G:23,ja:24,ka:25,ia:26,A:27,j:28,o:29,k:30,ca:31,Z:32,$:33,J:34,K:35,ba:36,aa:37,Y:38,B:39,R:40,v:41,X:42,V:43,h:48,C:49,I:500},Y=[1,2,3,4,5,6,9,10,11,13,14,28,29,30,34,35,37,38,39,40,41,42,43,48,49,500];var Z=l.b("0.001",1E-4),Ea=l.b("1",1),Fa=!1,Ga=!1;if(l.a("1")){var Ha=Math.random();Ha<=Z&&(Fa=!0);Ha<=Ea&&(Ga=!0)}var Ia=Da,$=null;function Ja(){var a=0,b=function(b,d){l.a(d)&&(a|=b)};b(1,"");b(2,"");b(4,"");b(8,"");return a}
function Ka(a,b){var c=Z,d=Fa,f;f=a;if(!$){$={};for(var e=0;e<Y.length;e++){var h=Y[e];$[h]=!0}}if(f=!!$[f])c=Ea,d=Ga;if(d){d=encodeURIComponent;g.rp?(f=g.rp(),f="-1"!=f?f:"1"):f="1";c=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&oge=",a,"&ogex=",d("17483"),"&ogev=",d("u5btU66jJcS9sASYhYKACg"),"&ogf=",g.bv.f,"&ogp=",d("22"),"&ogrp=",d(f),"&ogsr=",Math.round(1/c),"&ogv=",d("1407723702.0"),"&oggv="+
d("es_plusone_gc_20140723.0_p0"),"&ogd=",d("com"),"&ogl=",d("en"),"&ogc=",d("ITA"),"&ogus=",Ja()];if(b){"ogw"in b&&(c.push("&ogw="+b.ogw),delete b.ogw);var k;f=b;e=[];for(k in f)0!=e.length&&e.push(","),e.push(La(k)),e.push("."),e.push(La(f[k]));k=e.join("");""!=k&&(c.push("&ogad="),c.push(d(k)))}F(c.join(""))}}function La(a){"number"==typeof a&&(a+="");return"string"==typeof a?a.replace(".","%2E").replace(",","%2C"):a}C=Ka;p("il",C,G);var Ma={};H.il=Ma;setTimeout(function(){C(Ia.g)},0);}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var b=window.gbar.i.i;var c=window.gbar;var f=function(d){try{var a=document.getElementById("gbom");a&&d.appendChild(a.cloneNode(!0))}catch(e){b(e,"omas","aomc")}};c.aomc=f;}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var a=window.gbar;a.mcf("pm",{p:""});}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{window.gbar.rdl();}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
if (window['_OC_timingAction']) {window['_OC_timingAction']('patents_refpage');}</script><style>#gbar,#guser{font-size:13px;padding-top:1px !important;}#gbar{float:left;height:22px}#guser{padding-bottom:7px !important;text-align:right}.gbh,.gbd{border-top:1px solid #c9d7f1;font-size:1px}.gbh{height:0;position:absolute;top:24px;width:100%}#gbs,.gbm{background:#fff;left:0;position:absolute;text-align:left;visibility:hidden;z-index:1000}.gbm{border:1px solid;border-color:#c9d7f1 #36c #36c #a2bae7;z-index:1001}.gb1{margin-right:.5em}.gb1,.gb3{zoom:1}.gb2{display:block;padding:.2em .5em}.gb2,.gb3{text-decoration:none !important;border-bottom:none}a.gb1,a.gb4{text-decoration:underline !important}a.gb1,a.gb2,a.gb3,a.gb4{color:#00c !important}.gbi .gb3,.gbi .gb2,.gbi .gb4{color:#dd8e27 !important}.gbf .gb3,.gbf .gb2,.gbf .gb4{color:#900 !important}a.gb2:hover{background:#36c;color:#fff !important}#gbar .gbz0l{color:#000 !important;cursor:default;font-weight:bold;text-decoration:none !important}
#gbar { padding:.3em .6em !important;}</style></head><body  topmargin="3" marginheight="3"><div id=gbar><nobr><a onclick=gbar.qs(this);gbar.logger.il(1,{t:1}); class=gb1 id=gb_1 href="https://www.google.com/search?sa=N&tab=tw">Search</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:2}); class=gb1 id=gb_2 href="http://www.google.com/search?hl=en&tbm=isch&source=og&sa=N&tab=ti">Images</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:8}); class=gb1 id=gb_8 href="http://maps.google.com/maps?hl=en&sa=N&tab=tl">Maps</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:78}); class=gb1 id=gb_78 href="https://play.google.com/?hl=en&sa=N&tab=t8">Play</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:36}); class=gb1 id=gb_36 href="http://www.youtube.com/results?sa=N&tab=t1">YouTube</a> <a onclick=gbar.logger.il(1,{t:5}); class=gb1 id=gb_5 href="http://news.google.com/nwshp?hl=en&tab=tn">News</a> <a onclick=gbar.logger.il(1,{t:23}); class=gb1 id=gb_23 href="https://mail.google.com/mail/?tab=tm">Gmail</a> <a onclick=gbar.logger.il(1,{t:25}); class=gb1 id=gb_25 href="https://drive.google.com/?tab=to">Drive</a> <a class=gb3 href="http://www.google.com/intl/en/options/" onclick="this.blur();gbar.tg(event);return !1" aria-haspopup=true><u>More</u> <small>&#9660;</small></a><div class=gbm id=gbi><a onclick=gbar.logger.il(1,{t:24}); class=gb2 id=gb_24 href="https://www.google.com/calendar?tab=tc">Calendar</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:51}); class=gb2 id=gb_51 href="http://translate.google.com/?hl=en&sa=N&tab=tT">Translate</a><a onclick=gbar.logger.il(1,{t:17}); class=gb2 id=gb_17 href="http://www.google.com/mobile/?hl=en&tab=tD">Mobile</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:10}); class=gb2 id=gb_10 href="http://www.google.com/search?hl=en&tbo=u&tbm=bks&source=og&sa=N&tab=tp">Books</a><a onclick=gbar.logger.il(1,{t:212}); class=gb2 id=gb_212 href="https://wallet.google.com/manage/?tab=ta">Wallet</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:6}); class=gb2 id=gb_6 href="http://www.google.com/search?hl=en&tbo=u&tbm=shop&source=og&sa=N&tab=tf">Shopping</a><a onclick=gbar.logger.il(1,{t:30}); class=gb2 id=gb_30 href="http://www.blogger.com/?tab=tj">Blogger</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:27}); class=gb2 id=gb_27 href="http://www.google.com/finance?sa=N&tab=te">Finance</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:31}); class=gb2 id=gb_31 href="https://plus.google.com/photos?sa=N&tab=tq">Photos</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:12}); class=gb2 id=gb_12 href="http://www.google.com/search?hl=en&tbo=u&tbm=vid&source=og&sa=N&tab=tv">Videos</a><div class=gb2><div class=gbd></div></div><a onclick=gbar.logger.il(1,{t:66}); href="http://www.google.com/intl/en/options/" class=gb2>Even more &raquo;</a></div></nobr></div><div id=guser width=100%><nobr><span id=gbn class=gbi></span><span id=gbf class=gbf></span><span id=gbe></span><a target=_top id=gb_70 href="https://www.google.com/accounts/Login?service=&continue=http://www.google.com/patents%3Fhl%3Den&hl=en" class=gb4>Sign in</a><div style="display: none"><div class=gbm id=gbd5 aria-owner=gbg5><div class=gbmc><ol id=gbom class=gbmcc></ol></div></div></div></nobr></div><div class=gbh style=left:0></div><div class=gbh style=right:0></div><div role="alert" style="position: absolute; left: 0; right: 0;"><a href="http://www.google.com/patents/us6469012?hl=en&amp;output=html_text" title="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."><img border="0" src="http://www.google.com/images/cleardot.gif"alt="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."></a></div><div id="guser"><nobr></nobr></div><div style="clear:both;"></div><div id="gb-top-search-box" class="gb-top-search-box-small gb-reset"><table><tr><td class="logo"><a href="http://www.google.com/patents" class="logo-link"><img class="logo-img" src="/intl/en/images/logos/google_logo_41.png" alt="Go to Google Books Home" height="41"/></a></td><td><form action="http://www.google.com/search" name="f" id="vheadf" method="get"><span id="hf"></span><input type="hidden" name="tbm" value="pts"/><input type="hidden" name="tbo" value="1"/><input type="hidden" name="hl" value="en"/><table><tr><td><div class="inputs"><table><tr><td><div class="text-input"><input type="text" name="q" id="vheadq" class="text" maxlength="2048" size="31" value="" title="Search Patents" accesskey="s" autocomplete="off"/><script>window._OC_autoDir &&window._OC_autoDir('vheadq', 'tia-vheadq');</script></div></td><td><div class="submit-input"><input name="btnG" class="submit" type="submit" value=""/></div></td></tr></table></div></td><td class="col-ext-links"><div class="ext-links"><a href="http://www.google.com/advanced_patent_search">&lt;nobr&gt;Advanced Patent Search&lt;/nobr&gt;</a></div></td></tr></table></form></td></tr></table></div><div class="kd-appbar"><h2 class="kd-appname"><a href="/patents">Patents</a></h2><div class="kd-buttonbar left" id="left-toolbar-buttons"><a id="appbar-write-review-link" href=""></a><a id="appbar-view-print-sample-link" href=""></a><a id="appbar-view-ebook-sample-link" href=""></a><a id="appbar-patents-prior-art-finder-link" href="https://www.google.com/patents/related/US6469012"></a><a id="appbar-patents-discuss-this-link" href="http://www.google.com/url?id=kKJcBAABERAJ&amp;q=http://patents.stackexchange.com/redirect/google-patents%3Fpatent%3DUS6469012&amp;usg=AFQjCNGp6JmPTZxaJ57VN388SPx1GmkhYQ" data-is-grant="true"></a><a id="appbar-read-patent-link" href="//docs.google.com/viewer?url=patentimages.storage.googleapis.com/pdfs/US6469012.pdf"></a><a id="appbar-download-pdf-link" href="//patentimages.storage.googleapis.com/pdfs/US6469012.pdf"></a></div><div class="kd-buttonbar right" id="right-toolbar-buttons"></div></div><div id="books-microdata" itemscope=""itemtype="http://schema.org/Book"itemid="http://www.google.com/patents/US6469012" style="display:none"><span itemprop="description">The use of a compound of formula (I) wherein R1 is H; C1-C3 alkyl; C1-C3 perfluoroalkyl; or C3-C5 cycloalkyl; R2 is H; optionally substituted C1-C6 alkyl; C1-C3 perfluoroalkyl; or C3-C6 cycloalkyl; R3 is optionally substituted C1-C6 alkyl; C1-C6 perfluoroalkyl; C3-C5 cycloalkyl; C3-C6 alkenyl; or C3-C6...</span><span itemprop="url">http://www.google.com/patents/US6469012?utm_source=gb-gplus-share</span><span class="main-title" itemprop="name">Patent US6469012 - Pyrazolopyrimidinones for the treatment of impotence</span><img itemprop="image" src="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"alt="Patent US6469012 - Pyrazolopyrimidinones for the treatment of impotence" title="Patent US6469012 - Pyrazolopyrimidinones for the treatment of impotence"></div><div style="display: none"><ol id="ofe-gear-menu-contents" class="gbmcc"><li class="gbe gbmtc"><a class="gbmt goog-menuitem-content" id="" href="http://www.google.com/advanced_patent_search">Advanced Patent Search</a></li></ol></div><table id="viewport_table" cellpadding="0" style="clear:both" cellspacing="0"><tr><td id="viewport_td"><div class=vertical_module_list_row><div id=intl_patents class=about_content><div id=intl_patents_v><table class="patent-bibdata"><tr><td class="patent-bibdata-heading">Publication number</td><td class="single-patent-bibdata">US6469012 B1</td></tr><tr><td class="patent-bibdata-heading">Publication type</td><td class="single-patent-bibdata">Grant</td></tr><tr><td class="patent-bibdata-heading">Application number</td><td class="single-patent-bibdata">US 08/549,792</td></tr><tr><td class="patent-bibdata-heading">PCT number</td><td class="single-patent-bibdata">PCT/EP1994/001580</td></tr><tr><td class="patent-bibdata-heading">Publication date</td><td class="single-patent-bibdata">Oct 22, 2002</td></tr><tr><td class="patent-bibdata-heading">Filing date</td><td class="single-patent-bibdata">May 13, 1994</td></tr><tr><td class="patent-bibdata-heading">Priority date<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed."></span></td><td class="single-patent-bibdata">Jun 9, 1993</td></tr><tr><td class="patent-bibdata-heading">Fee status<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The fee status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status or dates listed."></span></td><td class="single-patent-bibdata">Paid</td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Also published as</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/CA2163446A1">CA2163446A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/CA2163446C">CA2163446C</a>, </span><span class="patent-bibdata-value"><a href="/patents/CN1071118C">CN1071118C</a>, </span><span class="patent-bibdata-value"><a href="/patents/CN1124926A">CN1124926A</a>, </span><span class="patent-bibdata-value"><a href="/patents/CN1742731A">CN1742731A</a>, </span><span class="patent-bibdata-value"><a href="/patents/CN1742731B">CN1742731B</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE69408981D1">DE69408981D1</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE69408981T2">DE69408981T2</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0702555A1">EP0702555A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0702555B1">EP0702555B1</a>, </span><span class="patent-bibdata-value"><a href="/patents/US20030027824">US20030027824</a>, </span><span class="patent-bibdata-value"><a href="/patents/WO1994028902A1">WO1994028902A1</a></span></span></td></tr><tr class="patent-bibdata-list-row alternate-patent-number"><td class="patent-bibdata-heading">Publication number</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value">08549792, </span><span class="patent-bibdata-value">549792, </span><span class="patent-bibdata-value">PCT/1994/1580, </span><span class="patent-bibdata-value">PCT/EP/1994/001580, </span><span class="patent-bibdata-value">PCT/EP/1994/01580, </span><span class="patent-bibdata-value">PCT/EP/94/001580, </span><span class="patent-bibdata-value">PCT/EP/94/01580, </span><span class="patent-bibdata-value">PCT/EP1994/001580, </span><span class="patent-bibdata-value">PCT/EP1994/01580, </span><span class="patent-bibdata-value">PCT/EP1994001580, </span><span class="patent-bibdata-value">PCT/EP199401580, </span><span class="patent-bibdata-value">PCT/EP94/001580, </span><span class="patent-bibdata-value">PCT/EP94/01580, </span><span class="patent-bibdata-value">PCT/EP94001580, </span><span class="patent-bibdata-value">PCT/EP9401580, </span><span class="patent-bibdata-value">US 6469012 B1, </span><span class="patent-bibdata-value">US 6469012B1, </span><span class="patent-bibdata-value">US-B1-6469012, </span><span class="patent-bibdata-value">US6469012 B1, </span><span class="patent-bibdata-value">US6469012B1</span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Inventors</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Peter+Ellis%22">Peter Ellis</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Nicholas+Kenneth+Terrett%22">Nicholas Kenneth Terrett</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Original Assignee</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=inassignee:%22Pfizer+Inc%22">Pfizer Inc</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Export Citation</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/US6469012.bibtex">BiBTeX</a>, </span><span class="patent-bibdata-value"><a href="/patents/US6469012.enw">EndNote</a>, </span><span class="patent-bibdata-value"><a href="/patents/US6469012.ris">RefMan</a></span></span></td></tr><tr class="patent-internal-links"><td colspan=2><span class="patent-bibdata-value"><a href="#backward-citations">Patent Citations</a> (27),</span> <span class="patent-bibdata-value"><a href="#npl-citations">Non-Patent Citations</a> (464),</span> <span class="patent-bibdata-value"><a href="#forward-citations">Referenced by</a> (24),</span> <span class="patent-bibdata-value"><a href="#classifications">Classifications</a> (19),</span> <span class="patent-bibdata-value"><a href="#legal-events">Legal Events</a> (9)</span> </td></tr><tr><td colspan=2 class="patent-bibdata-external-link-spacer-top"></td></tr><tr class="patent-bibdata-external-link-spacer-bottom"></tr><tr><td colspan=2><span class="patent-bibdata-heading">External Links:&nbsp;</span><span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=kKJcBAABERAJ&q=http://patft.uspto.gov/netacgi/nph-Parser%3FSect2%3DPTO1%26Sect2%3DHITOFF%26p%3D1%26u%3D/netahtml/PTO/search-bool.html%26r%3D1%26f%3DG%26l%3D50%26d%3DPALL%26RefSrch%3Dyes%26Query%3DPN/6469012&usg=AFQjCNG-4xmZRbdfmnMiieK9DdNowtWk8g">USPTO</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=kKJcBAABERAJ&q=http://assignments.uspto.gov/assignments/q%3Fdb%3Dpat%26pat%3D6469012&usg=AFQjCNEjdDh-MX28PGVSznfxhz51-EkOkA">USPTO Assignment</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=kKJcBAABERAJ&q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DUS%26NR%3D6469012B1%26KC%3DB1%26FT%3DD&usg=AFQjCNGDqFJAbt54r72D-1g-2ovNj-MG8A">Espacenet</a></span></span></td></tr><tr class="patent-bibdata-group-spacer"></tr></table><div class="number-and-title"><span class="patent-title"><invention-title mxw-id="PT54994146" lang="EN" load-source="patent-office">Pyrazolopyrimidinones for the treatment of impotence</invention-title></span><br><span class="patent-number">US 6469012 B1</span></div><div class="patent-section patent-abstract-section"><div class="patent-section-header"><span class="patent-section-title">Abstract</span></div><div class="patent-text"><abstract mxw-id="PA50398131" lang="EN" load-source="patent-office"> <div class="abstract">The use of a compound of formula (I) <chemistry> <div class="patent-image"> <a href="//patentimages.storage.googleapis.com/US6469012B1/US06469012-20021022-C00001.png"> <img id="EMI-C00001" file="US06469012-20021022-C00001.TIF" wi="160.09245" he="100.10385" img-content="chem" img-format="tif" alt="Figure US06469012-20021022-C00001" src="//patentimages.storage.googleapis.com/US6469012B1/US06469012-20021022-C00001.png" class="patent-full-image" width="640" height="400"> </a> </div> <attachments> <attachment idref="CHEMCDX-00001" attachment-type="cdx" file="US06469012-20021022-C00001.CDX"> </attachment> <attachment idref="CHEMMOL-00001" attachment-type="mol" file="US06469012-20021022-C00001.MOL"> </attachment> </attachments> </chemistry> </div>
    <div class="abstract">wherein R<sup>1 </sup>is H; C<sub>1</sub>-C<sub>3 </sub>alkyl; C<sub>1</sub>-C<sub>3 </sub>perfluoroalkyl; or C<sub>3</sub>-C<sub>5 </sub>cycloalkyl; R<sup>2 </sup>is H; optionally substituted C<sub>1</sub>-C<sub>6 </sub>alkyl; C<sub>1</sub>-C<sub>3 </sub>perfluoroalkyl; or C<sub>3</sub>-C<sub>6 </sub>cycloalkyl; R<sup>3 </sup>is optionally substituted C<sub>1</sub>-C<sub>6 </sub>alkyl; C<sub>1</sub>-C<sub>6 </sub>perfluoroalkyl; C<sub>3</sub>-C<sub>5 </sub>cycloalkyl; C<sub>3</sub>-C<sub>6 </sub>alkenyl; or C<sub>3</sub>-C<sub>6 </sub>alkynyl; R<sup>4 </sup>is optionally substituted C<sub>1</sub>-C<sub>4 </sub>alkyl, C<sub>2</sub>-C<sub>4 </sub>alkenyl, C<sub>2</sub>-C<sub>4 </sub>alkanoyl, (hydroxy)C<sub>2</sub>-C<sub>4 </sub>alkyl or (C<sub>2</sub>-C<sub>3 </sub>alkoxy)C<sub>1</sub>-C<sub>2 </sub>alkyl; CONR<sup>5</sup>R<sup>6</sup>; CO<sub>2</sub>R<sup>7</sup>; halo; NR<sup>5</sup>R<sup>6</sup>; NHSO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>; NHSO<sub>2</sub>R<sup>8</sup>; SO<sub>2</sub>NR<sup>9</sup>R<sup>10</sup>; or phenyl, pyridyl, pyrimidinyl, imidazolyl, oxazolyl, thiazolyl, thienyl or triazolyl any of which is optionally substituted with methyl; R<sup>5 </sup>and R<sup>6 </sup>are each independently H or C<sub>1</sub>-C<sub>4 </sub>alkyl, or together with the nitrogen atom to which they are attached form an optionally substituted pyrrolidinyl, piperidino, morpholino, 4-N(R<sup>11</sup>)-piperazinyl or imidazolyl group; R<sup>7 </sup>is H or C<sub>1</sub>-C<sub>4 alkyl; R</sub> <sup>8 </sup>is optionally substituted C<sub>1</sub>-C<sub>3 </sub>alkyl; R<sup>9 </sup>and R<sup>10 </sup>together with the nitrogen atom to which they are attached form an optionally substituted pyrrolidinyl, piperidino, morpholino or 4-N(R<sup>12</sup>)-piperazinyl group; R<sup>11 </sup>is H; optionally substituted C<sub>1</sub>-C<sub>3 </sub>alkyl; (hydroxy)C<sub>2</sub>-C<sub>3 </sub>alkyl; or C<sub>1</sub>-C<sub>4 </sub>alkanoyl; R<sup>12 </sup>is H; optionally substituted C<sub>1</sub>-C<sub>6 </sub>alkyl; CONR<sup>13</sup>R<sup>14</sup>; CSNR<sup>13</sup>R<sup>14</sup>; or C(NH)NR<sup>13</sup>R<sup>14</sup>; and R?13? and R<sup>14 </sup>are each independently H; C<sub>1</sub>-C<sub>4 </sub>alkyl; or substituted C<sub>2</sub>-C<sub>4 </sub>alkyl; or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity, for the manufacture of a medicament for the curative or prophylactic treatment of erectile dysfunction in a male animal, including man; a pharmaceutical composition for said treatment; and a method of said treatment of said male animal with said pharmaceutical composition or with said either entity.</div>
  </abstract></div></div><div class="patent-section patent-drawings-section"><div class="patent-section-header"><span class="patent-section-title">Images<span class="patent-section-count">(47)</span></span></div><div class="patent-drawings-body"><div class="patent-drawings-carousel"><div class="drawings"><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6469012-0.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6469012-0.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6469012-1.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6469012-1.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6469012-2.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6469012-2.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6469012-3.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6469012-3.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6469012-4.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6469012-4.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6469012-5.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6469012-5.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6469012-6.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6469012-6.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6469012-7.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6469012-7.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6469012-8.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6469012-8.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6469012-9.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6469012-9.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6469012-10.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6469012-10.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6469012-11.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6469012-11.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6469012-12.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6469012-12.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6469012-13.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6469012-13.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6469012-14.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6469012-14.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6469012-15.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6469012-15.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6469012-16.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6469012-16.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6469012-17.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6469012-17.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6469012-18.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6469012-18.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6469012-19.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6469012-19.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6469012-20.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6469012-20.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6469012-21.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6469012-21.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6469012-22.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6469012-22.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6469012-23.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6469012-23.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6469012-24.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6469012-24.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6469012-25.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6469012-25.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6469012-26.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6469012-26.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6469012-27.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6469012-27.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6469012-28.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6469012-28.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6469012-29.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6469012-29.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6469012-30.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6469012-30.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6469012-31.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6469012-31.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6469012-32.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6469012-32.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6469012-33.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6469012-33.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6469012-34.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6469012-34.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6469012-35.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6469012-35.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6469012-36.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6469012-36.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6469012-37.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6469012-37.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6469012-38.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6469012-38.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6469012-39.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6469012-39.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6469012-40.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6469012-40.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6469012-41.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6469012-41.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6469012-42.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6469012-42.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6469012-43.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6469012-43.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6469012-44.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6469012-44.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6469012-45.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6469012-45.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6469012-46.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6469012-46.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div></div></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img" alt="Previous page"src="/googlebooks/images/kennedy/page_left.png"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img" alt="Next page"src="/googlebooks/images/kennedy/page_right.png"width="21" height="21" /></div></div></div><div class="patent-post-drawings"></div><div class="patent-section patent-claims-section"><div class="patent-section-header"><span class="patent-section-title">Claims<span class="patent-section-count">(26)</span></span></div><div class="patent-text"><div mxw-id="PCLM8378671" lang="EN" load-source="patent-office" class="claims">
    <claim-statement>What is claimed is: </claim-statement> <div class="claim"> <div num="1" id="US-6469012-B1-CLM-00001" class="claim">
      <div class="claim-text">1. A method of treating erectile dysfunction in a male animal, comprising administering to a male animal in need of such treatment an effective amount of a compound of formula (I): <chemistry> <div class="patent-image"> <a href="//patentimages.storage.googleapis.com/US6469012B1/US06469012-20021022-C00003.png"> <img id="EMI-C00003" file="US06469012-20021022-C00003.TIF" wi="160.09245" he="100.10385" img-content="chem" img-format="tif" alt="Figure US06469012-20021022-C00003" src="//patentimages.storage.googleapis.com/US6469012B1/US06469012-20021022-C00003.png" class="patent-full-image" width="640" height="400"> </a> </div> <attachments> <attachment idref="CHEMCDX-00003" attachment-type="cdx" file="US06469012-20021022-C00003.CDX"> </attachment> <attachment idref="CHEMMOL-00003" attachment-type="mol" file="US06469012-20021022-C00003.MOL"> </attachment> </attachments> </chemistry> </div>
      <div class="claim-text">wherein:</div>
      <div class="claim-text">R<sup>1 </sup>is H; C<sub>1</sub>-C<sub>3 </sub>alkyl; C<sub>1</sub>-C<sub>3 </sub>perfluoroalkyl; or C<sub>3</sub>-C<sub>5 </sub>cycloalkyl; </div>
      <div class="claim-text">R<sup>2 </sup>is H; C<sub>1</sub>-C<sub>6 </sub>alkyl optionally substituted with C<sub>3</sub>-C<sub>6 </sub>cycloalkyl; C<sub>1</sub>-C<sub>3 </sub>perfluoroalkyl; or C<sub>3</sub>-C<sub>6 </sub>cycloalkyl; </div>
      <div class="claim-text">R<sup>3 </sup>is C<sub>1</sub>-C<sub>6 </sub>alkyl optionally substituted with C<sub>3</sub>-C<sub>6 </sub>cycloalkyl; C<sub>1</sub>-C<sub>6 </sub>perfluoroalkyl; C<sub>3</sub>-C<sub>5 </sub>cycloalkyl; C<sub>3</sub>-C<sub>6 </sub>alkenyl; or C<sub>3</sub>-C<sub>6 </sub>alkynyl; </div>
      <div class="claim-text">R<sup>4 </sup>is C<sub>1</sub>-C<sub>4 </sub>alkyl optionally substituted with OH, NR<sup>5</sup>R<sup>6</sup>, CN, CONR<sup>5</sup>R<sup>6 </sup>or CO<sub>2</sub>R<sup>7</sup>; C<sub>2</sub>-C<sub>4 </sub>alkenyl optionally substituted with CN, CONR<sub>5</sub>R<sup>6 </sup>or CO<sub>2</sub>R<sup>7</sup>; C<sub>2</sub>-C<sub>4 </sub>alkanoyl optionally substituted with NR<sup>5</sup>R<sup>6</sup>; (hydroxy)C<sub>2</sub>-C<sub>4 </sub>alkyl optionally substituted with NR<sup>5</sup>R<sup>6</sup>; (C<sub>2</sub>-C<sub>3 </sub>alkoxy)C<sub>1</sub>-C<sub>2 </sub>alkyl optionally substituted with OH or NR<sup>5</sup>R<sup>6</sup>; CONR<sup>5</sup>R<sup>6</sup>; CO<sub>2</sub>R<sup>7</sup>; halo; NR<sup>5</sup>R<sup>6</sup>; NHSO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>; NHSO<sub>2</sub>R<sup>8</sup>; SO<sub>2</sub>NR<sup>9</sup>R<sup>10</sup>; or phenyl pyridyl, pyrimidinyl, imidazolyl, oxazolyl, thiazolyl, thienyl or triazolyl any of which is optionally substituted with methyl; </div>
      <div class="claim-text">R<sup>5 </sup>and R<sup>6 </sup>are each independently H or C<sub>1</sub>-C<sub>4 </sub>alkyl, or together with the nitrogen atom to which they are attached form a pyrrolidinyl, piperidino, morpholino, 4-N(R<sup>11</sup>)-piperazinyl or imidazolyl group wherein said group is optionally substituted with methyl or OH; </div>
      <div class="claim-text">R<sup>7 </sup>is H or C<sub>1</sub>-C<sub>4 </sub>alkyl; </div>
      <div class="claim-text">R<sup>8 </sup>is C<sub>1</sub>-C<sub>3 </sub>alkyl optionally substituted with NR<sup>5</sup>R<sup>6</sup>; </div>
      <div class="claim-text">R<sup>9 </sup>and R<sup>10 </sup>together with the nitrogen atom to which they are attached form a pyrrolidinyl, piperidino, morpholino or 4-N(R<sup>12</sup>)-piperazinyl group wherein said group is optionally substituted with C<sub>1</sub>-C<sub>4 </sub>alkyl, C<sub>1</sub>-C<sub>3 </sub>alkoxy, NR<sup>13</sup>R<sup>14 </sup>or CONR<sup>13</sup>R<sup>14</sup>; </div>
      <div class="claim-text">R<sup>11 </sup>is H; C<sub>1</sub>-C<sub>3 </sub>alkyl optionally substituted with phenyl; (hydroxy)C<sub>2</sub>-C<sub>3 </sub>alkyl; or C<sub>1</sub>-C<sub>4 </sub>alkanoyl; </div>
      <div class="claim-text">R<sup>12 </sup>is H; C<sub>1</sub>-C<sub>6 </sub>alkyl; (C<sub>1</sub>-C<sub>3 </sub>alkoxy)C<sub>2</sub>-C<sub>6 </sub>alkyl; (hydroxy)C<sub>2</sub>-C<sub>6 </sub>alkyl; (R<sup>13</sup>R<sup>14</sup>N)C<sub>2</sub>-C<sub>6 </sub>alkyl; (R<sup>13</sup>R<sup>14</sup>NOC)C<sub>1</sub>-C<sub>6 </sub>alkyl; CONR<sup>13</sup>R<sup>14</sup>; CSNR<sup>13</sup>R<sup>14</sup>; or C(NH)NR<sup>13</sup>R<sup>14</sup>; and </div>
      <div class="claim-text">R<sup>13 </sup>and R<sup>14 </sup>are each independently H; C<sub>1</sub>-C<sub>4 </sub>alkyl; (C<sub>1</sub>-C<sub>3 </sub>alkoxy)C<sub>2</sub>-C<sub>4 </sub>alkyl; or (hydroxy)C<sub>2</sub>-C<sub>4 </sub>alkyl; </div>
      <div class="claim-text">or a pharmaceutically acceptable salt thereof; </div>
      <div class="claim-text">or a pharmaceutically acceptable composition containing either entity. </div>
    </div>
    </div> <div class="claim-dependent"> <div num="2" id="US-6469012-B1-CLM-00002" class="claim">
      <div class="claim-text">2. A method as defined in <claim-ref idref="US-6469012-B1-CLM-00001">claim 1</claim-ref>, wherein said treatment is veterinary treatment.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="3" id="US-6469012-B1-CLM-00003" class="claim">
      <div class="claim-text">3. A method as defined in <claim-ref idref="US-6469012-B1-CLM-00001">claim 1</claim-ref>, wherein said compound is 5-(2-ethoxy-5-morpholinoacetylphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="4" id="US-6469012-B1-CLM-00004" class="claim">
      <div class="claim-text">4. A method as defined in <claim-ref idref="US-6469012-B1-CLM-00001">claim 1</claim-ref>, wherein said compound is 5-[2-ethoxy-5-(4-methyl-1-piperazinyl-sulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="5" id="US-6469012-B1-CLM-00005" class="claim">
      <div class="claim-text">5. A method as defined in <claim-ref idref="US-6469012-B1-CLM-00001">claim 1</claim-ref>, wherein said compound, salt or composition is administered orally, intravenously, sublingually, or buccally.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="6" id="US-6469012-B1-CLM-00006" class="claim">
      <div class="claim-text">6. A method as defined in <claim-ref idref="US-6469012-B1-CLM-00001">claim 1</claim-ref>, wherein said compound, salt or composition is administered orally.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="7" id="US-6469012-B1-CLM-00007" class="claim">
      <div class="claim-text">7. A method as defined in <claim-ref idref="US-6469012-B1-CLM-00006">claim 6</claim-ref> wherein in the compound of formula (I) R<sup>1 </sup>is H, methyl or ethyl; R<sup>2 </sup>is C<sub>1</sub>-C<sub>3 </sub>alkyl; R<sup>3 </sup>is C<sub>2</sub>-C<sub>3 </sub>alkyl or allyl; R<sup>4 </sup>is C<sub>1</sub>-C<sub>2 </sub>alkyl optionally substituted with OH, NR<sup>5</sup>R<sup>6</sup>, CN, CONR<sup>5</sup>R<sup>6 </sup>or CO<sub>2</sub>R<sup>7</sup>; acetyl optionally substituted with NR<sup>5</sup>R<sup>6</sup>; hydroxyethyl optionally substituted with NR<sup>5</sup>R<sup>6</sup>; ethoxymethyl optionally substituted with OH or NR<sup>5</sup>R<sup>6</sup>; CH═CHCN; CH═CHCONR<sup>5</sup>R<sup>6</sup>; CH═CHCO<sub>2</sub>R<sup>7</sup>; CONR<sup>5</sup>R<sup>6</sup>; CO<sub>2</sub>H; Br; NR<sup>5</sup>R<sup>6</sup>; NHSO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>; NHSO<sub>2</sub>R<sup>8</sup>; SO<sub>2</sub>NR<sup>9</sup>R<sup>10</sup>; or pyridyl or imidazolyl either of which is optionally substituted with methyl; R<sup>5 </sup>and R<sup>6 </sup>are each independently H, methyl or ethyl, or together with the nitrogen atom to which they are attached form a piperidino, morpholino, 4-N(R<sup>11</sup>)-piperazinyl or imidazolyl group wherein said group is optionally substituted with methyl or OH; R<sup>7 </sup>is H or t-butyl; R<sup>8 </sup>is methyl or CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>; R<sup>9 </sup>and R<sup>10 </sup>together with the nitrogen atom to which they are attached form a piperidino or 4-N(R<sup>12</sup>)-piperazinyl group wherein said group is optionally substituted with NR<sup>13</sup>R<sup>14 </sup>or CONR<sup>13</sup>R<sup>14</sup>; R<sup>11 </sup>is H, methyl, benzyl, 2-hydroxyethyl or acetyl; R<sup>12 </sup>is H, C<sub>1</sub>-C<sub>3 </sub>alkyl, (hydroxy)C<sub>2</sub>-C<sub>3 </sub>alkyl, CSNR<sup>13</sup>R<sup>14 </sup>or C(NH)NR<sup>13</sup>R<sup>14</sup>; and R<sup>13 </sup>and R<sup>14 </sup>are each independently H or methyl.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="8" id="US-6469012-B1-CLM-00008" class="claim">
      <div class="claim-text">8. A method as defined in <claim-ref idref="US-6469012-B1-CLM-00007">claim 7</claim-ref> wherein in the compound of formula (I) R<sup>1 </sup>is methyl or ethyl; R<sup>2 </sup>is C<sub>1</sub>-C<sub>3 </sub>alkyl; R<sup>3 </sup>is ethyl, n-propyl or allyl; R<sup>4 </sup>is CH<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, COCH<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, CH(OH)CH<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, CH<sub>2</sub>OCH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>OCH<sub>2</sub>CH<sub>2</sub>OH, CH<sub>2</sub>OCH<sub>2</sub>CH<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, CH═CHCON(CH<sub>3</sub>)<sub>2</sub>, CH═CHCO<sub>2</sub>R<sup>7</sup>, CONR<sup>5</sup>R<sup>6</sup>, CO<sub>2</sub>H, Br, NHSO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, NHSO<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, SO<sub>2</sub>NR<sup>9</sup>R<sup>10</sup>, 2-pyridyl, 1-imidazolyl or 1-methyl-2-imidazolyl; R<sup>5 </sup>and R<sup>6 </sup>together with the nitrogen atom to which they are attached form a piperidino, 4-hydroxypiperidino, morpholino, 4-N(R<sup>11</sup>)-piperazinyl or 2-methyl-1-imidazolyl group; R<sup>7 </sup>is H or t-butyl; R<sup>9 </sup>and R<sup>10 </sup>together with the nitrogen atom to which they are attached form a 4-carbamoylpiperidino or 4-N(R<sup>12</sup>)-piperazinyl group; R<sup>11 </sup>is H, methyl, benzyl, 2-hydroxyethyl or acetyl; and R<sup>12 </sup>is H, C<sub>1</sub>-C<sub>3 </sub>alkyl, 2-hydroxyethyl or CSNH<sub>2</sub>.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="9" id="US-6469012-B1-CLM-00009" class="claim">
      <div class="claim-text">9. A method as defined in <claim-ref idref="US-6469012-B1-CLM-00008">claim 8</claim-ref> wherein in the compound of formula (I) R<sup>1 </sup>is methyl or ethyl; R<sup>2 </sup>is n-propyl; R<sup>3 </sup>is ethyl, n-propyl or allyl; R<sup>4 </sup>is COCH<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, CONR<sup>5</sup>R<sup>6</sup>, SO<sub>2</sub>NR<sup>9</sup>R<sup>10 </sup>or 1-methyl-2-imidazolyl; R<sup>5 </sup>and R<sup>6 </sup>together with the nitrogen atom to which they are attached form a morpholino or 4-N(R<sup>11</sup>)-piperazinyl group; R<sup>9 </sup>and R<sup>10 </sup>together with the nitrogen atom to which they are attached form a 4-N(R<sup>12</sup>)-piperazinyl group; R<sup>11 </sup>is methyl or acetyl; and R<sup>12 </sup>is H, methyl, 2-propyl or 2-hydroxyethyl.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="10" id="US-6469012-B1-CLM-00010" class="claim">
      <div class="claim-text">10. A method as defined in <claim-ref idref="US-6469012-B1-CLM-00009">claim 9</claim-ref> wherein the compound of formula (I) is selected from:</div>
      <div class="claim-text">5-(2-ethoxy-5-morpholinoacetylphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; </div>
      <div class="claim-text">5-(5-morpholinoacetyl-2-n-propoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; </div>
      <div class="claim-text">5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)-phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; </div>
      <div class="claim-text">5-[2-allyloxy-5-(4-methyl-1-piperazinylsulphonyl)-phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; </div>
      <div class="claim-text">5-{2-ethoxy-5-[4-(2-propyl)-1-piperazinyl-sulphonyl]phenyl}-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; </div>
      <div class="claim-text">5-{2-ethoxy-5-[4-(2-hydroxyethyl)-1-piperazinyl-sulphonyl]phenyl}-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; </div>
      <div class="claim-text">5-{5-[4-(2-hydroxyethyl)-1-piperazinylsulphonyl]-2-n-propoxyphenyl}-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; </div>
      <div class="claim-text">5-[2-ethoxy-5-(4-methyl-1-piperazinylcarbonyl)-phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; and </div>
      <div class="claim-text">5-[2-ethoxy-5-(1-methyl-2-imidazolyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one. </div>
    </div>
    </div> <div class="claim-dependent"> <div num="11" id="US-6469012-B1-CLM-00011" class="claim">
      <div class="claim-text">11. A method as defined in <claim-ref idref="US-6469012-B1-CLM-00010">claim 10</claim-ref> wherein the compound of formula (I) is 5-(2-ethoxy-5-morpholino-acetylphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="12" id="US-6469012-B1-CLM-00012" class="claim">
      <div class="claim-text">12. A method as defined in <claim-ref idref="US-6469012-B1-CLM-00010">claim 10</claim-ref> wherein the compound of formula (I) is 5-(5-morpholinoacetyl-2-n-propoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="13" id="US-6469012-B1-CLM-00013" class="claim">
      <div class="claim-text">13. A method as defined in <claim-ref idref="US-6469012-B1-CLM-00010">claim 10</claim-ref> wherein the compound of formula (I) is 5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)-phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="14" id="US-6469012-B1-CLM-00014" class="claim">
      <div class="claim-text">14. A method as defined in <claim-ref idref="US-6469012-B1-CLM-00010">claim 10</claim-ref> wherein the compound of formula (I) is 5-[2-allyloxy-5-(4-methyl-1-piperazinylsulphonyl)-phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="15" id="US-6469012-B1-CLM-00015" class="claim">
      <div class="claim-text">15. A method as defined in <claim-ref idref="US-6469012-B1-CLM-00010">claim 10</claim-ref> wherein the compound of formula (I) is 5-{2-ethoxy-5-[4-(2-propyl)-1-piperazinyl-sulphonyl]phenyl}-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="16" id="US-6469012-B1-CLM-00016" class="claim">
      <div class="claim-text">16. A method as defined in <claim-ref idref="US-6469012-B1-CLM-00010">claim 10</claim-ref> wherein the compound of formula (I) is 5-{2-ethoxy-5-[4-(2-hydroxyethyl)-1-piperazinyl-sulphonyl]phenyl}-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="17" id="US-6469012-B1-CLM-00017" class="claim">
      <div class="claim-text">17. A method as defined in <claim-ref idref="US-6469012-B1-CLM-00010">claim 10</claim-ref> wherein the compound of formula (I) is 5-{5-[4-(2-hydroxyethyl)-1-piperazinylsulphonyl]-2-n-propoxyphenyl}-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="18" id="US-6469012-B1-CLM-00018" class="claim">
      <div class="claim-text">18. A method as defined in <claim-ref idref="US-6469012-B1-CLM-00010">claim 10</claim-ref> wherein the compound of formula (I) is 5-[2-ethoxy-5-(4-methyl-1-piperazinylcarbonyl)-phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="19" id="US-6469012-B1-CLM-00019" class="claim">
      <div class="claim-text">19. A method as defined in <claim-ref idref="US-6469012-B1-CLM-00010">claim 10</claim-ref> wherein the compound of formula (I) is 5-[2-ethoxy-5-(1-methyl-2-imidazolyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="20" id="US-6469012-B1-CLM-00020" class="claim">
      <div class="claim-text">20. A method as defined in <claim-ref idref="US-6469012-B1-CLM-00006">claim 6</claim-ref>, wherein said animal is a human.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="21" id="US-6469012-B1-CLM-00021" class="claim">
      <div class="claim-text">21. A method as defined in <claim-ref idref="US-6469012-B1-CLM-00001">claim 1</claim-ref>, wherein said compound, salt or composition is administered intravenously.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="22" id="US-6469012-B1-CLM-00022" class="claim">
      <div class="claim-text">22. A method as defined in <claim-ref idref="US-6469012-B1-CLM-00001">claim 1</claim-ref>, wherein said compound, salt or composition is administered sublingually.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="23" id="US-6469012-B1-CLM-00023" class="claim">
      <div class="claim-text">23. A method as defined in <claim-ref idref="US-6469012-B1-CLM-00001">claim 1</claim-ref>, wherein said compound, salt or composition is administered buccally.</div>
    </div>
    </div> <div class="claim"> <div num="24" id="US-6469012-B1-CLM-00024" class="claim">
      <div class="claim-text">24. A method of treating erectile dysfunction in a male human, comprising orally administering to a male human in need of such treatment an effective amount of a selective cGMP PDE<sub>v </sub>inhibitor, or a pharmaceutically acceptable salt thereof, of a pharmaceutical composition containing either entity.</div>
    </div>
    </div> <div class="claim"> <div num="25" id="US-6469012-B1-CLM-00025" class="claim">
      <div class="claim-text">25. A method of treating erectile dysfunction in a male human, comprising orally administering to a male human in need of such treatment an effective amount of a compound selected from:</div>
      <div class="claim-text">5-(2-ethoxy-5-morpholinoacetylphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; </div>
      <div class="claim-text">5-(5-morpholinoacetyl-2-n-propoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; </div>
      <div class="claim-text">5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)-phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; </div>
      <div class="claim-text">5-[2-allyloxy-5-(4-methyl-1-piperazinylsulphonyl)-phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; </div>
      <div class="claim-text">5-{2-ethoxy-5-[4-(2-propyl)-1-piperazinyl-sulphonyl]phenyl}-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; </div>
      <div class="claim-text">5-{2-ethoxy-5-[4-(2-hydroxyethyl)-1-piperazinyl-sulphonyl]phenyl}-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; </div>
      <div class="claim-text">5-{5-[4-(2-hydroxyethyl)-1-piperazinylsulphonyl]-2-n-propoxyphenyl}-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; </div>
      <div class="claim-text">5-[2-ethoxy-5-(4-methyl-1-piperazinylcarbonyl)-phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; and </div>
      <div class="claim-text">5-[2-ethoxy-5-(1-methyl-2-imidazolyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; </div>
      <div class="claim-text">or a pharmaceutically acceptable salt thereof;</div>
      <div class="claim-text">or a pharmaceutical composition containing either entity.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="26" id="US-6469012-B1-CLM-00026" class="claim">
      <div class="claim-text">26. A method as defined in <claim-ref idref="US-6469012-B1-CLM-00025">claim 25</claim-ref>, wherein said compound is 5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)-phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity.</div>
    </div>
  </div> </div></div></div><div class="patent-section patent-description-section"><div class="patent-section-header"><span class="patent-section-title">Description</span></div><div class="patent-text"><div mxw-id="PDES53655047" lang="EN" load-source="patent-office" class="description">
    <p>This is a National Phase filing under 35 USC §371 based on PCT/EP94/01580, which was filed internationally on May 13, 1994.</p>
    <p>This invention relates to the use of a series of pyrazolo[4,3-d]pyrimidin-7-ones for the treatment of impotence.</p>
    <p>Impotence can be defined literally as a lack of power, in the male, to copulate and may involve an inability to achieve penile erection or ejaculation, or both. More specifically, erectile impotence or dysfunction may be defined as an inability to obtain or sustain an erection adequate for intercourse. Its prevalence is claimed to be between 2 and 7% of the human male population, increasing with age, up to 50 years, and between 18 and 75% between 55 and 80 years of age. In the USA alone, for example, it has been estimated that there are up to 10 million impotent males, with the majority suffering from problems of organic rather than of psychogenic origin.</p>
    <p>Reports of well-controlled clinical trials in man are few and the efficacy of orally administered drugs is low. Although many different drugs have been shown to induce penile erection, they are only effective after direct injection into the penis, e.g. intraurethrally or intracavernosally (i.c.), and are not approved for erectile dysfunction. Current medical treatment is based on the i.c injection of vasoactive substances and good results have been claimed with phenoxybenzamine, phentolamine, papaverine and prostaglandin E<sub>1</sub>, either alone or in combination; however, pain, priapism and fibrosis of the penis are associated with the i.c. administration of some of these agents. Potassium channel openers (KCO) and vasoactive intestinal polypeptide (VIP) have also been shown to be active i.c., but cost and stability issues could limit development of the latter. An alternative to the i.c. route is the use of glyceryl trinitrate (GTN) patches applied to the penis, which has been shown to be effective but produces side-effects in both patient and partner.</p>
    <p>As a general alternative to pharmacological intervention, a variety of penile prostheses has been used to assist achievement of an erection. The short term success rate is good, but problems with infection and ischaemia, especially in diabetic men, make this type of treatment a final option rather than first-line therapy.</p>
    <p>The compounds of the invention are potent inhibitors of cyclic guanosine 3′,5′-monophosphate phosphodiesterases (cGMP PDEs) in contrast to their inhibition of cyclic adenosine 3′,5′-monophosphate phosphodiesterases (cAMP PDEs). This selective enzyme inhibition leads to elevated cGMP levels which, in turn, provides the basis for the utilities already disclosed for the said compounds in EP-A-0463756 and EP-A-0526004, namely in the treatment of stable, unstable and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, congestive heart failure, atherosclerosis, conditions of reduced blood vessel patency e.g. post-percutaneous transluminal coronary angioplasty (post-PTCA), peripheral vascular disease, stroke, bronchitis, allergic asthma, chronic asthma, allergic rhinitis, glaucoma, and diseases characterised by disorders of gut motility, e.g. irritable bowel syndrome (IBS).</p>
    <p>Unexpectedly, it has now been found that these disclosed compounds are useful in the treatment of erectile dysfunction. Furthermore the compounds may be administered orally, thereby obviating the disadvantages associated with i.c. administration. Thus the present invention concerns the use of a compound of formula (I): <chemistry> <div class="patent-image"> <a href="//patentimages.storage.googleapis.com/US6469012B1/US06469012-20021022-C00002.png"> <img id="EMI-C00002" file="US06469012-20021022-C00002.TIF" wi="160.09245" he="100.10385" img-content="chem" img-format="tif" alt="Figure US06469012-20021022-C00002" src="//patentimages.storage.googleapis.com/US6469012B1/US06469012-20021022-C00002.png" class="patent-full-image" width="640" height="400"> </a> </div> <attachments> <attachment idref="CHEMCDX-00002" attachment-type="cdx" file="US06469012-20021022-C00002.CDX"> </attachment> <attachment idref="CHEMMOL-00002" attachment-type="mol" file="US06469012-20021022-C00002.MOL"> </attachment> </attachments> </chemistry> </p>
    <p>wherein</p>
    <p>R<sup>1 </sup>is H; C<sub>1</sub>-C<sub>3 </sub>alkyl; C<sub>1</sub>-C<sub>3 </sub>perfluoroalkyl; or C<sub>3</sub>-C<sub>5 </sub>cycloalkyl;</p>
    <p>R<sup>2 </sup>is H; C<sub>1</sub>-C<sub>6 </sub>alkyl optionally substituted with C<sub>3</sub>-C<sub>6 </sub>cycloalkyl; C<sub>1</sub>-C<sub>3 </sub>perfluoroalkyl; or C<sub>3</sub>-C<sub>6 </sub>cycloalkyl;</p>
    <p>R<sup>3 </sup>is C<sub>1</sub>-C<sub>6 </sub>alkyl optionally substituted with C<sub>3</sub>-C<sub>6 </sub>cycloalkyl; C<sub>1</sub>-C<sub>6 </sub>perfluoroalkyl; C<sub>3</sub>-C<sub>5 </sub>cycloalkyl; C<sub>3</sub>-C<sub>6 </sub>alkenyl; or C<sub>3</sub>-C<sub>6 </sub>alkynyl;</p>
    <p>R<sup>4 </sup>is C<sub>1</sub>-C<sub>4 </sub>alkyl optionally substituted with OH, NR<sup>5</sup>R<sup>6</sup>, CN, CONR<sup>5</sup>R<sup>6 </sup>or CO<sub>2</sub>R<sup>7</sup>; C<sub>2</sub>-C<sub>4 </sub>alkenyl optionally substituted with CN, CONR<sup>5</sup>R<sup>6 </sup>or CO<sub>2</sub>R<sup>7</sup>; C<sub>2</sub>-C<sub>4 </sub>alkanoyl optionally substituted with NR<sup>5</sup>R<sup>6</sup>; (hydroxy)C<sub>2</sub>-C<sub>4 </sub>alkyl optionally substituted with NR<sup>5</sup>R<sup>6</sup>; (C<sub>2</sub>-C<sub>3 </sub>alkoxy)C<sub>1</sub>-C<sub>2 </sub>alkyl optionally substituted with OH or NR<sup>5</sup>R<sup>6</sup>; CONR<sup>5</sup>R<sup>6</sup>; CO<sub>2</sub>R<sup>7</sup>; halo; NR<sup>5</sup>R<sup>6</sup>; NHSO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>; NHSO<sub>2</sub>R<sup>8</sup>; SO<sub>2</sub>NR<sup>9</sup>R<sup>10</sup>; or phenyl, pyridyl, pyrimidinyl, imidazolyl, oxazolyl, thiazolyl, thienyl or triazolyl any of which is optionally substituted with methyl;</p>
    <p>R<sup>5 </sup>and R<sup>6 </sup>are each independently H or C<sub>1</sub>-C<sub>4 </sub>alkyl, or together with the nitrogen atom to which they are attached form a pyrrolidinyl, piperidino, morpholino, 4-N(R<sup>11</sup>)-piperazinyl or imidazolyl group wherein said group is optionally substituted with methyl or OH;</p>
    <p>R<sup>7 </sup>is H or C<sub>1</sub>-C<sub>4 </sub>alkyl;</p>
    <p>R<sup>8 </sup>is C<sub>1</sub>-C<sub>3 </sub>alkyl optionally substituted with NR<sup>5</sup>R<sup>6</sup>;</p>
    <p>R<sup>9 </sup>and R<sup>10 </sup>together with the nitrogen atom to which they are attached form a pyrrolidinyl, piperidino, morpholino or 4-N(R<sup>12</sup>)-piperazinyl group wherein said group is optionally substituted with C<sub>1</sub>-C<sub>4 </sub>alkyl, C<sub>1</sub>-C<sub>3 </sub>alkoxy, NR<sup>13</sup>R<sup>14 </sup>or CONR<sup>13</sup>R<sup>14</sup>;</p>
    <p>R<sup>11 </sup>is H; C<sub>1</sub>-C<sub>3 </sub>alkyl optionally substituted with phenyl; (hydroxy)C<sub>2</sub>-C<sub>3 </sub>alkyl; or C<sub>1</sub>-C<sub>4 </sub>alkanoyl;</p>
    <p>R<sup>12 </sup>is H; C<sub>1</sub>-C<sub>6 </sub>alkyl; (C<sub>1</sub>-C<sub>3 </sub>alkoxy)C<sub>2</sub>-C<sub>6 </sub>alkyl; (hydroxy)C<sub>2</sub>-C<sub>6 </sub>alkyl; (R<sup>13</sup>R<sup>14</sup>N)C<sub>2</sub>-C<sub>6 </sub>alkyl; (R<sup>13</sup>R<sup>14</sup>NOC)C<sub>1</sub>-C<sub>6 </sub>alkyl; CONR<sup>13</sup>R<sup>14</sup>; CSNR<sup>13</sup>R<sup>14</sup>; or C(NH)NR<sup>13</sup>R<sup>14</sup>; and</p>
    <p>R<sup>13 </sup>and R<sup>14 </sup>are each independently H; C<sub>1</sub>-C<sub>4 </sub>alkyl; (C<sub>1</sub>-C<sub>3 </sub>alkoxy)C<sub>2</sub>-C<sub>4 </sub>alkyl; or (hydroxy)C<sub>2</sub>-C<sub>4 </sub>alkyl;</p>
    <p>or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity, for the manufacture of a medicament for the curative or prophylactic treatment of erectile dysfunction in a male animal, including man.</p>
    <p>In the above definition, unless otherwise indicated, alkyl groups having three or more carbon atoms, alkenyl and alkynyl groups having four or more carbon atoms, alkoxy groups having three carbon atoms and alkanoyl groups having four carbon atoms may be straight chain or branched chain. Halo means fluoro, chloro, bromo or iodo.</p>
    <p>The compounds of formula (I) may contain one or more asymmetric centres and thus they can exist as enantiomers or diastereoisomers. Furthermore, certain compounds of formula (I) which contain alkenyl groups may exist as cis-isomers or trans-isomers. In each instance, the invention includes both mixtures and separate individual isomers.</p>
    <p>The compounds of formula (I) may also exist in tautomeric forms and the invention includes both mixtures and separate individual tautomers.</p>
    <p>The pharmaceutically acceptable salts of the compounds of formula (I) which contain a basic centre are, for example, non-toxic acid addition salts formed with inorganic acids such as hydrochloric, hydrobromic, sulphuric and phosphoric acid, with organo-carboxylic acids, or with organo-sulphonic acids. Compounds of formula (I) can also provide pharmaceutically acceptable metal salts, in particular non-toxic alkali metal salts, with bases. Examples include the sodium and potassium salts.</p>
    <p>A preferred group of compounds of formula (I) is that wherein R<sup>1 </sup>is H, methyl or ethyl; R<sup>2 </sup>is C<sub>1</sub>-C<sub>3 </sub>alkyl; R<sup>3 </sup>is C<sub>2</sub>-C<sub>3 </sub>alkyl or allyl; R<sup>4 </sup>is C<sub>1</sub>-C<sub>2 </sub>alkyl optionally substituted with OH, NR<sup>5</sup>R<sup>6</sup>, CN, CONR<sup>5</sup>R<sup>6 </sup>or CO<sub>2</sub>R<sup>7</sup>; acetyl optionally substituted with NR<sup>5</sup>R<sup>6</sup>; hydroxyethyl optionally substituted with NR<sup>5</sup>R<sup>6</sup>; ethoxymethyl optionally substituted with OH or NR<sup>5</sup>R<sup>6</sup>; CH═CHCN; CH═CHCONR<sup>5</sup>R<sup>6</sup>; CH═CHCO<sub>2</sub>R<sup>7</sup>; CONR<sup>5</sup>R<sup>6</sup>; CO<sub>2</sub>H; Br; NR<sup>5</sup>R<sup>6</sup>; NHSO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>; NHSO<sub>2</sub>R<sup>8</sup>; SO<sub>2</sub>NR<sup>9</sup>R<sup>10</sup>; or pyridyl or imidazolyl either of which is optionally substituted with methyl; R<sup>5 </sup>and R<sup>6 </sup>are each independently H, methyl or ethyl, or together with the nitrogen atom to which they are attached form a piperidino, morpholino, 4-N(R<sup>11</sup>)-piperazinyl or imidazolyl group wherein said group is optionally substituted with methyl or OH; R<sup>7 </sup>is H or t-butyl; R<sup>8 </sup>is methyl or CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>; R<sup>9 </sup>and R<sup>10 </sup>together with the nitrogen atom to which they are attached form a piperidino or 4-N(R<sup>12</sup>)-piperazinyl group wherein said group is optionally substituted with NR<sup>13</sup>R<sup>14 </sup>or CONR<sup>13</sup>R<sup>14</sup>; R<sup>11 </sup>is H, methyl, benzyl, 2-hydroxyethyl or acetyl; R<sup>12 </sup>is H, C<sub>1</sub>-C<sub>3 </sub>alkyl, (hydroxy)C<sub>2</sub>-C<sub>3 </sub>alkyl, CSNR<sup>13</sup>R<sup>14 </sup>or C(NH)NR<sup>13</sup>R<sup>14</sup>; and R<sup>13 </sup>and R<sup>14 </sup>are each independently H or methyl.</p>
    <p>A more preferred group of compounds of formula (I) is that wherein R<sup>1 </sup>is methyl or ethyl; R<sup>2 </sup>is C<sub>1</sub>-C<sub>3 </sub>alkyl; R<sup>3 </sup>is ethyl, n-propyl or allyl; R<sup>4 </sup>is CH<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, COCH<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, CH(OH)CH<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, CH<sub>2</sub>OCH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>OCH<sub>2</sub>CH<sub>2</sub>OH, CH<sub>2</sub>OCH<sub>2</sub>CH<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, CH═CHCON(CH<sub>3</sub>)<sub>2</sub>, CH═CHCO<sub>2</sub>R<sup>7</sup>, CONR<sup>5</sup>R<sub>6</sub>, CO<sub>2</sub>H, Br, NHSO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, NHSO<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, SO<sub>2</sub>NR<sup>9</sup>R<sup>10</sup>, 2-pyridyl, 1-imidazolyl or 1-methyl-2-imidazolyl; R<sup>5 </sup>and R<sup>6 </sup>together with the nitrogen atom to which they are attached form a piperidino, 4-hydroxypiperidino, morpholino, 4-N(R<sup>11</sup>)-piperazinyl or 2-methyl-1-imidazolyl group; R<sup>7 </sup>is H or t-butyl; R<sup>9 </sup>and R<sup>10 </sup>together with the nitrogen atom to which they are attached form a 4-carbamoylpiperidino or 4-N(R<sup>12</sup>)-piperazinyl group; R<sup>11 </sup>is H, methyl, benzyl, 2-hydroxyethyl or acetyl; and R<sup>12 </sup>is H, C<sub>1</sub>-C<sub>3 </sub>alkyl, 2-hydroxyethyl or CSNH<sub>2</sub>.</p>
    <p>A particularly preferred group of compounds of formula (I) is that wherein R<sup>1 </sup>is methyl or ethyl; R<sup>2 </sup>is n-propyl; R<sup>3 </sup>is ethyl, n-propyl or allyl; R<sup>4 </sup>is COCH<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, CONR<sup>5</sup>R<sup>6</sup>, SO<sub>2</sub>NR<sup>9</sup>R<sup>10 </sup>or 1-methyl-2-imidazolyl; R<sup>5 </sup>and R<sup>6 </sup>together with the nitrogen atom to which they are attached form a morpholino or 4-N(R<sup>11</sup>)-piperazinyl group; R<sup>9 </sup>and R<sub>10 </sub>together with the nitrogen atom to which they are attached form a 4-N(R<sup>12</sup>)-piperazinyl group; R<sup>11 </sup>is methyl or acetyl; and R<sup>12 </sup>is H, methyl, 2-propyl or 2-hydroxyethyl.</p>
    <p>Especially preferred individual compounds of the invention include:</p>
    <p>5-(2-ethoxy-5-morpholinoacetylphenyl)-1-methyl-3-n-propyl-1, 6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;</p>
    <p>5-(5-morpholinoacetyl-2-n-propoxyphenyl)-1-methyl-3-n-propyl-1, 6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;</p>
    <p>5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)-phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;</p>
    <p>5-[2-allyloxy-5-(4-methyl-1-piperazinylsulphonyl)-phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;</p>
    <p>5-{2-ethoxy-5-[4-(2-propyl)-1-piperazinyl-sulphonyl]phenyl}-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;</p>
    <p>5-{2-ethoxy-5-[4-(2-hydroxyethyl)-1-piperazinyl-sulphonyl]phenyl}-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;</p>
    <p>5-{5-[4-(2-hydroxyethyl)-1-piperazinylsulphonyl]-2-n-propoxyphenyl}-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;</p>
    <p>5-[2-ethoxy-5-(4-methyl-1-piperazinylcarbonyl)-phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; and</p>
    <p>5-[2-ethoxy-5-(1-methyl-2-imidazolyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one.</p>
    <p>The compounds of formula (I) and their pharmaceutically acceptable salts, processes for the preparation thereof, in vitro test methods for determining the cGMP PDE and cAMP PDE inhibitory activities thereof, pharmaceutical compositions thereof and routes of administration for human use, are described in EP-A-0463756 and EP-A-0526004.</p>
    <p>A preliminary investigation was carried out with a view to isolating and characterising the cyclic nucleotide PDEs of human corpus cavernosum, relaxation of which leads to penile erection. Studies of substrate specificity, response to activators and inhibitor sensitivity, have demonstrated that human corpus cavernosum contains three distinct PDE enzymes.</p>
    <heading>METHODS</heading> <p>Fresh frozen human penis was obtained from IIAM (Pennsylvania). Tissue was thawed at room temperature, the corpus cavernosum was dissected from the penis to yield approximately 2-4 g of tissue and the following isolation protocol was followed. Tissue was coarsely chopped in ice-cold isotonic buffer (35 ml) containing 250 mM sucrose, 1 mM EDTA, 0.5 mM PMSF and 20 mM HEPES, pH 7.2, and the mixture subjected to brief (1 min.) treatment with a Silversen mixer/emulsifier. Homogenates were prepared using homogeniser tubes with teflon pestles and soluble fraction was prepared by centrifugation at 100,000×g for 60 min. at 4° C. 10 ml of high speed supernatant was applied to a Pharmacia Mono Q anion exchange column (1 ml bed volume) equilibrated with buffer containing 1 mM EDTA, 0.5 mM PMSF and 20 mM lhEPES, pH 7.2 (chromatography buffer). The column was then washed with 5 bed volumes of chromatography buffer, after which PDEs were eluted using a continuous gradient of 0-500 mM NaCl (total volume 35 ml) and 1 ml fractions collected.</p>
    <p>Column fractions were assayed for PDE activity using 500 nM cGMP or 500 nM cAMP as substrate. cAMP PDE activity was also determined in the presence of 1 μM unlabelled cGMP and the PDE activity of selected fractions was determined in the presence of 10 mM CaCl<sub>2 </sub>and 10 units/ml bovine brain calmodulin. Appropriate fractions were pooled and stored at 4° C. during the course of the study.</p>
    <p>Inhibition studies were performed using a substrate concentration of 500 nM throughout. All inhibitors were dissolved in DMSO and concentration-response curves were constructed over the range 3×10<sup>−10 </sup>to 1×10<sup>−4 </sup>M in half log increments. IC<sub>50 </sub>values were calculated using the sigmoidal curve fitting algorithm of biostat.</p>
    <heading>RESULTS</heading> <p>Human corpus cavernosum soluble PDEs were separated into three distinct fractions of activity. The first, fraction I, (designated by order of elution) represents the major PDE present and is highly selective for cGMP as substrate. This fraction was found to be insensitive to stimulation by calcium/calmodulin and was classified as PDE<sub>V</sub>. Fraction II hydrolyses cGMP and cAMP, with the latter activity being stimulated in the presence of cGMP, and is classified as PDE<sub>II</sub>, whilst fraction III is cAMP selective and this activity is inhibited in the presence of cGMP, consistent with PDE<sub>III </sub>activity.</p>
    <p>In order to further characterise the PDE isoenzymes present in the tissue, studies were performed using a variety of inhibitors. Inhibitor studies with fractions I and II were performed using cGMP as substrate, whilst fraction III studies utilised cAMP. These studies confirmed that fraction I corresponds to PDE<sub>V</sub>, whilst fraction III was clearly identified as PDE<sub>III</sub>; fraction II (PDE<sub>II</sub>) was relatively insensitive to all the inhibitors tested.</p>
    <p>In summary, the above investigation identified three PDE isoenzymes in human corpus cavernosum tissue. The predominant PDE is the cGMP-specific PDE<sub>V</sub>, whilst cGMP-stimulated cAMP PDE<sub>II </sub>and cGMP-inhibited cAMP PDE<sub>III </sub>are also present.</p>
    <p>The compounds of the invention have been tested in vitro and found to be potent and selective inhibitors of the cGMP-specific PDE<sub>V</sub>. For example, one of the especially preferred compounds of the invention has an IC<sub>50</sub>=6.8 nM v. the PDE<sub>V </sub>enzyme, but demonstrates only weak inhibitory activity against the PDE<sub>II </sub>and PDE<sub>III </sub>enzymes with IC<sub>50</sub>=&gt;100 μM and 34 μM respectively. Thus relaxation of the corpus cavernosum tissue and consequent penile erection is presumably mediated by elevation of cGMP levels in the said tissue, by virtue of the PDE inhibitory profile of the compounds of the invention.</p>
    <p>Furthermore, none of the compounds of the invention tested in rat and dog, both intravenously (i.v.) and orally (p.o.) at up to 3 mg/Kg, has shown any overt sign of adverse acute toxicity. In mouse, no deaths occurred after doses of up to 100 mg/Kg i.v. Certain especially preferred compounds showed no toxic effects on chronic p.o. administration to rat at up to 10 mg/Kg and to dog at up to 20 mg/Kg.</p>
    <p>In man, certain especially preferred compounds have been tested orally in both single dose and multiple dose volunteer studies. Moreover, patient studies conducted thus far have confirmed that one of the especially preferred compounds induces penile erection in impotent males.</p>
    <p>Although the compounds of the invention are envisaged primarily for the treatment of erectile dysfunction or sexual dysfunction, they may also be useful for the treatment of female sexual dysfunction including orgasmic dysfunction related to clitoral disturbances.</p>
    <p>Generally, in man, oral administration of the compounds of the invention is the preferred route, being the most convenient and avoiding the disadvantages associated with i.c. administration. A preferred dosing regimen for a typical man is 5 to 75 mg of compound three times daily. In circumstances where the recipient suffers from a swallowing disorder or from impairment of drug absorption after oral administration, the drug may be administered parenterally, e.g. sublingually or buccally.</p>
    <p>For veterinary use, a compound of formula (I) or a non-toxic salt thereof is administered as a suitably acceptable formulation in accordance with normal veterinary practice and the veterinary surgeon will determine the dosing regimen and route of administration which will be most appropriate for a particular male animal.</p>
    <p>Thus the invention includes a pharmaceutical composition for the curative or prophylactic treatment of erectile dysfunction in a male animal, including man, comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable diluent or carrier.</p>
    <p>There is further provided a process for the preparation of a pharmaceutical composition for the curative or prophylactic treatment of erectile dysfunction in a male animal, including man, comprising formulating a compound of formula (I), or a pharmaceutically acceptable salt thereof, with a pharmaceutically acceptable diluent or carrier.</p>
    <p>The invention also provides a method of treating a male animal, including man, to cure or prevent erectile dysfunction which comprises treating said male animal with an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity.</p>
    <p>In a further aspect, the invention includes the use of a cGMP PDE inhibitor, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity, for the oral treatment of erectile dysfunction in man.</p>
    <p>The invention also includes a method of orally treating man to cure or prevent erectile dysfunction, which comprises treatment with an orally effective amount of a cGMP PDE inhibitor, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity.</p>
    <p>Moreover, the invention includes the use of a cGMP PDE inhibitor, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity, for the manufacture of a medicament for the curative or prophylactic oral treatment of erectile dysfunction in man.</p>
    </div></div></div><div class="patent-section patent-tabular-section"><a id="backward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Cited Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US3987160">US3987160</a></td><td class="patent-data-table-td patent-date-value">May 29, 1973</td><td class="patent-data-table-td patent-date-value">Oct 19, 1976</td><td class="patent-data-table-td ">May &amp; Baker Limited</td><td class="patent-data-table-td ">Pharmaceutical compositions comprising azapurinones useful in treating allergic respiratory disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4521421">US4521421</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 26, 1983</td><td class="patent-data-table-td patent-date-value">Jun 4, 1985</td><td class="patent-data-table-td ">Eli Lilly And Company</td><td class="patent-data-table-td ">Using 2-amino-octahydropyrimido(4,5-g)quinoline compound</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5145852">US5145852</a></td><td class="patent-data-table-td patent-date-value">Jul 10, 1990</td><td class="patent-data-table-td patent-date-value">Sep 8, 1992</td><td class="patent-data-table-td ">Ronald Virag</td><td class="patent-data-table-td ">Vaso-active medicament to treat impotence</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5270323">US5270323</a></td><td class="patent-data-table-td patent-date-value">Mar 11, 1993</td><td class="patent-data-table-td patent-date-value">Dec 14, 1993</td><td class="patent-data-table-td ">Pfizer Inc.</td><td class="patent-data-table-td ">Method of treating impotence</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5278192">US5278192</a></td><td class="patent-data-table-td patent-date-value">Jul 2, 1992</td><td class="patent-data-table-td patent-date-value">Jan 11, 1994</td><td class="patent-data-table-td ">The Research Foundation Of State University Of New York</td><td class="patent-data-table-td ">Administering isobutyl nitrite and isoamyl nitrite</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5399581">US5399581</a></td><td class="patent-data-table-td patent-date-value">Dec 26, 1990</td><td class="patent-data-table-td patent-date-value">Mar 21, 1995</td><td class="patent-data-table-td ">Laragh; John H.</td><td class="patent-data-table-td ">Administering mixture of nonselective alpha 1-alpha 2, and beta adrenergic blocking agents having vasodilator activity</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5436272">US5436272</a></td><td class="patent-data-table-td patent-date-value">Oct 15, 1992</td><td class="patent-data-table-td patent-date-value">Jul 25, 1995</td><td class="patent-data-table-td ">The Boots Company (Usa), Inc.</td><td class="patent-data-table-td ">Treatment of obesity</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5489610">US5489610</a></td><td class="patent-data-table-td patent-date-value">Jun 30, 1993</td><td class="patent-data-table-td patent-date-value">Feb 6, 1996</td><td class="patent-data-table-td ">Research Foundation Of The State University Of New York</td><td class="patent-data-table-td ">Sustained release organic nitrite therapy</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5565466">US5565466</a></td><td class="patent-data-table-td patent-date-value">Aug 9, 1994</td><td class="patent-data-table-td patent-date-value">Oct 15, 1996</td><td class="patent-data-table-td ">Zonagen, Inc.</td><td class="patent-data-table-td ">Methods for modulating the human sexual response</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5891904">US5891904</a></td><td class="patent-data-table-td patent-date-value">Sep 29, 1997</td><td class="patent-data-table-td patent-date-value">Apr 6, 1999</td><td class="patent-data-table-td ">Wolf-Georg Forssmann</td><td class="patent-data-table-td ">Gastrointestinal and urogenital disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6037346">US6037346</a></td><td class="patent-data-table-td patent-date-value">Oct 27, 1998</td><td class="patent-data-table-td patent-date-value">Mar 14, 2000</td><td class="patent-data-table-td ">Vivus, Inc.</td><td class="patent-data-table-td ">Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction</td></tr><tr><td class="patent-data-table-td citation-patent"></td><td class="patent-data-table-td ">CN93117097A</td><td class="patent-data-table-td patent-date-value"></td><td class="patent-data-table-td patent-date-value"></td><td class="patent-data-table-td "> </td><td class="patent-data-table-td citation-no-title">Title not available</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/DE4230755A1?cl=en">DE4230755A1</a></td><td class="patent-data-table-td patent-date-value">Sep 14, 1992</td><td class="patent-data-table-td patent-date-value">Mar 17, 1994</td><td class="patent-data-table-td ">Schering Ag</td><td class="patent-data-table-td ">Phosphodiesterase IV inhibitors for kidney and ureter disease treatment - with eg (4-(3-(cyclopentyl oxy) 4-methoxyphenyl-2-pyrrolidinone) being specific for kidney and ureter tissue relaxation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0143357A1?cl=en">EP0143357A1</a></td><td class="patent-data-table-td patent-date-value">Oct 31, 1984</td><td class="patent-data-table-td patent-date-value">Jun 5, 1985</td><td class="patent-data-table-td ">Matsushita Electric Industrial Co., Ltd.</td><td class="patent-data-table-td ">Optical device and document reader using the same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0201188A2?cl=en">EP0201188A2</a></td><td class="patent-data-table-td patent-date-value">Apr 1, 1986</td><td class="patent-data-table-td patent-date-value">Dec 17, 1986</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">5-Substituted pyrazolo[4,3-d] pyrimidine-7-ones, process for preparing the compounds and pharmaceutical compositions comprising the compounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0439320A1?cl=en">EP0439320A1</a></td><td class="patent-data-table-td patent-date-value">Jan 22, 1991</td><td class="patent-data-table-td patent-date-value">Jul 31, 1991</td><td class="patent-data-table-td ">Yamanouchi Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">Erectile dysfunction treatment</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0463756A1?cl=en">EP0463756A1</a></td><td class="patent-data-table-td patent-date-value">Jun 7, 1991</td><td class="patent-data-table-td patent-date-value">Jan 2, 1992</td><td class="patent-data-table-td ">Pfizer Limited</td><td class="patent-data-table-td ">Pyrazolopyrimidinone antianginal agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0526004A1?cl=en">EP0526004A1</a></td><td class="patent-data-table-td patent-date-value">Jul 2, 1992</td><td class="patent-data-table-td patent-date-value">Feb 3, 1993</td><td class="patent-data-table-td ">Pfizer Limited</td><td class="patent-data-table-td ">Pyrazolopyrimidinone antianginal agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="http://www.google.com/url?id=kKJcBAABERAJ&amp;q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DFR%26NR%3D2547501A1%26KC%3DA1%26FT%3DD&amp;usg=AFQjCNEGDBeUpRpZScoFXhD7L1wFPyIvaQ">FR2547501A1</a></td><td class="patent-data-table-td patent-date-value"></td><td class="patent-data-table-td patent-date-value"></td><td class="patent-data-table-td "> </td><td class="patent-data-table-td citation-no-title">Title not available</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="http://www.google.com/url?id=kKJcBAABERAJ&amp;q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DJP%26NR%3DH0344324A%26KC%3DA%26FT%3DD&amp;usg=AFQjCNFtC0PyjvVdrVwuo6Om9XvXhKCL7g">JPH0344324A</a></td><td class="patent-data-table-td patent-date-value"></td><td class="patent-data-table-td patent-date-value"></td><td class="patent-data-table-td "> </td><td class="patent-data-table-td citation-no-title">Title not available</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="http://www.google.com/url?id=kKJcBAABERAJ&amp;q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DJP%26NR%3DH09503996A%26KC%3DA%26FT%3DD&amp;usg=AFQjCNHH_ax5b1AaX4QTce6B2Ac0Jkn-Jg">JPH09503996A</a></td><td class="patent-data-table-td patent-date-value"></td><td class="patent-data-table-td patent-date-value"></td><td class="patent-data-table-td "> </td><td class="patent-data-table-td citation-no-title">Title not available</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="http://www.google.com/url?id=kKJcBAABERAJ&amp;q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DJP%26NR%3DS5310599A%26KC%3DA%26FT%3DD&amp;usg=AFQjCNHUXJjOD-EPn9pVIkUVJaY7o_-c3g">JPS5310599A</a></td><td class="patent-data-table-td patent-date-value"></td><td class="patent-data-table-td patent-date-value"></td><td class="patent-data-table-td "> </td><td class="patent-data-table-td citation-no-title">Title not available</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1989010123A1?cl=en">WO1989010123A1</a></td><td class="patent-data-table-td patent-date-value">Apr 19, 1989</td><td class="patent-data-table-td patent-date-value">Nov 2, 1989</td><td class="patent-data-table-td ">Recordati Chem Pharm</td><td class="patent-data-table-td ">Flevoxate and derivatives for erectile dysfunctions</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1994028902A1?cl=en">WO1994028902A1</a></td><td class="patent-data-table-td patent-date-value">May 13, 1994</td><td class="patent-data-table-td patent-date-value">Dec 22, 1994</td><td class="patent-data-table-td ">Peter Ellis</td><td class="patent-data-table-td ">Pyrazolopyrimidinones for the treatment of impotence</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1996016644A1?cl=en">WO1996016644A1</a></td><td class="patent-data-table-td patent-date-value">Oct 16, 1995</td><td class="patent-data-table-td patent-date-value">Jun 6, 1996</td><td class="patent-data-table-td ">Simon Fraser Campbell</td><td class="patent-data-table-td ">cGMP-PDE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1999021562A1?cl=en">WO1999021562A1</a></td><td class="patent-data-table-td patent-date-value">Oct 28, 1998</td><td class="patent-data-table-td patent-date-value">May 6, 1999</td><td class="patent-data-table-td ">Vivus Inc</td><td class="patent-data-table-td ">Treatment of female sexual dysfunction</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2000066114A1?cl=en">WO2000066114A1</a></td><td class="patent-data-table-td patent-date-value">Apr 26, 2000</td><td class="patent-data-table-td patent-date-value">Nov 9, 2000</td><td class="patent-data-table-td ">Lora L Allemeier</td><td class="patent-data-table-td ">Treatment of female arousal disorder</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="npl-citations"></a><div class="patent-section-header"><span class="patent-section-title">Non-Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th colspan="3"class="patent-data-table-th">Reference</th></tr></thead><tr><td class="patent-data-table-td ">1</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">"<a href='http://scholar.google.com/scholar?q="Chemical+A+Factor+in+Male+Impotence"'>Chemical A Factor in Male Impotence</a>", Jan. 9, 1992, NY Times, D. Blakeslee.</td></tr><tr><td class="patent-data-table-td ">2</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">"<a href='http://scholar.google.com/scholar?q="Double+Blind+Trial+of+Oral+Prostaglandin+E1+on+Impotence"'>Double Blind Trial of Oral Prostaglandin E1 on Impotence</a>" (1992) (abstract submitted in English).</td></tr><tr><td class="patent-data-table-td ">3</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">"<a href='http://scholar.google.com/scholar?q="Stop+Fancying+Each+Other"'>Stop Fancying Each Other</a>", News Paper Article.</td></tr><tr><td class="patent-data-table-td ">4</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">"<a href='http://scholar.google.com/scholar?q="What+About+the+Female+Partner%27s+Quality+of+Life+in+ED%3F"'>What About the Female Partner's Quality of Life in ED?</a>" (2000), Chevret-Measson et al.</td></tr><tr><td class="patent-data-table-td ">5</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">11487 Appeal.</td></tr><tr><td class="patent-data-table-td ">6</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">15th World Congress of Sexology. Jun. 24, 2001, M. A. Perelman, Abstract Book:181.</td></tr><tr><td class="patent-data-table-td ">7</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">15th World Congress of Sexology. Jun. 24, 2001; Van Lunsen Abstract Book:240.</td></tr><tr><td class="patent-data-table-td ">8</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">28th British Congress of Obstetrics and Gynaecology Abstract Status Report (1998), No. 7085.</td></tr><tr><td class="patent-data-table-td ">9</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">A Pilot Study of the Effect of Viagra (sildenafil citrate) on Vaginal Blood Flow in Female Subjects (2000).</td></tr><tr><td class="patent-data-table-td ">10</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">A) Notification of refusal of Jun. 19, 1997 in Japanese Patent Application 7501234 B) Response dated Jan. 8, 1998 from the patentees C) Further response dated Feb. 17, 1998 and Tables attached thereto D) Footnotes by the present opponents referring to 4(C).</td></tr><tr><td class="patent-data-table-td ">11</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">ABPI Data Sheet Compendium 1990-91—D9, pp. 740-742.</td></tr><tr><td class="patent-data-table-td ">12</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">ABPI Data Sheet Compendium 1991-1992 (Datapharm Publications Limited 1991) p. 588 Entry on Trental.</td></tr><tr><td class="patent-data-table-td ">13</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Abstract 88:6075 from IPA database (1988).</td></tr><tr><td class="patent-data-table-td ">14</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Action to declare void and to re-establish the right of Pfizer Research and Development Company.</td></tr><tr><td class="patent-data-table-td ">15</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Admissions by Respondent by letters.</td></tr><tr><td class="patent-data-table-td ">16</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Affidavit of Dr. Yaakov Ramon (unsigned).</td></tr><tr><td class="patent-data-table-td ">17</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Am J Psychiatry; Oct. 1999; 156(10):1664.</td></tr><tr><td class="patent-data-table-td ">18</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">American College of Obstetrics and Gynecologists (ACOG) 48th Annual Clinical Meeting: Abstract Status Report (May 20-24, 2000), No. 7217.</td></tr><tr><td class="patent-data-table-td ">19</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Angiology. vol. 42(5), 1991, p. 418-420 Kent S. Allenby et al "<a href='http://scholar.google.com/scholar?q="Pentoxifylline+in+the+treatment+of+vascular+impotence%E2%80%94Case+reports"'>Pentoxifylline in the treatment of vascular impotence—Case reports</a>".</td></tr><tr><td class="patent-data-table-td ">20</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Annex A to Petitioner's Skeleton Argument.</td></tr><tr><td class="patent-data-table-td ">21</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Annexes to Appellant's Notice of Appeal.</td></tr><tr><td class="patent-data-table-td ">22</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Answer.</td></tr><tr><td class="patent-data-table-td ">23</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Anti-Impotence Drug by Debra McGarry, CBS Market Watch (Jan. 12, 2000).</td></tr><tr><td class="patent-data-table-td ">24</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Appeal Brief.</td></tr><tr><td class="patent-data-table-td ">25</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Appellant's Notice.</td></tr><tr><td class="patent-data-table-td ">26</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Appellant's Skeleton Argument.</td></tr><tr><td class="patent-data-table-td ">27</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Application as Filed.</td></tr><tr><td class="patent-data-table-td ">28</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Argument Papers from Dutch Revocation Proceeding.</td></tr><tr><td class="patent-data-table-td ">29</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Aronson et al (1991) J. Urology 145: Abstract 516-D1.</td></tr><tr><td class="patent-data-table-td ">30</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Arzneimittel-Forschung (Germany), 1988, vol. 38, pp. 379-382; by P. Cazzulani et al.</td></tr><tr><td class="patent-data-table-td ">31</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Asia Pacific Journal of Pharmacology, 1991, pp. 213-227 by Adaikan et al.</td></tr><tr><td class="patent-data-table-td ">32</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Bayer 1.</td></tr><tr><td class="patent-data-table-td ">33</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Bayer 2.</td></tr><tr><td class="patent-data-table-td ">34</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Bayer Exhibits (2 volumes).</td></tr><tr><td class="patent-data-table-td ">35</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Bayer Opposition Statement (with Exhibits).</td></tr><tr><td class="patent-data-table-td ">36</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Bayer: SCRAPS BAY 19-8004 for Asthma and COPD in P2-Jun. 14, 2001(vardenafil).</td></tr><tr><td class="patent-data-table-td ">37</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Bayer's Exhibits Produced During Opening Speeches and Cross-Examination (2 binders).</td></tr><tr><td class="patent-data-table-td ">38</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Bayer's Statement of Argument (D1-16) (w/attachments).</td></tr><tr><td class="patent-data-table-td ">39</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Biochemical Pharmacology, 46(5), p. 833-839 (1993), Sacki et al.</td></tr><tr><td class="patent-data-table-td ">40</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Bowman, Anne et al., British J. Pharmac., 81, 665-674 (1984).</td></tr><tr><td class="patent-data-table-td ">41</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Br J Obstet Gynaecol. Jun. 2001; 108:Editor's Choice Introduction.</td></tr><tr><td class="patent-data-table-td ">42</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Br. J. Dis. Chest (1986) 80, 157; by J. Reiser et al.</td></tr><tr><td class="patent-data-table-td ">43</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Br. J. Pharmacol. (1983), 108, 562-568; by J. Cortijo et al.</td></tr><tr><td class="patent-data-table-td ">44</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">BR. J. Pharmocol. (1993) 108, 562-568.</td></tr><tr><td class="patent-data-table-td ">45</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Brief Requesting Urgent Prosecution of Appeal May 31, 2001.</td></tr><tr><td class="patent-data-table-td ">46</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Brit. J. Urology, 71: 365 (Mar. 1993).</td></tr><tr><td class="patent-data-table-td ">47</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">British Journal of Diseases of the Chest, 77, p78-86 (1983), Rudd et al.</td></tr><tr><td class="patent-data-table-td ">48</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">British Journal of Obstetrics &amp; Gynaecology, Jun. 2001, vol. 108, pp. 623-628.</td></tr><tr><td class="patent-data-table-td ">49</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">British Journal of Pharmacology (1998) 124, 000-000, Cellek et al.</td></tr><tr><td class="patent-data-table-td ">50</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">British Journal of Pharmacology, (1992), 106, p. 1028-1034, de Boer et al.</td></tr><tr><td class="patent-data-table-td ">51</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">British Journal of Urology (1996), 78, 257-261 by Boolell et al.</td></tr><tr><td class="patent-data-table-td ">52</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Bush, Peggy A., et al., J. of Urology, 147, 1650-1655 (1992).</td></tr><tr><td class="patent-data-table-td ">53</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Butcher and Sutherland, Biochem J, 1962, 237: 1244-1250.</td></tr><tr><td class="patent-data-table-td ">54</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Challiss et al, Br J Pharmacol (1998) 124, 47-52.</td></tr><tr><td class="patent-data-table-td ">55</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Cialis (SD) Launch '<a href='http://scholar.google.com/scholar?q="02E%2C+Pk+sales+Est+%241B%2C+30%25+SOM+"'>02E, Pk sales Est $1B, 30% SOM </a>'07E (Jan. 9, 2001).</td></tr><tr><td class="patent-data-table-td ">56</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Cialis's Unfavorable Results in Female Sexual Dysfunction ( SG Cowen Securities/Scala, Jun. 18, 2001).</td></tr><tr><td class="patent-data-table-td ">57</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Clin. Res. vol. 36(1), 123A, 1988, Korenman SG "<a href='http://scholar.google.com/scholar?q="Treatment+of+vasculogenic+sexual+dysfunctionwith+pentoxifylline"'>Treatment of vasculogenic sexual dysfunctionwith pentoxifylline</a>".</td></tr><tr><td class="patent-data-table-td ">58</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Clinics in Endocrinology and Metabolism (1982), 11(3), Nov., pp. 785-789, by John Bancroft.</td></tr><tr><td class="patent-data-table-td ">59</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Closing Submissions of Pfizer.</td></tr><tr><td class="patent-data-table-td ">60</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">CNN interactive on line—"<a href='http://scholar.google.com/scholar?q="Viagra%3F+No%2C+vuka+vuka%3F"'>Viagra? No, vuka vuka?</a>" Jun. 19, 1998 (www.cnn.com).</td></tr><tr><td class="patent-data-table-td ">61</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Curr Psychiatry Rep. 2001 (3): 188-194, Shabsigh.</td></tr><tr><td class="patent-data-table-td ">62</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Current Opinion in Neurobiology (1999) 9: 751-758, Pfaus.</td></tr><tr><td class="patent-data-table-td ">63</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Day Eight Minuscript: Dec. 19, 2000.</td></tr><tr><td class="patent-data-table-td ">64</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Day Five Minuscript: Nov. 30, 2000.</td></tr><tr><td class="patent-data-table-td ">65</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Day Four Minuscript: Nov. 29, 2000.</td></tr><tr><td class="patent-data-table-td ">66</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Day Nine Minuscript: Jan. 17, 2001.</td></tr><tr><td class="patent-data-table-td ">67</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Day Seven Minuscript: Dec. 18, 2000.</td></tr><tr><td class="patent-data-table-td ">68</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Day Six Minuscript: Dec. 17, 2000.</td></tr><tr><td class="patent-data-table-td ">69</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Day Three Minuscript: Nov. 28, 2000.</td></tr><tr><td class="patent-data-table-td ">70</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Day Two Minuscript: Nov. 27, 2000.</td></tr><tr><td class="patent-data-table-td ">71</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Decision Dated Dec. 21, 2001.</td></tr><tr><td class="patent-data-table-td ">72</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Decision Dated Mar. 27, 2001.</td></tr><tr><td class="patent-data-table-td ">73</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Decision of the District Court of Hague dated Oct. 4, 2000 (including English Translation).</td></tr><tr><td class="patent-data-table-td ">74</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Declaration of Alonso Acuna Canas.</td></tr><tr><td class="patent-data-table-td ">75</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Declaration of Cesar Jaramillo.</td></tr><tr><td class="patent-data-table-td ">76</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Declaration of Clive Page.</td></tr><tr><td class="patent-data-table-td ">77</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Declaration of David Goren (with Appendixes).</td></tr><tr><td class="patent-data-table-td ">78</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Declaration of Dr. Inigo Saenz de Tejada.</td></tr><tr><td class="patent-data-table-td ">79</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Declaration of Ian Eardley (w/Annexes).</td></tr><tr><td class="patent-data-table-td ">80</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Declaration of Ken Murray (w/exhibits).</td></tr><tr><td class="patent-data-table-td ">81</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Declaration of Laurence Howard Skillern (w/attachments).</td></tr><tr><td class="patent-data-table-td ">82</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Declaration of Laurence Howard Skillern.</td></tr><tr><td class="patent-data-table-td ">83</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Declaration of Louis J. Ignarro (with References).</td></tr><tr><td class="patent-data-table-td ">84</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Declaration of Nicolas K. Terrett (co-inventor).</td></tr><tr><td class="patent-data-table-td ">85</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Declaration of Peter Ellis (with References).</td></tr><tr><td class="patent-data-table-td ">86</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Declaration of R.A. John Chaliss (w/Annexes).</td></tr><tr><td class="patent-data-table-td ">87</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Declaration of Stephen A. Ballard (in the Korean Industrial Property Office).</td></tr><tr><td class="patent-data-table-td ">88</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Declaration of Steven Ballard.</td></tr><tr><td class="patent-data-table-td ">89</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Defendant's Schedule in relation to Commercial Success.</td></tr><tr><td class="patent-data-table-td ">90</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Disclosure Document # 110: The Lancet, vol. 340. Oct. 10, 1992.</td></tr><tr><td class="patent-data-table-td ">91</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Disclosure Document # 117: Science, vol. 258. Dec. 18, 1992.</td></tr><tr><td class="patent-data-table-td ">92</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Disclosure Document # 18 : DN&amp;P 4(7), Sep. 1991.</td></tr><tr><td class="patent-data-table-td ">93</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Disclosure Document # 368: Pfizer's Public Affairs Briefing: Press Reports on Clinical Trials of UK-92,480 Jan. 1995.</td></tr><tr><td class="patent-data-table-td ">94</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Dissertation of Margaret Bush (part of "<a href='http://scholar.google.com/scholar?q="BQ"'>BQ</a>").</td></tr><tr><td class="patent-data-table-td ">95</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Doctors Find Viagra Works Just as Well in Women (The Sunday Telegraph—UK).</td></tr><tr><td class="patent-data-table-td ">96</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Documents Being Submitted by Lilly in EPO Opposition (May 14, 2001).</td></tr><tr><td class="patent-data-table-td ">97</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Documents Containing Production of Exhibits, also Containing Skeleton Arguments (w/translation) &amp; Letter of Jul. 7, 2000.</td></tr><tr><td class="patent-data-table-td ">98</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Documents Filed by the Proprietors: D 86-D 118 (Binder B).</td></tr><tr><td class="patent-data-table-td ">99</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Documents Filed with EPO by Opponent 2 (May 14, 2001).</td></tr><tr><td class="patent-data-table-td ">100</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Documents Filed with the EPO: D 119-D 140 (Binder C).</td></tr><tr><td class="patent-data-table-td ">101</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Documents Filed with the EPO: D 141-D 163 (Binder D).</td></tr><tr><td class="patent-data-table-td ">102</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Drug Therapy, vol. 19(8), 102-111, 1989, Fishman I. J. "<a href='http://scholar.google.com/scholar?q="Treating+Erectile+dysfunction"'>Treating Erectile dysfunction</a>".</td></tr><tr><td class="patent-data-table-td ">103</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Eardley, Current Opinion in Urology, 3(2): V 24.</td></tr><tr><td class="patent-data-table-td ">104</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Eardley, Current Opinion in Urology, 3(5): II-40.</td></tr><tr><td class="patent-data-table-td ">105</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Effect of Vasoactive Agents in Modulating Vaginal Smooth Muscle Contractility: Implications for Treatment of Female Sexual Dysfunction (2000), Berman et al.</td></tr><tr><td class="patent-data-table-td ">106</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Efficacy and Safety of Viagra (sildenafil citrate) in Estrogenised Women with Sexual Dysfunction Associated with FSAD.</td></tr><tr><td class="patent-data-table-td ">107</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Efficacy and Safety of Viagra (sildenafil citrate) in Non-Oestrogenised Women with Sexual Dysfunction Associated with FSAD (2000).</td></tr><tr><td class="patent-data-table-td ">108</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">English Translation of Argument Filed on Jan. 8, 1998.</td></tr><tr><td class="patent-data-table-td ">109</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">English Translation: Haen &amp; Emslander: Optimizing Therapy with Methylxanthines; German Gazette for Physicians, 86 (33), 1989, C-1435-C-1437 (Reference D3 from the opposition of Bayer AG).</td></tr><tr><td class="patent-data-table-td ">110</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">English Translation: Prof. Dr. Med. J. C. Frolich, Oct. 12, 1998. (Exhibit 2 from the opposition of Bristol Myers Squibb).</td></tr><tr><td class="patent-data-table-td ">111</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">English Translation: Rote Liste 1992, pp. 36 073 and 54 108, (Persantin®, INN: Dipyridamole and Trental®, INN: Pentoxyfyline). (Reference 5 from the opposition of Bristol Myers Squibb).</td></tr><tr><td class="patent-data-table-td ">112</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">English Translation: von Koenen: "<a href='http://scholar.google.com/scholar?q="Heil-und+Giftpflanzen+in+Sudwestafrika"'>Heil-und Giftpflanzen in Sudwestafrika</a>", Akademischer Verlag Winkhoek, S.W.A., 1979, p. 61. (Reference D13 from the opposition of Bayer AG).</td></tr><tr><td class="patent-data-table-td ">113</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">EPO Preliminary Opinion.</td></tr><tr><td class="patent-data-table-td ">114</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">European Heart Journal (1993, 14, (Supp. 1), pp. 141-148—Lugnier et al.</td></tr><tr><td class="patent-data-table-td ">115</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">European Journal of Pharmacology 400(2000) 305-312, Frith et al.</td></tr><tr><td class="patent-data-table-td ">116</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Excerpts from the UCLA doctoral dissertation of Margaret Ann Bush, including pp. ii-Xvii, 1 and 154-161, 1993.</td></tr><tr><td class="patent-data-table-td ">117</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Exhibit 1; Gray's Anatomie, Churchill Livingstone, 38th Edition.</td></tr><tr><td class="patent-data-table-td ">118</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Exhibit 2; Prof. Dr. Med. J. C. Frölich, Oct. 12, 1998.</td></tr><tr><td class="patent-data-table-td ">119</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Exhibits Produced at Trial.</td></tr><tr><td class="patent-data-table-td ">120</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Exp. Clin. Endocrinol. vol. 98, No. 2, 1991, pp. 61-69 by R. J. Levin.</td></tr><tr><td class="patent-data-table-td ">121</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Experimental Report to Israeli Opposition Statement.</td></tr><tr><td class="patent-data-table-td ">122</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Expert Report of Dennis Smith (w/Annexes).</td></tr><tr><td class="patent-data-table-td ">123</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Expert Report of Ian Eardley (w/Annexes).</td></tr><tr><td class="patent-data-table-td ">124</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Expert Report of John Pryor (w/Annexes).</td></tr><tr><td class="patent-data-table-td ">125</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Expert Report of Kenneth Duncan Macrae (w/Annexes).</td></tr><tr><td class="patent-data-table-td ">126</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Expert Report of Lawrence Kruse (w/Annexes).</td></tr><tr><td class="patent-data-table-td ">127</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Expert Report of Louis Ignarro (w/Annexes).</td></tr><tr><td class="patent-data-table-td ">128</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Expert Report of Peter Ellis (w/Annexes).</td></tr><tr><td class="patent-data-table-td ">129</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Expert Report of Robert Challis (w/Annexes).</td></tr><tr><td class="patent-data-table-td ">130</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Expert Report of Robert Gristwood (w/Annexes).</td></tr><tr><td class="patent-data-table-td ">131</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Expert Report of Robin Leatherbarrow (w/Annexes).</td></tr><tr><td class="patent-data-table-td ">132</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">F. Holmquist et al., Arta Physiol Scand, 1991, vol. 143, pp. 299-304.</td></tr><tr><td class="patent-data-table-td ">133</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Female Sexual Dysfunction by Cheryl Terhorst (Apr. 18, 2001).</td></tr><tr><td class="patent-data-table-td ">134</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Female Sexual Dysfunction—Mosaic Study #16—Nov. 1999.</td></tr><tr><td class="patent-data-table-td ">135</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Fernandes et al, Am J Prspir Crit Care Med vol. 150, 1384-1390.</td></tr><tr><td class="patent-data-table-td ">136</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Fertil Steril. Sep. 2001; 76(3 Suppl 1): S255 (#P-430).</td></tr><tr><td class="patent-data-table-td ">137</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Fifth Witness Statement of Mark Thomas Hodgson (w/Exhibits).</td></tr><tr><td class="patent-data-table-td ">138</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Fifth Witness Statement of Trevor Martin Cook.</td></tr><tr><td class="patent-data-table-td ">139</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">FIGO World Congress of Gynecology and Obstetrics (2000), Abstract Status Report, Nos. 7279, 7280 &amp; 7281.</td></tr><tr><td class="patent-data-table-td ">140</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">First Declaration of Stephen A. Ballard (in the U. S. Patent and Trademark Office).</td></tr><tr><td class="patent-data-table-td ">141</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">First Witness Statement of Dr. Kenneth M. Ferguson (w/Exhibits).</td></tr><tr><td class="patent-data-table-td ">142</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">First Witness Statement of James Michael Marshall (w/Exhibits).</td></tr><tr><td class="patent-data-table-td ">143</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">First Witness Statement of Mark Thomas Hodgson (w/Exhibits).</td></tr><tr><td class="patent-data-table-td ">144</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">First Witness Statement of Robert Geoffrey Paget Williams (w/Exhibits).</td></tr><tr><td class="patent-data-table-td ">145</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">First Witness Statement of Trevor Martin Cook (w/Exhibits).</td></tr><tr><td class="patent-data-table-td ">146</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Fourth Witness Statement of Mark Thomas Hodgson (w/Exhibits).</td></tr><tr><td class="patent-data-table-td ">147</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Fourth Witness Statement of Trevor Martin Cook.</td></tr><tr><td class="patent-data-table-td ">148</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Further Substantive Submission by O-6 (May 2, 2001).</td></tr><tr><td class="patent-data-table-td ">149</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Further Substantive Submissions (in German) (May 2, 2001) (w/translation).</td></tr><tr><td class="patent-data-table-td ">150</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Further Substantive Submissions by O-10 (May 16, 2001).</td></tr><tr><td class="patent-data-table-td ">151</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Further Substantive Submissions by O-11 (May 16, 2001).</td></tr><tr><td class="patent-data-table-td ">152</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Further Substantive Submissions by O-12 (May 16, 2001).</td></tr><tr><td class="patent-data-table-td ">153</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Further Substantive Submissions by O-3 (May 14, 2001).</td></tr><tr><td class="patent-data-table-td ">154</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Further Substantive Submissions by O-8 (May 30, 2001).</td></tr><tr><td class="patent-data-table-td ">155</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Further Substantive Submissions by O-9 (w/English Translation) (May 11, 2001).</td></tr><tr><td class="patent-data-table-td ">156</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Further Substantive Submissions on Behalf of O-2 and O-5 (Jul. 4, 2001).</td></tr><tr><td class="patent-data-table-td ">157</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">German Gazette for Physicians 86, No. 33, Aug. 17, 1989, C-1436 to 1440, Haer et al.</td></tr><tr><td class="patent-data-table-td ">158</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Gristwood and Owen, British Journal of Pharmacology, 1986, 87, 91P.</td></tr><tr><td class="patent-data-table-td ">159</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Gristwood et al, Br J Pharmacol, 1986, 89: 573P.</td></tr><tr><td class="patent-data-table-td ">160</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Grounds for Rejection.</td></tr><tr><td class="patent-data-table-td ">161</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Grounds of Opposition of Opponent II, ICOS Corp, to EP-B-0702555.</td></tr><tr><td class="patent-data-table-td ">162</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Gruetter et al, J Cyclic Nucleotide Res 5: 211-124, 1979.</td></tr><tr><td class="patent-data-table-td ">163</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Hager's Handbuch der Pharmazeutischen Praxis, 4. Aufl., 1971, S. 675-676.</td></tr><tr><td class="patent-data-table-td ">164</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Harvey C. Taub, et al., Urology, 1993, vol. 42, No. 6, pp. 698-704.</td></tr><tr><td class="patent-data-table-td ">165</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Hysterectomy &amp; Sexual Dysfunction: Effects of Sildenafil in a Clinical Setting (May 2, 2000), Berman et al.</td></tr><tr><td class="patent-data-table-td ">166</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Impotence, 1995, vol. 22, No. 4, pp. 879-886—Morales et al.</td></tr><tr><td class="patent-data-table-td ">167</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Int J Impot Res (2000); 12 Supp 3:S32-S39, Min et al.</td></tr><tr><td class="patent-data-table-td ">168</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Int J Impot Res (2000); 12 Supp 4:S152-S157, Goldstein.</td></tr><tr><td class="patent-data-table-td ">169</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Int J Impot Res Apr. 2000;12(Supp 2):S17.</td></tr><tr><td class="patent-data-table-td ">170</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Int. J. Impotence Res. (1992) 4 Suppl. 2, Abstracts of the 5th World Congress on Impotence, Milan, Sep. 14-17, 1992, Taher et.</td></tr><tr><td class="patent-data-table-td ">171</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Int. J. Impotence Res. (1992) 4, Suppl. 2 p. 11, Taher et al.</td></tr><tr><td class="patent-data-table-td ">172</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">International Journal Impotence Research, 1995, pp. 13, by H. H. Knispel et al.</td></tr><tr><td class="patent-data-table-td ">173</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">International Journal of Impotence Research (Jun. 1996), vol. 8, No. 2, pp. 47-52, Boolell et al.</td></tr><tr><td class="patent-data-table-td ">174</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">International Journal of Impotence Research vol. 6, No. 1, Mar. 1994, pp. 33-35.</td></tr><tr><td class="patent-data-table-td ">175</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">International Journal of Impotence Research, 4 (Suppl. 2) (1992) p. 19.</td></tr><tr><td class="patent-data-table-td ">176</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">International Journal of Impotence Research, Supp 12: S32-S39, Min et al.</td></tr><tr><td class="patent-data-table-td ">177</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">International Journal of Impotence Research, Supplement 1, Sep. 1995.</td></tr><tr><td class="patent-data-table-td ">178</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Israeli Opposition Statement of Bayer Aktiengesellschaft.</td></tr><tr><td class="patent-data-table-td ">179</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">J Sex Marital Ther (2000) Apr.-Jun.; 26:133-140.</td></tr><tr><td class="patent-data-table-td ">180</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">J Sex Marital Ther. 2001: 27:427-433, Berman et al.</td></tr><tr><td class="patent-data-table-td ">181</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">J Sex Marital Ther. 2001; 27:411-420, Berman et al.</td></tr><tr><td class="patent-data-table-td ">182</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">J Sex Martial Ther. Oct. 2001; 27(5):421-425, Berman et al.</td></tr><tr><td class="patent-data-table-td ">183</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">J Sex Res. 2001; 38(2): 89-96.</td></tr><tr><td class="patent-data-table-td ">184</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">J Urol. 2001, May; 165(5) Supplement: P227 (#935).</td></tr><tr><td class="patent-data-table-td ">185</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">J. Berman's Poster at 1999 AUA Conference.</td></tr><tr><td class="patent-data-table-td ">186</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">J. Mol. Cell. Cardio vol. 12(10), 1980, 939-954, 1980, Argel M.I. et al., "<a href='http://scholar.google.com/scholar?q="Effect+of+phosphodiesterase+inhibitors+onheart+contractile+behaviour%2C+protein+kinase+activity+and+cyclic+nucleotide+level"'>Effect of phosphodiesterase inhibitors onheart contractile behaviour, protein kinase activity and cyclic nucleotide level</a>"(abstract).</td></tr><tr><td class="patent-data-table-td ">187</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">J. of Ethnopharmacology, 12 (1984) 35-74, particularly p. 42, Arnold et al.</td></tr><tr><td class="patent-data-table-td ">188</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">J. of Sexual &amp; Marital Therapy, 27:411-420, 2001, Berman et al.</td></tr><tr><td class="patent-data-table-td ">189</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">J. of Steroid Biochemistry &amp; Molecular Biology 69 (1999) 177-184, S.R. Davis.</td></tr><tr><td class="patent-data-table-td ">190</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">J. of Urol. (1993), vol. 149(4), p. 285A.</td></tr><tr><td class="patent-data-table-td ">191</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">J. Steroid Biochem. Molec. Biol. vol. 39, No. 6 pp. 873-881, 1991 by Williams-Ashman et al.</td></tr><tr><td class="patent-data-table-td ">192</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">JAGS 41: 363-366, 1993; by Stanley G. Korenman et al.</td></tr><tr><td class="patent-data-table-td ">193</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Journal of Ethnopharmacology, 12 (1984) 35-74.</td></tr><tr><td class="patent-data-table-td ">194</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Journal of Japanese Society of Urology, 83(10, p 1655-1661 (1992), Kawanishi et al.</td></tr><tr><td class="patent-data-table-td ">195</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Journal of Medicine, vol. 10, No. 6, 1979; by J. L. Ambrus et al.</td></tr><tr><td class="patent-data-table-td ">196</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Journal of Sex &amp; Marital Therapy, 26: 191-208 (2000).</td></tr><tr><td class="patent-data-table-td ">197</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Journal of Urology (1999), 161, pp. 940-944 by Tarcan et al.</td></tr><tr><td class="patent-data-table-td ">198</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Journal of Urology 147, 4th Supplement, p. 454A, 1992, No. 967, Aronson et al.</td></tr><tr><td class="patent-data-table-td ">199</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Journal of Urology 149:285A (Apr. 1993).</td></tr><tr><td class="patent-data-table-td ">200</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Journal of Urology 150: 1310-1315 (Oct. 1993), Holmquist.</td></tr><tr><td class="patent-data-table-td ">201</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Journal of Urology, vol. 149, 872-877, 1993, Trigo-Rocha et al, The role of cyclic adenosine monophosphate, cyclic guanosine monophosphate, endothelium and nonadrenergic, noncholinergic neurotransmission in canine penile erection.</td></tr><tr><td class="patent-data-table-td ">202</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Judgment Given at Hearing on Aug. 17, 2000.</td></tr><tr><td class="patent-data-table-td ">203</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Judgment given by Justice Laddie in the Revocation Action Nov. 10, 2000 (part of "<a href='http://scholar.google.com/scholar?q="BQ"'>BQ</a>").</td></tr><tr><td class="patent-data-table-td ">204</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Judgment of Invalidity Proceedings in the District Court of the Netherlands Oct. 4, 2001 (part of "<a href='http://scholar.google.com/scholar?q="BQ"'>BQ</a>").</td></tr><tr><td class="patent-data-table-td ">205</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Judgment of Nov. 8, 2000.</td></tr><tr><td class="patent-data-table-td ">206</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Karl-Erik Anderson et al. The American Physiological Society, 1995, vol. 75, pp. 191-236.</td></tr><tr><td class="patent-data-table-td ">207</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Krall, Fittinghoff and Rajfer, Biol Reprod, 39(4): 913-22.</td></tr><tr><td class="patent-data-table-td ">208</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Kukovetz et al (1979) Naunyn-Schmiedeberg's Arch. Pharmacol. 310: 129-138—D6.</td></tr><tr><td class="patent-data-table-td ">209</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Lepakhin Publication (1988) (w/excerpt translated).</td></tr><tr><td class="patent-data-table-td ">210</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Letter by Opponent Bayer (Mar. 30, 2001).</td></tr><tr><td class="patent-data-table-td ">211</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Letter Dated Dec. 20, 2000 to European Patent Office.</td></tr><tr><td class="patent-data-table-td ">212</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Letter Dated Dec. 21, 2000 with Submissions to European Patent Office.</td></tr><tr><td class="patent-data-table-td ">213</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Letter Dated Jun. 14, 2000 (including English Translation) with the New Notice of Experiments Attached.</td></tr><tr><td class="patent-data-table-td ">214</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Letter Dated Jun. 30, 2000 (w/English translation) with Additional Exhibits 1-5 Attached.</td></tr><tr><td class="patent-data-table-td ">215</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Letter Enclosing Annex G by O-2 (May 16, 2001).</td></tr><tr><td class="patent-data-table-td ">216</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Letter from Opponent VII of May 16, 2000.</td></tr><tr><td class="patent-data-table-td ">217</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Letter of Feb. 22, 2000.</td></tr><tr><td class="patent-data-table-td ">218</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Letter of Jul. 3, 2000 (w/translation).</td></tr><tr><td class="patent-data-table-td ">219</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Letter of Mar. 27, 2000.</td></tr><tr><td class="patent-data-table-td ">220</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Letter of Mar. 28, 2000.</td></tr><tr><td class="patent-data-table-td ">221</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Letter to by O-2 (May 16, 2001).</td></tr><tr><td class="patent-data-table-td ">222</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Letter to EPO by O-2 dated Jun. 14, 2001.</td></tr><tr><td class="patent-data-table-td ">223</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Letter to EPO by O-5 dated Jun. 15, 2001.</td></tr><tr><td class="patent-data-table-td ">224</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Letter to EPO dated Dec. 30, 2000.</td></tr><tr><td class="patent-data-table-td ">225</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Letter to EPO Filing Further Documents (Apr. 5, 2001) (w/documents).</td></tr><tr><td class="patent-data-table-td ">226</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Letter to Patentee dated Jun. 14, 2001.</td></tr><tr><td class="patent-data-table-td ">227</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Letters dated Apr. 30, 2000 &amp; Sep. 8, 1999.</td></tr><tr><td class="patent-data-table-td ">228</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Letters Discussing Repeats of Experiments.</td></tr><tr><td class="patent-data-table-td ">229</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">M. F. Meyer et al., Ann Urol., 1993, vol. 27, No. 3, pp. 179-182.</td></tr><tr><td class="patent-data-table-td ">230</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Martindale Extra Pharmacopoeia 29th Edition 1989, p. 1423, Heading 14026-m.</td></tr><tr><td class="patent-data-table-td ">231</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Minutes of the Oral Proceedings before the Opposition Division (w/annexes) (Jul. 16, 2001).</td></tr><tr><td class="patent-data-table-td ">232</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Mirone, V., et al., British J. of Urology, 71, 3, 365 (1993).</td></tr><tr><td class="patent-data-table-td ">233</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Mol Cell Biol Res Commun (1999) 2(2): 131-137, Traish et al.</td></tr><tr><td class="patent-data-table-td ">234</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Molecular Pharmacology 36(5), 773-781, 1989, Gillespie P. G. Et Beavo J. A. "<a href='http://scholar.google.com/scholar?q="Inhibition+and+stimulation+of+photoreceptor+phosphodiesterases+by+dipyridamole+and+M%26amp%3BB22%2C+948"'>Inhibition and stimulation of photoreceptor phosphodiesterases by dipyridamole and M&amp;B22, 948</a>".</td></tr><tr><td class="patent-data-table-td ">235</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Murray, Kenneth J., Drug News &amp; Perspectives, 6, 150-156 (1993).</td></tr><tr><td class="patent-data-table-td ">236</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">New Scientist, Mar. 1999, p. 15.</td></tr><tr><td class="patent-data-table-td ">237</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Nicholson et al., TIPS, Jan. 1991, vol. 12, pp. 19-27.</td></tr><tr><td class="patent-data-table-td ">238</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Notice of Acceptance of Request for Invalidation Re: Patent Invention No. 94192386.X.</td></tr><tr><td class="patent-data-table-td ">239</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Notice of Opposition (Lab. Rec.) Feb. 12, 1999 (w/translation).</td></tr><tr><td class="patent-data-table-td ">240</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Notice of Opposition to EPO Patent (Merck) (w/translations).</td></tr><tr><td class="patent-data-table-td ">241</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Notice of Opposition to EPO Patent (Vivus).</td></tr><tr><td class="patent-data-table-td ">242</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Nullity Action and Restitution Against Resolution Nos. 0112 of Jan. 18, 2000 and 10169 of May 16, 2000.</td></tr><tr><td class="patent-data-table-td ">243</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Nullity Action.</td></tr><tr><td class="patent-data-table-td ">244</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Observations After Viagra: Study on "<a href='http://scholar.google.com/scholar?q="Estrogenized"'>Estrogenized</a>" Women is Released (2000), Berman et al.</td></tr><tr><td class="patent-data-table-td ">245</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Offer of Information (12 references) (w/references).</td></tr><tr><td class="patent-data-table-td ">246</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Offer of Information (7 references) (w/references).</td></tr><tr><td class="patent-data-table-td ">247</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Offer of Information (Japan) citing 12 documents.</td></tr><tr><td class="patent-data-table-td ">248</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Offer of Information (Japan) citing 7 documents.</td></tr><tr><td class="patent-data-table-td ">249</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Offer of Information with translations (4 references) (w/references).</td></tr><tr><td class="patent-data-table-td ">250</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Offer of Information with translations (7 references) (w/references).</td></tr><tr><td class="patent-data-table-td ">251</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Opponents' Submissions from Apr. 6, 2001 onwards (Binder A, Tabs 5-20).</td></tr><tr><td class="patent-data-table-td ">252</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Opposition (w/references) (w/translation).</td></tr><tr><td class="patent-data-table-td ">253</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Opposition by Bayer to Pfizer's Patent Application No. 121836.</td></tr><tr><td class="patent-data-table-td ">254</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Opposition Statement by Opponent 1: Virus.</td></tr><tr><td class="patent-data-table-td ">255</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Opposition Statement of Bayer AG.</td></tr><tr><td class="patent-data-table-td ">256</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Opposition Statement of Bristol-Myers Squibb.</td></tr><tr><td class="patent-data-table-td ">257</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Opposition Statement of Eisai Co., Ltd.</td></tr><tr><td class="patent-data-table-td ">258</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Opposition Statement of Eli Lilly and Company.</td></tr><tr><td class="patent-data-table-td ">259</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Opposition Statement of Fujisawa.</td></tr><tr><td class="patent-data-table-td ">260</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Opposition Statement of ICOS Corporation.</td></tr><tr><td class="patent-data-table-td ">261</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Opposition Statement of Merck Patent Gmblt.</td></tr><tr><td class="patent-data-table-td ">262</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Opposition Statement of Mochida Pharmaceutical Co.</td></tr><tr><td class="patent-data-table-td ">263</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Opposition Statement of Ortho McNeil Pharmaceutical, Inc.</td></tr><tr><td class="patent-data-table-td ">264</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Opposition Statement of Schering-Plough Corp.</td></tr><tr><td class="patent-data-table-td ">265</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Opposition Statement of Synthelabo.</td></tr><tr><td class="patent-data-table-td ">266</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Opposition Statement of Tanabe Seiyaku Co., Ltd.</td></tr><tr><td class="patent-data-table-td ">267</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Oral Arguments on C.J.J.C. Van Nispen (w/translation).</td></tr><tr><td class="patent-data-table-td ">268</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Order of Mr. Justice Laddie—Dec. 5, 2000.</td></tr><tr><td class="patent-data-table-td ">269</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Original First Pleadings Regarding Jurisdiction, Admissibility of Certain Claims and Setting Aside Certain Parties.</td></tr><tr><td class="patent-data-table-td ">270</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Original Fourth Pleadings Regarding Jurisdiction and Admissibility of Claims.</td></tr><tr><td class="patent-data-table-td ">271</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Original Second Pleadings Containing Counterclaim for Abuse of Procedure.</td></tr><tr><td class="patent-data-table-td ">272</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Original Third Pleadings Regarding Jurisdiction and Admissibility of Claims.</td></tr><tr><td class="patent-data-table-td ">273</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Original Writ of Summons.</td></tr><tr><td class="patent-data-table-td ">274</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Paediatrics, Andrology, Infertility, Editorial Comment, by Ian Eardley, Department of Urology, Apr. 1993, Leeds General Infirmary, Leeds, UK.</td></tr><tr><td class="patent-data-table-td ">275</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Paediatrics, Andrology, Infertility, Editorial Comment, by Ian Eardley, Department of Urology, Sep. 1993, Norfolk and Norwich Hospital, UK.</td></tr><tr><td class="patent-data-table-td ">276</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Patent in Suit.</td></tr><tr><td class="patent-data-table-td ">277</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Petition for Leave to Appeal.</td></tr><tr><td class="patent-data-table-td ">278</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Petition for Reconsideration Against Resolution No. 358.</td></tr><tr><td class="patent-data-table-td ">279</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Petition of Lilly Icos LLC, for Leave to Cross Appeal.</td></tr><tr><td class="patent-data-table-td ">280</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Petition.</td></tr><tr><td class="patent-data-table-td ">281</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Petitioner's Civil Evidence Act Notices and attachments.</td></tr><tr><td class="patent-data-table-td ">282</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Petitioner's Closing Submissions.</td></tr><tr><td class="patent-data-table-td ">283</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Petitioner's Letter to Respondent (Jul. 4, 2000).</td></tr><tr><td class="patent-data-table-td ">284</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Petitioner's Notice of Experiments.</td></tr><tr><td class="patent-data-table-td ">285</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Petitioner's Opening Submissions for Trial Before Laddie J.—Oct. 4, 2000.</td></tr><tr><td class="patent-data-table-td ">286</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Petitioner's response to Notice to Admit Facts.</td></tr><tr><td class="patent-data-table-td ">287</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Petition—Feb. 17, 1998.</td></tr><tr><td class="patent-data-table-td ">288</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Pfizer Statement on Salvatore Caruso's Study (May 21, 2001).</td></tr><tr><td class="patent-data-table-td ">289</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Pfizer-Exhibits of the Opening Speeches.</td></tr><tr><td class="patent-data-table-td ">290</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Pfizer—Exhibits of the Opening Speeches.</td></tr><tr><td class="patent-data-table-td ">291</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Pfizer's Combined Response.</td></tr><tr><td class="patent-data-table-td ">292</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Pfizer's Exhibits Produced During Opening Speeches and Cross-Examination.</td></tr><tr><td class="patent-data-table-td ">293</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Pfizer's Reply to Statement of Argument (w/attachments).</td></tr><tr><td class="patent-data-table-td ">294</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Pfizer's Response to Bayer's Reply to the Application to Amend the Claims (w/translation).</td></tr><tr><td class="patent-data-table-td ">295</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Pfizer's Skeleton Argument.</td></tr><tr><td class="patent-data-table-td ">296</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Pharmac. Ther. vol. 51, pp-13-31, 1991; by W. Joseph Thompson.</td></tr><tr><td class="patent-data-table-td ">297</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Pharmacological Reviews 43(2) (1991) pp. 109-142, Moncada et al.</td></tr><tr><td class="patent-data-table-td ">298</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Physicians' Desk Reference, 46th edition, 1992, p. 409, 905, 1190.</td></tr><tr><td class="patent-data-table-td ">299</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Physiol. Rev 75(4), 725-748, 1995, Beavo J. A., "<a href='http://scholar.google.com/scholar?q="Cyclic+nucleotide+phosphodiesterases%3A+Functional+implications+of+multiple+isoforms"'>Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms</a>".</td></tr><tr><td class="patent-data-table-td ">300</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Pilot Study on the Effectiveness of Viagra for Treatment of Female Sexual Dysfunction: Physiologic Predictor for Success (2000), Chai et al.</td></tr><tr><td class="patent-data-table-td ">301</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Pleading Notes of Mr. L. Oosting (w/translation).</td></tr><tr><td class="patent-data-table-td ">302</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Podium 18, "<a href='http://scholar.google.com/scholar?q="Alpha+Blockade+and+Vaginal+Blood+Flow+Response+in+Postmenopausal+Women+with+Female+Sexual+Arousal+Disorder"'>Alpha Blockade and Vaginal Blood Flow Response in Postmenopausal Women with Female Sexual Arousal Disorder</a>" by Rubio et al. pp. 55 (2000).</td></tr><tr><td class="patent-data-table-td ">303</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Porst, J Urol (1993) 149, 1280-1283.</td></tr><tr><td class="patent-data-table-td ">304</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Positive Effects of Sildenafil in Female Sexual Dysfunction Following Hysterectomy (2000).</td></tr><tr><td class="patent-data-table-td ">305</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Post Graduate Medicine 88(2) (1990) 139-152, Whitehead, et al.</td></tr><tr><td class="patent-data-table-td ">306</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Post Graduate Medicine, vol. 88(2), 139-152, 1990 Whithead E. D. "<a href='http://scholar.google.com/scholar?q="Treatment+alternatives+for+impotence"'>Treatment alternatives for impotence</a>".</td></tr><tr><td class="patent-data-table-td ">307</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Postgraduate Medicine, vol. 93, No. 3, Impotence, Feb. 15, 1993, Morley.</td></tr><tr><td class="patent-data-table-td ">308</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Premenopausal Health Care, 20 (2), Jun. 1993 by Gloria A. Bachman, MD.</td></tr><tr><td class="patent-data-table-td ">309</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Priority Document.</td></tr><tr><td class="patent-data-table-td ">310</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Proceedings of the American Urological Association, vol. 155, May 1996, Supplement 623A.</td></tr><tr><td class="patent-data-table-td ">311</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Progress with Viagra for FSD (Scrip daily News) Mar. 15, 2000.</td></tr><tr><td class="patent-data-table-td ">312</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Proprietor's Submissions from May 16, 2001 onwards (Binder A, Tabs 1-4).</td></tr><tr><td class="patent-data-table-td ">313</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Psychiatric Services; Aug. 1999; 50(8):1076-1078.</td></tr><tr><td class="patent-data-table-td ">314</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Psychosomatic Medicine, vol. 38, No. 6 (Nov.-Dec. 1976) pp. 418-425 by Leon A. Abramov.</td></tr><tr><td class="patent-data-table-td ">315</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Pyrazolopyrimidinones for the Treatment of Impotence (submitted by Opponent II, ICOS Corp.).</td></tr><tr><td class="patent-data-table-td ">316</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Radiology 2000, 214(2):611.</td></tr><tr><td class="patent-data-table-td ">317</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Rajfer, Jacob, et al., New England Journal of Medicine, 326, 2, 90-94 (1992).</td></tr><tr><td class="patent-data-table-td ">318</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Re-amended Particulars of Objections.</td></tr><tr><td class="patent-data-table-td ">319</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Reason for Revocation.</td></tr><tr><td class="patent-data-table-td ">320</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Rebuttal Brief by Appellant.</td></tr><tr><td class="patent-data-table-td ">321</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Rebuttal Brief by Plaintiff.</td></tr><tr><td class="patent-data-table-td ">322</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">References Filed wit the EPO: D 1-D85 (2 binders).</td></tr><tr><td class="patent-data-table-td ">323</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Reissue of Summons (Dec. 4, 2000).</td></tr><tr><td class="patent-data-table-td ">324</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Reply to Opposition Dec. 7, 1999.</td></tr><tr><td class="patent-data-table-td ">325</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Report of Repeat Experments the subject of the Repsondent's Notice of Experiments dated Aug. 11, 2000 (w/Appendixes).</td></tr><tr><td class="patent-data-table-td ">326</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Reports of Repeats of the Petitioner's Notice of Experiments 1-4.</td></tr><tr><td class="patent-data-table-td ">327</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Request for Correction—Feb. 19, 2001.</td></tr><tr><td class="patent-data-table-td ">328</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Request for Invalidation.</td></tr><tr><td class="patent-data-table-td ">329</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Resolution No. 00112 dated Jan. 18, 2000.</td></tr><tr><td class="patent-data-table-td ">330</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Respondent's Notice in the Court of Appeal.</td></tr><tr><td class="patent-data-table-td ">331</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Respondent's Notice of Experiments.</td></tr><tr><td class="patent-data-table-td ">332</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Respondent's Response to Notice to Admit Facts.</td></tr><tr><td class="patent-data-table-td ">333</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Respondent's Skeleton Argument.</td></tr><tr><td class="patent-data-table-td ">334</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Response to Opposition Preliminary Opinion by Patent Office (w/attachments) (May 16, 2001).</td></tr><tr><td class="patent-data-table-td ">335</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Response to Reasons for Revocation.</td></tr><tr><td class="patent-data-table-td ">336</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Response to the Non-Compliance Action.</td></tr><tr><td class="patent-data-table-td ">337</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Response to the Notice of Acceptance of Request for Invalidation of the Above Patent Issued by the Patent Reexamination Board.</td></tr><tr><td class="patent-data-table-td ">338</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Response to the Request for Adjournment (w/translation).</td></tr><tr><td class="patent-data-table-td ">339</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Response.</td></tr><tr><td class="patent-data-table-td ">340</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Rote Liste 1992 (Persantin®, INN: Dipyridamole and Trental®, INN: Pentoxifylline), ECV.</td></tr><tr><td class="patent-data-table-td ">341</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Ruling of Dutch Court: Nov. 11, 1999 (w/translation).</td></tr><tr><td class="patent-data-table-td ">342</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Science, vol. 257, Jul. 17, 1992, pp. 401-403—Burnett et al.</td></tr><tr><td class="patent-data-table-td ">343</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">SCRIP Daily News (Apr. 25, 2000).</td></tr><tr><td class="patent-data-table-td ">344</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">SCRIP No. 2369 Sep. 11th 1998 p 22.</td></tr><tr><td class="patent-data-table-td ">345</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Scrip's Complete Guide to Women's Health Care, 2000, Chapters 1-8.</td></tr><tr><td class="patent-data-table-td ">346</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Scrip's Complete Guide to Women's Healthcare: Female Sexual Dysfunction (Chapter 7) (2000).</td></tr><tr><td class="patent-data-table-td ">347</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Second Declaration by Dr. Kenneth Murray Dated Apr. 9, 2001.</td></tr><tr><td class="patent-data-table-td ">348</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Second Expert Report of Robert Gristwood (w/Annexes).</td></tr><tr><td class="patent-data-table-td ">349</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Second Witness Statement of Dr. Javier Angulo.</td></tr><tr><td class="patent-data-table-td ">350</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Second Witness Statement of Dr. Margaret Bush.</td></tr><tr><td class="patent-data-table-td ">351</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Second Witness Statement of Mark Thomas Hodgson (w/Exhibits).</td></tr><tr><td class="patent-data-table-td ">352</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Second Witness Statement of Trevor Martin Cook (w/Exhibits).</td></tr><tr><td class="patent-data-table-td ">353</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Sixth Witness Statement of Trevor Martin Cook.</td></tr><tr><td class="patent-data-table-td ">354</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Skeleton for the Hearing on Oral Arguments on Jul. 7, 2000 (w/translation).</td></tr><tr><td class="patent-data-table-td ">355</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Slides.</td></tr><tr><td class="patent-data-table-td ">356</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Statement Containing Submission of Exhibits (w/translation) with Exhibits.</td></tr><tr><td class="patent-data-table-td ">357</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Statement of Claims with Exhibits (w/translation).</td></tr><tr><td class="patent-data-table-td ">358</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Statement of Defense by Pfzer in the District Court of the Hague.</td></tr><tr><td class="patent-data-table-td ">359</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Statement of Defense, also Containing A Request for Suspension (w/translation).</td></tr><tr><td class="patent-data-table-td ">360</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Statement of the Patentee's Case on Claims 10 and 11.</td></tr><tr><td class="patent-data-table-td ">361</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Statement of Villouta.</td></tr><tr><td class="patent-data-table-td ">362</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Submission to EPO dated Dec. 21, 2000.</td></tr><tr><td class="patent-data-table-td ">363</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Submissions to the EPO (S 14-15; S 17; S 19; S 20; S 35-36; S47-52).</td></tr><tr><td class="patent-data-table-td ">364</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Summary of Interview—Feb. 19, 2000.</td></tr><tr><td class="patent-data-table-td ">365</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Summary of KIPO Answer.</td></tr><tr><td class="patent-data-table-td ">366</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Supplementary Expert Report of Kenneth Duncan Macrae (w/Annexes).</td></tr><tr><td class="patent-data-table-td ">367</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Sutherland, J Biol Chem, 1958, 32: 1077-1091.</td></tr><tr><td class="patent-data-table-td ">368</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Tanaka et al, 1992, Xenobiotica, vol. 22, pp 57-64.</td></tr><tr><td class="patent-data-table-td ">369</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Technical Primer from the High Court Proceedings.</td></tr><tr><td class="patent-data-table-td ">370</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">The Berman Sisters, Pioneers in the Study of Women's Sexual Dysfunction (LA Times) (Feb. 12, 2001).</td></tr><tr><td class="patent-data-table-td ">371</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">The Intellectual Property Tribunal 13th Panel—Trial Decision.</td></tr><tr><td class="patent-data-table-td ">372</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">The Journal of Pharmacology and Experimental Therapeutics, 251(3), pp. 1000-1005 (1989), McMahon et al.</td></tr><tr><td class="patent-data-table-td ">373</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">The Journal of Reproductive Medicine, 44(6) 535-542 (Jun. 1999).</td></tr><tr><td class="patent-data-table-td ">374</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">The Journal of Urology (Apr. 1997), vol. 157, No. 4, Suppl. 1, and p. 204.</td></tr><tr><td class="patent-data-table-td ">375</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">The Journal of Urology (May 1996), vol. 155, No. 5, AUA Ninety-First Annual Meeting, 495A, 676A.</td></tr><tr><td class="patent-data-table-td ">376</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">The Journal of Urology, 1989, vol. 141 pp. 546-548 by Owen et al.</td></tr><tr><td class="patent-data-table-td ">377</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">The Journal of Urology, vol. 151, No. 5, p. 495A, 1994.</td></tr><tr><td class="patent-data-table-td ">378</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">The Orgasm Pill: Are You Ready for It? By Erin Kelly, Cosmopolitan.</td></tr><tr><td class="patent-data-table-td ">379</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">The Second Sexual Revolution by Jack Hitt, NY Times Magazine, (Feb. 20, 2000).</td></tr><tr><td class="patent-data-table-td ">380</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Thesis Statement of Margaret Ann Bush, PhD.</td></tr><tr><td class="patent-data-table-td ">381</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Third Declaration of Stephen A. Ballard (in the USPTO).</td></tr><tr><td class="patent-data-table-td ">382</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Third Expert Report of Robert Gristwood.</td></tr><tr><td class="patent-data-table-td ">383</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Third Witness Statement of Mark Thomas Hodgson (w/Exhibits).</td></tr><tr><td class="patent-data-table-td ">384</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Third Witness Statement of Trevor Martin Cook (w/Exhibits).</td></tr><tr><td class="patent-data-table-td ">385</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Title Page of the Braunwald Publication (w/excerpt translated).</td></tr><tr><td class="patent-data-table-td ">386</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Tohoku J. Exp. Med. by Yoshlastu Takahashi et al., published in 1991, 165-49-58.</td></tr><tr><td class="patent-data-table-td ">387</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Torphy et al, Journal Pharmacol Exper Ther, 1993, 265: 1213-1223.</td></tr><tr><td class="patent-data-table-td ">388</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Trail Transcripts-Dec. 17-19, 2000.</td></tr><tr><td class="patent-data-table-td ">389</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Trail Transcripts—Dec. 17-19, 2000.</td></tr><tr><td class="patent-data-table-td ">390</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Transcript of Hearing on Jul. 19, 2000.</td></tr><tr><td class="patent-data-table-td ">391</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Transcript of Hearing on Jun. 22, 2000.</td></tr><tr><td class="patent-data-table-td ">392</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Transcript of Hearing on May 17, 2000.</td></tr><tr><td class="patent-data-table-td ">393</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Transcript of Hearing on May 26, 2000.</td></tr><tr><td class="patent-data-table-td ">394</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Transcript of Ian Eardley Examined by Mr. Kitchell w/attachments.</td></tr><tr><td class="patent-data-table-td ">395</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Transcript of Ian Eardley with Attachments.</td></tr><tr><td class="patent-data-table-td ">396</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Transcript of Proceedings from Day Five: Dec. 17, 2001.</td></tr><tr><td class="patent-data-table-td ">397</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Transcript of Proceedings from Day Four: Dec. 14, 2001.</td></tr><tr><td class="patent-data-table-td ">398</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Transcript of Proceedings from Day One: Dec. 11, 2001.</td></tr><tr><td class="patent-data-table-td ">399</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Transcript of Proceedings from Day Three: Dec. 13, 2001.</td></tr><tr><td class="patent-data-table-td ">400</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Transcript of Proceedings from Day Two: Dec. 12, 2001.</td></tr><tr><td class="patent-data-table-td ">401</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Translation of Tab 10 from Binder A.</td></tr><tr><td class="patent-data-table-td ">402</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Translation of Tab 17 from Binder A.</td></tr><tr><td class="patent-data-table-td ">403</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Translation of the Petition Filed on Feb. 17, 1998.</td></tr><tr><td class="patent-data-table-td ">404</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Trends in Pharmacological Sciences including Toxicological Sciences, 11, No. 4, pp 150-155 (1990, Apr.), Bearo et al.</td></tr><tr><td class="patent-data-table-td ">405</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Trends Pharmacol. Sci. (TiPS), vol. 12, pp. 19 to 27 (1991), Nicholson et al, Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes.</td></tr><tr><td class="patent-data-table-td ">406</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Trial Transcript-Oct. 10, 2000.</td></tr><tr><td class="patent-data-table-td ">407</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Trial Transcript—Oct. 10, 2000.</td></tr><tr><td class="patent-data-table-td ">408</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Trial Transcript-Oct. 11, 2000.</td></tr><tr><td class="patent-data-table-td ">409</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Trial Transcript—Oct. 11, 2000.</td></tr><tr><td class="patent-data-table-td ">410</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Trial Transcript-Oct. 12, 2000.</td></tr><tr><td class="patent-data-table-td ">411</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Trial Transcript—Oct. 12, 2000.</td></tr><tr><td class="patent-data-table-td ">412</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Trial Transcript-Oct. 13, 2000.</td></tr><tr><td class="patent-data-table-td ">413</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Trial Transcript—Oct. 13, 2000.</td></tr><tr><td class="patent-data-table-td ">414</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Trial Transcript-Oct. 17, 2000.</td></tr><tr><td class="patent-data-table-td ">415</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Trial Transcript—Oct. 17, 2000.</td></tr><tr><td class="patent-data-table-td ">416</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Trial Transcript-Oct. 18, 2000.</td></tr><tr><td class="patent-data-table-td ">417</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Trial Transcript—Oct. 18, 2000.</td></tr><tr><td class="patent-data-table-td ">418</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Trial Transcript-Oct. 4, 2000.</td></tr><tr><td class="patent-data-table-td ">419</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Trial Transcript—Oct. 4, 2000.</td></tr><tr><td class="patent-data-table-td ">420</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Trial Transcript-Oct. 5, 2000.</td></tr><tr><td class="patent-data-table-td ">421</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Trial Transcript—Oct. 5, 2000.</td></tr><tr><td class="patent-data-table-td ">422</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Trial Transcript-Oct. 6, 2000.</td></tr><tr><td class="patent-data-table-td ">423</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Trial Transcript—Oct. 6, 2000.</td></tr><tr><td class="patent-data-table-td ">424</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Trial Transcripts-Nov. 26-30, 2000.</td></tr><tr><td class="patent-data-table-td ">425</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Trial Transcripts—Nov. 26-30, 2000.</td></tr><tr><td class="patent-data-table-td ">426</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Trigo-Rocha, Flavio, et al., Am. Physiological Society, 264, H419-H422 (1993).</td></tr><tr><td class="patent-data-table-td ">427</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">UK Appeal Judgment.</td></tr><tr><td class="patent-data-table-td ">428</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">UK Confidentiality Appeal Judgment.</td></tr><tr><td class="patent-data-table-td ">429</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Urology 1999; 53 (3): 481-486, Kaplan et al.</td></tr><tr><td class="patent-data-table-td ">430</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Urology 54 (1999): 385-391 by Berman et al.</td></tr><tr><td class="patent-data-table-td ">431</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Urology 55(6) 812-815 (2000), Sipski et al.</td></tr><tr><td class="patent-data-table-td ">432</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Vaginal Sildenafil: A Preliminary Report of a Novel Method to Improve Uterine Artery Blood Flow and Endometrial Development in Patients Undergoing in Vitro Fertilization, Sher et al.</td></tr><tr><td class="patent-data-table-td ">433</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Viagra Doesn't Work in Women (SCRIP No. 2419, Mar. 12th 1999, p 23).</td></tr><tr><td class="patent-data-table-td ">434</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Viagra Fails in Female Study ( Scrip Daily News) (May 31, 2000).</td></tr><tr><td class="patent-data-table-td ">435</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Viagra Fails Test to Help Women by Phil Galewitz, AP Business Writer.</td></tr><tr><td class="patent-data-table-td ">436</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Viagra Priapism ( SCRIP No. 2387 Nov. 13th 1998 p 12).</td></tr><tr><td class="patent-data-table-td ">437</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Voluntary Further Information concerning para 2(I) and 2(IV).</td></tr><tr><td class="patent-data-table-td ">438</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">von Koenen: "<a href='http://scholar.google.com/scholar?q="Heil-und+Giftpflanzen+in+S%C3%BCdwestafrika"'>Heil-und Giftpflanzen in Südwestafrika</a>", Akademischer Verlag Windhoek, S.W.A., 1979, p. 61.</td></tr><tr><td class="patent-data-table-td ">439</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">W. Meinhardt et al., International Journal of Impotence Research, 1997, vol. 9, pp. 17-26.</td></tr><tr><td class="patent-data-table-td ">440</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Why Viagra Doesn't Work for Women by James Le Fanu, The Daily Telegraph.</td></tr><tr><td class="patent-data-table-td ">441</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Witness Statement of Dr. Francois Hyafil (w/Annexes).</td></tr><tr><td class="patent-data-table-td ">442</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Witness Statement of Dr. Javier Angulo (w/Annexes).</td></tr><tr><td class="patent-data-table-td ">443</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Witness Statement of Dr. Stephen Ballard.</td></tr><tr><td class="patent-data-table-td ">444</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Witness Statement of Julianna Jenkins (part of "<a href='http://scholar.google.com/scholar?q="BQ"'>BQ</a>").</td></tr><tr><td class="patent-data-table-td ">445</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Witness Statement of Julianna Jenkins (w/Annexes).</td></tr><tr><td class="patent-data-table-td ">446</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Witness Statement of Kate Loughney (w/Annexes).</td></tr><tr><td class="patent-data-table-td ">447</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Witness Statement of Lothar Uher (w/Annexes).</td></tr><tr><td class="patent-data-table-td ">448</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Witness Statement of Margaret Bush (part of "<a href='http://scholar.google.com/scholar?q="BQ"'>BQ</a>").</td></tr><tr><td class="patent-data-table-td ">449</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Witness Statement of Margaret Bush (w/Annexes).</td></tr><tr><td class="patent-data-table-td ">450</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Witness Statement of Martyn Burslem.</td></tr><tr><td class="patent-data-table-td ">451</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Witness Statement of Michael J. Allen (from Chinese Prosecution).</td></tr><tr><td class="patent-data-table-td ">452</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Witness Statement of Mitradev Boolell (from Chinese Prosecution).</td></tr><tr><td class="patent-data-table-td ">453</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Witness Statement of Nicholas Kenneth Terrett (co-inventor) (from Chinese Prosecution).</td></tr><tr><td class="patent-data-table-td ">454</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Witness Statement of Peter Ellis (w/Annex).</td></tr><tr><td class="patent-data-table-td ">455</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Witness Statement of Peter Ellis.</td></tr><tr><td class="patent-data-table-td ">456</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Witness Statement of Sharon Wolda (w/Annexes).</td></tr><tr><td class="patent-data-table-td ">457</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Women are Eager to Participate in the Viagra Revolution by Lan N. Nguyen.</td></tr><tr><td class="patent-data-table-td ">458</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Women Could Get Viagra in 3 Years by Helen Rumbelow, The Times, Oct. 27, 1999.</td></tr><tr><td class="patent-data-table-td ">459</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">World Foundation for Medical Studies in Female Health, (1999), Abstract Status Report, Nos. 7214, 7215.</td></tr><tr><td class="patent-data-table-td ">460</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">WPIDS abstract, AN 95-051606 [07], Coates et al., WO 9429277 (1994).*</td></tr><tr><td class="patent-data-table-td ">461</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Writ of Summons in Accelerated Proceedings on the Merits (w/translation).</td></tr><tr><td class="patent-data-table-td ">462</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Written Decision to Revoke Patent by EPO (Oct. 11, 2001) (Adverse EPO decision).</td></tr><tr><td class="patent-data-table-td ">463</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Written Submissions/Presentations Made During the Hearing from Jul. 16-18, 2001 (Binder A, Tabs 21-26).</td></tr><tr><td class="patent-data-table-td ">464</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Y.-M. Lin et al., Urol. Res, 1990, vol. 24, pp. 27-32.</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="forward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Referenced by</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Citing Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6541487">US6541487</a></td><td class="patent-data-table-td patent-date-value">Sep 1, 2000</td><td class="patent-data-table-td patent-date-value">Apr 1, 2003</td><td class="patent-data-table-td ">R.T. Alamo Ventures I, Llc</td><td class="patent-data-table-td ">Administering 5-bromoquinoline, 5-nitroisoquinoline, 8-nitroisoquinoline, 3,4-dihydro-6-hydroxy-2(1H)-quinolone or 1-methylisoquinoline to relax corpus cavernosa smooth-muscle tissue in males or females</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6821978">US6821978</a></td><td class="patent-data-table-td patent-date-value">Aug 28, 2001</td><td class="patent-data-table-td patent-date-value">Nov 23, 2004</td><td class="patent-data-table-td ">Schering Corporation</td><td class="patent-data-table-td ">Xanthine phosphodiesterase V inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6943171">US6943171</a></td><td class="patent-data-table-td patent-date-value">Nov 7, 2002</td><td class="patent-data-table-td patent-date-value">Sep 13, 2005</td><td class="patent-data-table-td ">Schering Corporation</td><td class="patent-data-table-td ">For therapy of urological, vascular or pulmonary disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6960592">US6960592</a></td><td class="patent-data-table-td patent-date-value">Dec 16, 2003</td><td class="patent-data-table-td patent-date-value">Nov 1, 2005</td><td class="patent-data-table-td ">Baoshun Liu</td><td class="patent-data-table-td ">erectile dysfunction; halosulfonation of 2-ethoxy benzoic acid, sulfonamidation, haloacylation, deacylation and amidation, cyclization; phosphodiesterase inhibitor; side-effect reduction; long lasting</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7192962">US7192962</a></td><td class="patent-data-table-td patent-date-value">May 30, 2003</td><td class="patent-data-table-td patent-date-value">Mar 20, 2007</td><td class="patent-data-table-td ">Schering Corporation</td><td class="patent-data-table-td ">Enzyme hydrolase inhibitors such as 1-ethyl-3,7-dihydro-8-((1 R,2R)-(hydroxycyclopentyl)amino)-3-(2-hydroxyethyl)-7-((3-bromo-4 -methoxyphenyl)methyl)-1H-Purine-2,6-dione, used for physiological effects</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7268141">US7268141</a></td><td class="patent-data-table-td patent-date-value">Feb 12, 2004</td><td class="patent-data-table-td patent-date-value">Sep 11, 2007</td><td class="patent-data-table-td ">Schering Corporation</td><td class="patent-data-table-td ">Xanthine phosphodiesterase V inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7531544">US7531544</a></td><td class="patent-data-table-td patent-date-value">Sep 10, 2007</td><td class="patent-data-table-td patent-date-value">May 12, 2009</td><td class="patent-data-table-td ">Schering Corporation</td><td class="patent-data-table-td ">Xanthine phosphodiesterase V inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8101579">US8101579</a></td><td class="patent-data-table-td patent-date-value">Sep 28, 2009</td><td class="patent-data-table-td patent-date-value">Jan 24, 2012</td><td class="patent-data-table-td ">Ironwood Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Methods and compositions for the treatment of gastrointestinal disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8227453">US8227453</a></td><td class="patent-data-table-td patent-date-value">Nov 10, 2006</td><td class="patent-data-table-td patent-date-value">Jul 24, 2012</td><td class="patent-data-table-td ">Emotional Brain B.V.</td><td class="patent-data-table-td ">Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8563605">US8563605</a></td><td class="patent-data-table-td patent-date-value">May 13, 2009</td><td class="patent-data-table-td patent-date-value">Oct 22, 2013</td><td class="patent-data-table-td ">Sbi Pharmaceuticals Co., Ltd.</td><td class="patent-data-table-td ">Therapeutic agent for male sterility</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8575139">US8575139</a></td><td class="patent-data-table-td patent-date-value">Nov 2, 2007</td><td class="patent-data-table-td patent-date-value">Nov 5, 2013</td><td class="patent-data-table-td ">Emotional Brain B.V.</td><td class="patent-data-table-td ">Use of testosterone and a 5-HT1a agonist in the treatment of sexual dysfunction</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8609728">US8609728</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 14, 2011</td><td class="patent-data-table-td patent-date-value">Dec 17, 2013</td><td class="patent-data-table-td ">United Therapeutics Corporation</td><td class="patent-data-table-td ">Treatment for pulmonary hypertension</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8648060">US8648060</a></td><td class="patent-data-table-td patent-date-value">Nov 2, 2007</td><td class="patent-data-table-td patent-date-value">Feb 11, 2014</td><td class="patent-data-table-td ">Emotional Brain B.V.</td><td class="patent-data-table-td ">Use of 3-alpha-androstanediol in combination with a 5-HT1a agonist, in the treatment of sexual dysfunction</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8653051">US8653051</a></td><td class="patent-data-table-td patent-date-value">Nov 2, 2007</td><td class="patent-data-table-td patent-date-value">Feb 18, 2014</td><td class="patent-data-table-td ">Emotional Brain B.V.</td><td class="patent-data-table-td ">Use of 3-alpha-androstanediol in combination with a PDE5 inhibitor, in the treatment of sexual dysfunction</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8669242">US8669242</a></td><td class="patent-data-table-td patent-date-value">Jul 10, 2012</td><td class="patent-data-table-td patent-date-value">Mar 11, 2014</td><td class="patent-data-table-td ">Emotional Brain B.V.</td><td class="patent-data-table-td ">Use of testosterone and a 5-HT1A agonist in the treatment of sexual dysfunction</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20110224236">US20110224236</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 14, 2011</td><td class="patent-data-table-td patent-date-value">Sep 15, 2011</td><td class="patent-data-table-td ">United Therapeutics Corporation</td><td class="patent-data-table-td ">Treatment for pulmonary hypertension</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2486921A1?cl=en">EP2486921A1</a></td><td class="patent-data-table-td patent-date-value">Feb 12, 2008</td><td class="patent-data-table-td patent-date-value">Aug 15, 2012</td><td class="patent-data-table-td ">DMI Biosciences, Inc.</td><td class="patent-data-table-td ">Reducing Side Effects of Tramadol</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2486927A1?cl=en">EP2486927A1</a></td><td class="patent-data-table-td patent-date-value">Feb 12, 2008</td><td class="patent-data-table-td patent-date-value">Aug 15, 2012</td><td class="patent-data-table-td ">DMI Biosciences, Inc.</td><td class="patent-data-table-td ">Treatment of Comorbid Premature Ejaculation and Erectile Dysfunction</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2008100933A2?cl=en">WO2008100933A2</a></td><td class="patent-data-table-td patent-date-value">Feb 12, 2008</td><td class="patent-data-table-td patent-date-value">Aug 21, 2008</td><td class="patent-data-table-td ">Dmi Biosciences Inc</td><td class="patent-data-table-td ">Reducing side effects of tramadol</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2009139156A1?cl=en">WO2009139156A1</a></td><td class="patent-data-table-td patent-date-value">May 13, 2009</td><td class="patent-data-table-td patent-date-value">Nov 19, 2009</td><td class="patent-data-table-td ">Sbi Ala Promo Co., Ltd.</td><td class="patent-data-table-td ">Therapeutic agent for male sterility</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2010070617A1?cl=en">WO2010070617A1</a></td><td class="patent-data-table-td patent-date-value">Dec 18, 2009</td><td class="patent-data-table-td patent-date-value">Jun 24, 2010</td><td class="patent-data-table-td ">Shimoda Biotech (Pty) Ltd</td><td class="patent-data-table-td ">Inclusion complexes of alpha-cyclodextrin and sildenafil salt</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2010146407A1?cl=en">WO2010146407A1</a></td><td class="patent-data-table-td patent-date-value">Jun 18, 2010</td><td class="patent-data-table-td patent-date-value">Dec 23, 2010</td><td class="patent-data-table-td ">Nanoform Hungary Ltd.</td><td class="patent-data-table-td ">Nanostructured sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011051928A1?cl=en">WO2011051928A1</a></td><td class="patent-data-table-td patent-date-value">Oct 3, 2010</td><td class="patent-data-table-td patent-date-value">May 5, 2011</td><td class="patent-data-table-td ">Medispec Ltd</td><td class="patent-data-table-td ">Method and apparatus for treatment of erectile dysfunction with extracorporeal shockwaves</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011075801A1?cl=en">WO2011075801A1</a></td><td class="patent-data-table-td patent-date-value">Dec 21, 2009</td><td class="patent-data-table-td patent-date-value">Jun 30, 2011</td><td class="patent-data-table-td ">Acef S.A.</td><td class="patent-data-table-td ">Cubebin, dibenzylbutyrolactone lignan, semi-synthetic and synthetic derivatives thereof, and other lignans and neolignans as vasodilating agents in the therapy of erectile dysfunction</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="classifications"></a><div class="patent-section-header"><span class="patent-section-title">Classifications</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th"> </th><th class="patent-data-table-th"> </th></tr></thead><tr><td class="patent-data-table-td ">U.S. Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=kKJcBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S234500">514/234.5</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=kKJcBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S252160">514/252.16</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=kKJcBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S262100">514/262.1</a></span></td></tr><tr><td class="patent-data-table-td ">International Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=kKJcBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07D0487040000">C07D487/04</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=kKJcBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0045000000">A61K45/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=kKJcBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031519000">A61K31/519</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=kKJcBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61P0015100000">A61P15/10</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=kKJcBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61P0013020000">A61P13/02</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=kKJcBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031529000">A61K31/529</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=kKJcBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031000000">A61K31/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=kKJcBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031522000">A61K31/522</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=kKJcBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61P0015000000">A61P15/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=kKJcBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031505000">A61K31/505</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=kKJcBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K">A61K</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=kKJcBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031535000">A61K31/535</a></span></td></tr><tr><td class="patent-data-table-td ">Cooperative Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=kKJcBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K31/535">A61K31/535</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=kKJcBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K31/505">A61K31/505</a></span></td></tr><tr><td class="patent-data-table-td ">European Classification</td><td class="patent-data-table-td "><span class="nested-value">A61K31/535</span>, <span class="nested-value">A61K31/505</span></td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="legal-events"></a><div class="patent-section-header"><span class="patent-section-title">Legal Events</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Date</th><th class="patent-data-table-th">Code</th><th class="patent-data-table-th">Event</th><th class="patent-data-table-th">Description</th></tr></thead><tr><td class="patent-data-table-td patent-date-value">Mar 26, 2014</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">12</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Nov 2, 2010</td><td class="patent-data-table-td ">B1</td><td class="patent-data-table-td ">Reexamination certificate first reexamination</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">THE PATENTABILITY OF CLAIMS 1-23, 25 AND 26 IS CONFIRMED. CLAIM 24 IS CANCELLED.</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Mar 23, 2010</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">8</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Mar 28, 2006</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">4</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Aug 23, 2005</td><td class="patent-data-table-td ">RR</td><td class="patent-data-table-td ">Request for reexamination filed</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20050705</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">May 17, 2005</td><td class="patent-data-table-td ">RR</td><td class="patent-data-table-td ">Request for reexamination filed</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20050323</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Aug 24, 2004</td><td class="patent-data-table-td ">RR</td><td class="patent-data-table-td ">Request for reexamination filed</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20040707</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jan 27, 2004</td><td class="patent-data-table-td ">RR</td><td class="patent-data-table-td ">Request for reexamination filed</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20031215</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Mar 4, 1996</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">PFIZER INC., NEW YORK</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ELLIS, PETER;TERRETT, NICHOLAS K.;REEL/FRAME:007983/0143</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">19960227</span></div></td></tr></table><div class="patent-section-footer"></div></div><div class="modal-dialog" id="patent-images-lightbox"><div class="patent-lightbox-controls"><div class="patent-lightbox-rotate-controls"><div class="patent-lightbox-rotation-text">Rotate</div><div class="rotate-icon rotate-ccw-icon"></div><div class="rotate-icon rotate-cw-icon"></div></div><div class="patent-lightbox-index-counter"></div><a class="patent-lightbox-fullsize-link" target="_blank">Original Image</a><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_right.png" alt="Next page"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_left.png" alt="Previous page"width="21" height="21" /></div></div><div class="modal-dialog-content"><div class="patent-lightbox-image-holder"><div class="patent-lightbox-placeholder"></div></div></div></div><script>_OC_initPatentsAtb({image_not_available_html: " Image not available"});</script></div></div></div></td></tr></table><script>(function() {var href = window.location.href;if (href.indexOf('?') !== -1) {var parameters = href.split('?')[1].split('&');for (var i = 0; i < parameters.length; i++) {var param = parameters[i].split('=');if (param[0] == 'focus') {var elem = document.getElementById(param[1]);if (elem) {elem.focus();}}}}})();</script><script>_OC_addFlags({LockSrc:"/books/javascript/lock_8a2b04e7bf975d5171d8e4c0b6365c7a.js", Host:"http://www.google.com/", IsBooksRentalEnabled:1, IsWebstoreDisplayCaseEnabled:1, IsObfuscationEnabled:1, IsBrowsingHistoryEnabled:1, IsWebReaderSvgEnabled:0, IsGeoLayerEnabled:1, IsImageModeNotesEnabled:1, IsCopyMenuItemEnabled:1, IsGiftingEnabled:0, IsWebReaderUniversalPaginatorEnabled:0, IsOfflineBubbleEnabled:1, IsReaderEnabledForPlayRequests:1, IsFutureOnSaleVolumesEnabled:1, IsOfflineRestrictedCopyEnabled:1, IsBooksUnifiedLeftNavEnabled:1, IsRestrictedCopyEnabled:1, IsZipitFolderCollectionEnabled:1, IsEndOfSampleRecommendationsEnabled:1, IsRatingsOnBookcardsEnabled:1, IsAdsDisabled:0, IsIframePageDisplayEnabled:0, IsEmbeddedMediaEnabled:1, IsImageModeAnnotationsEnabled:1, IsMyLibraryGooglePlusEnabled:1, IsImagePageProviderEnabled:0, IsBookcardListPriceSmall:0, IsInternalUser:0, IsBooksShareButtonEnabled:0, IsPreOrdersEnabled:0, IsDisabledRandomBookshelves:0, WebstoreDisplayCasePosition:3});_OC_Run({"enable_p13n":false,"add_vol_to_collection_base_url":"http://www.google.com/patents?op=add\u0026sig=ACfU3U3FbwcthYDwPmRGHY_Db-NluXRDmg\u0026id=kKJcBAABERAJ","remove_vol_from_collection_base_url":"http://www.google.com/patents?op=remove\u0026sig=ACfU3U1BTooZ8M1ZU14uHKmzNnoN6_YF0Q\u0026id=kKJcBAABERAJ","logged_in":false,"p13n_save_user_settings_url":"http://www.google.com/patents?op=edit_user_settings\u0026sig=ACfU3U1y8_6whrTOfAjbmbkqGz-alSf-rg","is_cobrand":false,"sign_in_url":"https://www.google.com/accounts/Login?service=\u0026continue=http://www.google.com/patents%3Fhl%3Den\u0026hl=en","is_play_enabled":true}, {"volume_id":"","is_ebook":true,"volumeresult":{"has_flowing_text":false,"has_scanned_text":true,"can_download_pdf":false,"can_download_epub":false,"is_pdf_drm_enabled":false,"is_epub_drm_enabled":false,"download_pdf_url":"http://www.google.com/patents/download/Pyrazolopyrimidinones_for_the_treatment.pdf?id=kKJcBAABERAJ\u0026output=pdf\u0026sig=ACfU3U0jpvxFYf4VWHX2vC-vSz0yo6AV2g"},"sample_url":"http://www.google.com/patents/reader?id=kKJcBAABERAJ\u0026printsec=frontcover\u0026output=reader\u0026source=gbs_atb_hover","is_browsable":true,"is_public_domain":true}, {});</script><div id="footer_table" style="font-size:83%;text-align:center;position:relative;top:20px;height:4.5em;margin-top:2em"><div style="margin-bottom:8px"><a href=http://www.google.com/><nobr>Google&nbsp;Home</nobr></a> - <a href=//www.google.com/patents/sitemap/><nobr>Sitemap</nobr></a> - <a href=http://www.google.com/googlebooks/uspto.html><nobr>USPTO Bulk Downloads</nobr></a> - <a href=/intl/en/privacy/><nobr>Privacy Policy</nobr></a> - <a href=/intl/en/policies/terms/><nobr>Terms of Service</nobr></a> - <a href=https://support.google.com/faqs/answer/2539193?hl=en><nobr>About Google Patents</nobr></a> - <a href="http://www.google.com/tools/feedback/intl/en/error.html" onclick="try{_OC_startFeedback({productId: '72792',locale: 'en'});return false;}catch(e){}"><nobr>Send Feedback</nobr></a></div><span>Data provided by IFI CLAIMS Patent Services</span><br><span >&copy;2012 Google</span></div> <script type="text/javascript">var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));</script><script type="text/javascript">var pageTracker = _gat._getTracker("UA-27188110-1");pageTracker._setCookiePath("/patents/");pageTracker._trackPageview();</script> </body></html>